Title: COMPOSITIONS FOR THE TREATMENT OF PERIPHERAL NEUROPATHIES CONTAINING ANTIDEPRESSANTS AND/OR MONOAMINE OXIDASE INHIBITORS AND/OR VITAMIN B12 AND/OR PRECURSORS OR INDUCERS OF A NEUROTRANSMITTER

Applicant/Assignee: THE WWK TRUST

Application No.: 09/214314   Filing Date: 04/Mar/1999

Abstract:

Methods and compositions for treatment of a patient suffering from a form of peripheral neuropathy are disclosed. The method comprises administering to the patient any one of the following combinations of components: I. A, B and C

II. A and B

III. B and C

IV. A and C, wherein A is an antidepressant or a monoamine oxidase inhibitor, B is vitamin B12, and C is a precursor or inducer of a neurotransmitter, e.g. L-phenylalanine.

Priority: GB19960014121 Applic. Date: 1996-07-05; GB19960016019 Applic. Date: 1996-07-31; WO1997GB01822 Applic. Date: 1997-07-04

Inventor: WORSLEY ANDREW PETER [GB]

Title: Pseudopolymorphic forms of 2-[2-[4-[Bis (4-fluorophenyl) methyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride

Applicant/Assignee: UCB, S.A

Application No.: 09/800665   Filing Date: 08/Mar/2001

Abstract:

The present invention relates to new pseudopolymorphic forms of 2-[2-[4-[bis (4-fluorophenyl)methyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride, namely, anhydrous 2-[2-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride and 2-[2-[4-[bis(4-fluorophenyl)methyl]-1-piperazinyl]ethoxy]acetic acid dihydrochloride monohydrate. It also relates to processes for the preparation of these pseudopolymorphic forms and to pharmaceutical compositions containing them.

Priority: EP19970870193 Applic. Date: 1997-11-26; US2000-555021 Applic. Date: 2000-05-23

Inventor: BERWAER MONIQUE [BE]; BODSON GUY [BE]; DELEERS MICHEL [BE]; DOGIMONT CHARLES [BE]; FANARA DOMENICO [BE]; TIMMERMANS JACQUES [BE]

Title: Biologically active materials

Applicant/Assignee: ML LABORATORIES

Application No.: 09/445793   Filing Date: 23/Mar/2000

Abstract:

A polymer-drug conjugate, in which the polymer is the polysaccharide dextrin, linked directly or indirectly to the drug, is effective to deliver the drug to a target site and is biodegradable. The conjugate may be prepared by succinoylating dextrin followed by reaction with the drug or a derivative thereof.

Priority: GB19970012100 Applic. Date: 1997-06-12; WO1998GB01567 Applic. Date: 1998-06-12; US19970054277P Applic. Date: 1997-07-30

Inventor: DUNCAN RUTH [GB]; CASSIDY JAMES [GB]; GERMAN LISA [GB]; HIRST DALE [GB]

Title: Compositions of lipid lowering agents

Applicant/Assignee: JANSSEN PHARMACEUTICA N.V

Application No.: 09/530170   Filing Date: 24/Apr/2000

Abstract:

The present invention is concerned with novel pharmaceutical compositions of lipid lowering agents which can be administered to a mammal suffering from hyperlipidemia, obesitas or atherosclerosis, whereby a single such dosage form can be administered once daily, and in addition at any time of the day independently of the food taken in by said mammal. These novel compositions comprise particles obtainable by melt-extruding a mixture comprising a lipid lowering agent and an appropriate water-soluble polymer and subsequently milling said melt-extruded mixture.

Priority: EP19970203407 Applic. Date: 1997-11-03; WO1998EP06998 Applic. Date: 1998-10-27

Inventor: BAERT LIEVEN [BE]; VERRECK GEERT [BE]

Title: Derivatives of (-)-venlafaxine and methods of preparing and using the same

Applicant/Assignee: SEPRACOR, INC

Application No.: 09/450690   Filing Date: 30/Nov/1999

Abstract:

Methods of preparing, and compositions comprising, derivatives of (-)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.

Priority: US19980110488P Applic. Date: 1998-12-01

Inventor: JERUSSI THOMAS P [US]; SENANAYAKE CHRISANTHA H [US]

Title: Composition and method for treatment of symptoms associated with insufficient estrogen production

Applicant/Assignee: WAKUNAGA OF AMERICA CO., LTD

Application No.: 09/612299   Filing Date: 07/Jul/2000

Abstract:

A composition and method are provided for the treatment of symptoms associated with reduced estrogen production, such as occurs in perimenopausal and menopausal women, wherein the composition contains at least one phytoestrogen containing food, herb or extract thereof, and at least four herbs or extracts which are effective at treating conventional menopausal symptoms.

Priority:

Inventor: FRY KATHLEEN K [US]; WINGO CLAUDIA J [US]

Title: Double capsule for the administration of active principles in multiple therapies

Applicant/Assignee: AXCAN PHARMA INC

Application No.: 09/581721   Filing Date: 16/Jun/2000

Abstract:

A pharmaceutical dosage form particularly suitable for the administration of active principles in multiple therapies is disclosed. The pharmaceutical dosage form is a double capsule where in an internal capsule is placed inside an external one. Each internal and external capsule includes one or more active principles. A double capsule according to the invention is preferably used in triple or quadruple therapies against the microorganisms Helicobacter Pylori. Advantages of this pharmaceutical dosage form consist in providing a simple posology for administration of two and more active principles, allowing the active principles to activate at the right intervals of time and in the preestablished quantities, and preventing interactions between active principles. In a preferred embodiment of the invention, the pharmaceutical dosage form has an external capsule containing bismuth subcitrate and metronidazole, and an internal capsule containing tetracycline and optionally omeprazole, which is used in therapy for eradication of Helicobacter pylori.

Priority: WO1998EP08167 Applic. Date: 1998-12-14; IT1997MI02788 Applic. Date: 1997-12-17

Inventor: SANSO GIOVANNI [IT]

Title: Over-coated chewing gum formulations

Applicant/Assignee: WM. WRIGLEY JR. COMPANY

Application No.: 09/510878   Filing Date: 23/Feb/2000

Abstract:

Methods and products for delivering a medicament or agent to an individual are provided. The product includes a coating having a medicament or agent. The medicament or agent is present within the coating that surrounds a gum center (the water soluble portion and a water insoluble base portion). By chewing the gum, the medicament or agent is released from the product. Continuing to chew the chewing gum creates a pressure within the buccal cavity forcing the agent or medicament directly into the systemic system of the individual through the oral mucosa contained in the buccal cavity. This greatly enhances the absorption of the drug into the systemic system as well as the bioavailability of the drug within the system.

Priority: US1999-286818 Applic. Date: 1999-04-06; WO1999US29742 Applic. Date: 1999-12-14

Inventor: REAM RONALD L [US]; GREENBERG MICHAEL J [US]; WOKAS WILLIAM J [US]; CORRIVEAU CHRISTINE L [US]

Title: Complex between carrageenan and a water soluble drug having a specific granulometry and relative controlled release pharamaceutical compositions

Applicant/Assignee: EURAND INTERNATIONAL S.P.A

Application No.: 09/530245   Filing Date: 26/Apr/2000

Abstract:

A complex between carrageenan and a water soluble drug characterized in powder form having an average particle size comprised between 10 and 100 mum, and the basic water drug is contained in the complex in amounts ranging from 1.5 and 5 mmol/g carrageenan, a process for preparing this complex and relative controlled release pharmaceutical compositions containing it.

Priority: WO1998EP06864 Applic. Date: 1998-10-29; IT1997PV00009 Applic. Date: 1997-10-29

Inventor: CARAMELLA CARLA MARCELLA [IT]; BONFERONI MARIA CRISTINA [IT]

Title: Fumaric acid micro tablets

Applicant/Assignee: FUMAPHARM AG

Application No.: 09/743978   Filing Date: 17/Jan/2001

Abstract:

The present invention relates to the use of one or more salts of fumaric acid monoalkyl esters of the general formulaoptionally in admixture with dialkyl fumarate of the formulawherein A is a bivalent cation from the series consisting of Ca, Mg, Zn or Fe or a monovalent cation from the series Li, Na or K, respectively, and n denotes the numeral 1 or 2 depending on the type of cation, and, optionally, commonly used pharmaceutical excipients and vehicles for preparing a pharmaceutical composition in the form of micro-tablets or micro-pellets for the treatment of psoriatic arthritis, neurodermatitis, psoriasis and enteritis regionalis Crohn.

Priority: DE19981048260 Applic. Date: 1998-10-20; WO1999EP07568 Applic. Date: 1999-10-08

Inventor: JOSHI RAJENDRA KUMAR [CH]; STREBEL HANS-PETER [CH]

Title: Hydrophilic ampholytic polymer

Applicant/Assignee: PMD HOLDINGS CORP

Application No.: 09/222495   Filing Date: 29/Dec/1998

Abstract:

A novel hydrophilic ampholytic polymer synthesized by reacting polymerizable amino and carboxy functional ethylenically unsaturated monomers, together with a non-ionic hydrophilic monomer, to provide a polymer having a glass transition temperature (Tg) above about 50 DEG C., and optionally hydrophobic monomer(s), and cross-linking monomer(s). The copolymer is precipitated from a polymerization media which includes a suitable organic solvent. The resulting copolymer is in the form of a fine powder, with submicron particle size. As such it is suitable for use as a thickener or rheology modifier in personal care formulations, such as shampoo, conditioner, and the like, as a bioadhesive, and for other pharmaceutical applications.

Priority:

Inventor: GALLEGUILLOS RAMIRO [US]; BUDREVICH JODI A [US]; CHIARELLI JOSEPH A [US]; BATHINA HARINATH B [US]; AMJAD ZAHID [US]

Title: Method of making ibuprofen and narcotic analgesic composition

Applicant/Assignee: BASF CORPORATION

Application No.: 08/872217   Filing Date: 10/Jun/1997

Abstract:

Provided herein are compositions and methods of making compositions of ibuprofen in combination with a narcotic analgesic. Specifically provided is a pharmaceutical tablet composition comprising ibuprofen

a narcotic analgesic

colloidal silicon dioxide

a filler selected from the group consisting of microcrystalline cellulose and powdered cellulose

a disintegrant selected from the group consisting of croscarmellose sodium, crospovidone, and sodium starch glycolate

a binder consisting of an akylhydroxy methylcellulose

a starch

and a lubricant. Also provided herein is a method of preparing a pharmaceutical tablet composition comprising: (a) Granulating ibuprofen, a narcotic analgesic, a first glidant, a first disintegrant, a binder, and starch to form granules wherein said granulating step comprises a wet granulation process

(b) blending the granules with extra-granular material comprised of a second glidant, a second disintegrant, a filler and starch to form a blend of granules and extra-granular material

and (c) compressing the blend into a tablet.

Priority: US19960020973P Applic. Date: 1996-06-12

Inventor: KUSHLA GREGORY P [US]; LAI JIN-WANG [US]; POLLI GERALD P [US]

Title: Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID

Applicant/Assignee: ASTRAZENECA AB

Application No.: 09/471958   Filing Date: 23/Dec/1999

Abstract:

An oral pharmaceutical dosage form comprising an acid susceptible proton pump inhibitor and one or more NSAIDs in a fixed formulation, wherein the proton pump inhibitor is protected by an enteric coating layer. The fixed formulation is in the form of an enteric coating layered tablet, a capsule or a multiple unit tableted dosage form. The multiple unit dosage forms are most preferred. The new fixed formulation is especially useful in the treatment of gastrointestinal side-effects associated with NSAID treatment.

Priority: SE19960000070 Applic. Date: 1996-01-08

Inventor: DEPUI HELENE [SE]; LUNDBERG PER [SE]

Title: Solid mixtures of cyclodextrins prepared via meltextrusion

Applicant/Assignee: JANSSEN PHARMACEUTICA, N.V

Application No.: 09/081808   Filing Date: 20/May/1998

Abstract:

Process for preparing a solid mixture comprising one or more cyclodextrins and an insoluble active ingredient characterized in that said process comprises a melt-extrusion step, wherein the active ingredient is embedded into the cyclodextrin carrier.

Priority: EP19950203219 Applic. Date: 1995-11-23

Inventor: BAERT LIEVEN ELVIRE COLETTE [BE]; PEETERS JOZEF [BE]; VERRECK GEERT [BE]

Title: Controlled release solid dosage forms of lithium carbonate

Applicant/Assignee: SMITHKLINE BEECHAM CORPORATION

Application No.: 09/509880   Filing Date: 18/May/2000

Abstract:

A process for preparing controlled release solid dosage forms of lithium carbonate by using a dissolution rate stabilizer and a hydrophobic waxy material.

Priority: US19970060909P Applic. Date: 1997-10-03; WO1998US20579 Applic. Date: 1998-10-01

Inventor: VENKATESH GOPADI M [US]; PALEPU NAGESWARA R [US]

Title: Liquid dispersion polymer compositions, their preparation and their use

Applicant/Assignee: CIBA SPECIALTY CHEMICALS CORPORATION

Application No.: 09/543287   Filing Date: 05/Apr/2000

Abstract:

Liquid dispersion polymer compositions which comprise microparticles of a hydrophilic, water soluble or swellable polymer, preferably an acrylic-based polymer, dispersed in a di- or triglyceride oil such as soybean oil and an oil-in-water surfactant, are useful to prepare microparticulate thickening systems to thicken aqueous or aqueous/organic compositions, particularly for use in personal care and pharmaceutical formulations. The preparation and the use of these liquid dispersion polymer compositions is described.

Priority: US19990128114P Applic. Date: 1999-04-07

Inventor: GREEN MICHAEL [GB]; RIDLEY ELEANOR BERNICE [GB]; GAVIN DWAYNE ERICK [US]

Title: Pharmaceutical compositions containing antibody-enzyme conjugates in combination with prodrugs

Applicant/Assignee: THE SCHOOL OF PHARMACY, UNIVERSITY OF LONDON

Application No.: 09/445732   Filing Date: 22/May/2000

Abstract:

Prodrugs which can be activated by enzymes, are formulated for sequential administration, with enzyme conjugates. Either or each component comprises a polymeric carrier which allows it to be directed preferentially to the target tissue. A new polymer-prodrug conjugate is cleavable by cathepsin-B or othe invention is of particular utility for targeting solid tumours.

Priority: EP19970304070 Applic. Date: 1997-06-11; WO1998GB01700 Applic. Date: 1998-06-11

Inventor: DUNCAN RUTH [GB]; SATCHI-FAINARO RONIT [IL]

Title: Formulations comprising lipid-regulating agents

Applicant/Assignee: ABBOTT LABORATORIES

Application No.: 09/330589   Filing Date: 11/Jun/1999

Abstract:

The present invention is directed to a semi-solid formulation comprising a lipid-regulating agent. Said formulation is prepared by solubilizing said lipid-regulating agent in one or more liquid components to form a clear liquid solution, then solidifying said solution by adding one or more solid or semi-solid components to said solution to form a semi-solid formulation. Said formulation can melt or dissolve upon mixing with a bulk aqueous medium. The resulting formulation results in an increase in drug solubility and oral bioavailability, and an improved dissolution rate.

Priority:

Inventor: LIU RONG RON [US]; PAN QINGHAI [US]; HANSRANI PAWAN [US]

Title: Palatable, sustained release drug granules

Applicant/Assignee: UNIVERSITY OF IOWA RESEARCH FOUNDATION

Application No.: 09/437449   Filing Date: 10/Nov/1999

Abstract:

A means and method for manufacturing palatable drug granules using a polymer having at least one free carboxyl group and PVP is described. This is achieved by (1) dissolving/suspending a drug in an aqueous solution of polymers and subsequently adjusting the pH of the solution to an acidic pH or (2) suspending a drug in an organic solution of one of the aforementioned polymers and then adding the other polymer solution, with constant agitation. The polymers form a complex and consequently entraps the drug and produce palatable drug granules that are suitable for preparing sustained release pharmaceutical dosage forms (powders, suspension, tablets, chewable tablets).

Priority:

Inventor: KUMAR VIJAY [US]

Title: Pharmaceutical composition comprising a combination of metformin and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia

Applicant/Assignee: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG

Application No.: 09/601618   Filing Date: 30/Nov/2000

Abstract:

A pharmaceutical composition comprising: (i) metformin, optionally in the form one of its pharmaceutically acceptable salts

(ii) a fibrate selected from fenofibrate and bezafibrate

and optionally one or more pharmaceutically acceptable excipients, is suitable for use in the treatment of non-insulin-dependent diabetes.

Priority: WO1999EP00614 Applic. Date: 1999-01-30; FR19980001709 Applic. Date: 1998-02-12

Inventor: BONHOMME YVES [FR]; BRIET PHILIPPE [FR]

Title: Stable multi-unitary pharmaceutical preparations containing substituted benzimidazoles

Applicant/Assignee: LABORATORIO MENDIFAR-PRODUTOS FARMACEUTICOS, S.A

Application No.: 09/580551   Filing Date: 30/May/2000

Abstract:

The present invention relates to oral multi-unitary pharmaceutical preparations containing substituted benzimidazoles being inhibitors of H+, K+-ATPase (i.e. omeprazole, lansoprazole, pantoprazole, leminoprazole and pariprazole) or their pharmaceutically acceptable salts. Such pharmaceutical preparations are stable pellet preparations containing substituted benzimidazole(s) or their salts and they comprise a quantity of active ingredient of between 1 and 50 mg, an inert core of spherical symmetry with a diameter of 600-1000 mum, constituted by inert excipients, coated with an active layer containing at least one substituted benzimidazole in the micronized form and various pharmaceutically acceptable inert excipients, mixed in suitable proportions in order to allow the disaggregation of the formulations and dissolution of the active ingredient(s) in an appropriate manner, coated in turn with an insulating layer of a strictly polymeric nature, soluble in water, free from alkaline and/or alkaline-earthy metallic salts, of a minimum thickness of 15 mum, this layer being coated lastly with a gastroresistant or enteric layer of a minimum thickness of 30 mum. This invention also refers to the process for the preparation of said pharmaceutical preparations.

Priority: EP19990670010 Applic. Date: 1999-12-16

Inventor: MENDES CARLA PATRICIA GONCALVE [PT]; DE OLIVEIRA MARIA JULIA CAEIRO [PT]

Title: Inorganic shaped bodies and methods for their production and use

Applicant/Assignee: VITA SPECIAL PURPOSE CORPORATION

Application No.: 09/253556   Filing Date: 19/Feb/1999

Abstract:

Shaped, preferably porous, inorganic bodies are provided which are prepared from a reactive blend. In accordance with one preferred embodiment, the solution is absorbed into a porous sacrificial substrate such as a cellulose sponge. The solution-saturated substrate is heated and an oxidation-reduction reaction occurs thereby forming an inorganic solid. A shaped, inorganic body is formed in situ. Optional, but preferred additional thermal treatment of the shaped, inorganic body removes the organic substrate, leaving an inorganic body that faithfully mimics the porosity, shape, and other physical characteristics of the organic substrate. Inorganic substrates may also be used to good effect. Large varieties of shaped bodies can be prepared in accordance with other embodiments of the invention and such shapes find wide use in surgery, laboratory and industrial processes and otherwise. The invention also provides chemically and morphologically uniform powders, including those having uniformly small sizes.

Priority: US19990117254P Applic. Date: 1999-01-26; US2002-263399 Applic. Date: 2002-10-02

Inventor: SAPIESZKO RONALD S [US]; DYCHALA DAVID H [US]; ERBE ERIK M [US]

Title: Compositions for treating allergic and other disorders using norastemizole in combination with other active ingredients

Applicant/Assignee: SEPRACOR INC

Application No.: 09/956003   Filing Date: 20/Sep/2001

Abstract:

Methods and compositions are disclosed utilizing metabolic derivatives of astemizole for the treatment of allergic disorders while avoiding the concomitant liability of adverse effects associated with the astemizole. The metabolic derivatives of astemizole are also useful for the treatment of retinopathy and other small vessel disorders associated with diabetes mellitus and such other conditions as may be related to the antihistamine activity of astemizole. For example, the metabolic derivatives of astemizole are useful for the treatment of asthma, motion sickness, and vertigo, without the concomitant liability of adverse effects associated with astemizole. Furthermore, the metabolic derivatives of astemizole, in combination with non-steroidal anti-inflammatory agents or other non-narcotic analgesics, or in combination with a decongestant, cough suppressant/antitussive or expectorant, are useful for the treatment of cough, cold, cold-like, and/or flu symptoms and the discomfort, headache, pain, fever, and general malaise associated therewith, without the concomitant liability of adverse effects associated with astemizole.

Priority: US2001-835149 Applic. Date: 2001-04-16; US2000-650645 Applic. Date: 2000-08-30; US2000-551613 Applic. Date: 2000-04-17; US2000-481439 Applic. Date: 2000-01-12; US1996-766094 Applic. Date: 1996-12-16; US1994-182685 Applic. Date: 1994-01-18; US1992-940054 Applic. Date: 1992-09-03

Inventor: WOOSLEY RAYMOND L [US]; ABERG A K GUNNAR [US]

Title: Anti-inflammatory pharmaceutical formulations

Applicant/Assignee:

Application No.: US 2000-479430   Filing Date: 07/Jan/2000

Abstract:

An oral pharmaceutical dosage form including a mixture of a delay release formulation of a non-steroidal anti-inflammatory drug (NSAID) and a mixture containing a prostaglandin and one or more excipients.

Priority: US1999-414673 Applic. Date: 1999-10-07; US1999-394179 Applic. Date: 1999-09-10; US19980099814P Applic. Date: 1998-09-10

Inventor: WOOLFE AUSTEN JOHN [GB]; GREENE SIOBHAN [IE]; MCINTYRE GORDON [GB]; SHETH NITIN VADILAL [US]

Title: Directly compressible high load acetaminophen formulations

Applicant/Assignee: EDWARD MENDELL CO., INC

Application No.: 09/798755   Filing Date: 02/Mar/2001

Abstract:

Direct compressed solid pharmaceutical dosage forms containing:a) from about 40 to about 95% by weight acetaminophen

b) from about 1 to about 60% by weight of a direct compression vehicle comprising microcrystalline cellulose

andc) from about 0.01 to about 4.0% by weight of a pharmaceutically-acceptable lubricantare disclosed. The acetaminophen and direct compression vehicle are combined under high shear conditions which are sufficient to transform acetaminophen and direct compression vehicle into a homogenous granulate without degradation. In preferred aspects of the invention, the lubricant is also combined with the acetaminophen and direct compression vehicle under high shear conditions. Methods of preparing the directly compressed solid pharmaceutical dosage forms and methods of treatment with the dosage forms are also disclosed.

The methods are particularly well suited for preparing directly compressed dosage forms containing high load (i.e., up to 80% or greater) amounts of acetaminophen based on the weight of the total tablet.

Priority: US1999-331210 Applic. Date: 1999-07-29; US1997-964917 Applic. Date: 1997-11-05; US1995-558335 Applic. Date: 1995-11-15; US1999-311210 Applic. Date: 1999-05-13

Inventor: HUNTER EDWARD A [US]; SHERWOOD BOB E [US]; ZELEZNIK JOSEPH A [US]

Title: Gastroresistant multi-unitary pharmaceutical preparations containing piroxicam

Applicant/Assignee:

Application No.: 09/580552   Filing Date: 30/May/2000

Abstract:

The present invention relates to multi-unitary pharmaceutical preparations containing piroxicam for oral administration. Such pharmaceutical preparations are stable pellet pharmaceutical preparations containing piroxicam and they comprise an amount of active ingredient of between 5 and 50 mg, an inert core with spherical symmetry and a diameter of 600-850 mum, constituted by inert excipients, coated with an active layer containing piroxicam in micronized form and various pharmaceutically acceptable inert excipients, mixed in appropriate proportions in order to allow the adequate disaggregation of the formulations and dissolution of the active ingredient, coated in it turn with an insulating layer of a polymeric nature and soluble in water, this layer being coated finally with a gastroresistant or enteric layer of a minimum thickness of 20 mum. This invention also refers to the process for the preparation of said pharmaceutical preparations.

Priority: EP19990670011 Applic. Date: 1999-12-16

Inventor: MENDES CARLA PATRICIA GONCALVE [PT]; DE OLIVEIRA MARIA JULIA CAEIRO [PT]

Title: Crystallization of lactitol, crystalline lactitol product and use thereof

Applicant/Assignee: XYROFIN OY

Application No.: 09/646411   Filing Date: 09/Nov/2000

Abstract:

The present invention relates to a novel process for the crystallization of lactitol, to a particulate crystalline lactitol product having novel properties, to the use thereof as in foodstuffs, pharmaceuticals and oral hygiene products, as well as to special lactitol sweeteners. The process comprises: contacting a liquid containing dissolved lactitol with gas suspended fine solid particles containing microcrystalline lactitol

causing substantial removal of the solvent component of said liquid and allowing the resulting lactitol material to form an essentially solid composition of matter comprising a multitude of microcrystals of lactitol

and causing said lactitol composition to be conditioned during a further step to provide a product consisting essentially throughtout its entire structure of a multitude of microcrystals of lactitol agglomerated together in a random manner. The invention provides a crystalline lactitol product consisting essentially throughout its entire structure of a multitude of microcrystals of lactitol agglomerated together in a random manner.

Priority: FI19980000600 Applic. Date: 1998-03-18; WO1999FI00206 Applic. Date: 1999-03-17

Inventor: HEIKKILAE HEIKKI [FI]; NYGREN JOHANNA [FI]; SARKKI MARJA-LEENA [FI]; GROS HAAKAN [FI]; EROMA OLLI-PEKKA [FI]; PEARSON JULITA [GB]; PEPPER TAMMY [GB]

Title: Orthorhombic crystalline form of fluticasone propionate and pharmaceutical compositions thereof

Applicant/Assignee: SMITHKLINE BEECHAM CORPORATION

Application No.: 09/284245   Filing Date: 15/Apr/1999

Abstract:

The invention relates to a new polymorphic crystalline form of S-fluoromethyl 6alpha,9alpha-difluoro-11beta-hydroxy-16alpha-methyl-3-oxo-17alpha-propionyloxyandrosta-1,4-diene-17beta-carbothiate (fluticasone propionate). The new polymorphic crystalline form is easily handled and easily fluidised and its particle size and shape can be controlled. The invention also relates to the use of this new material in therapy, particularly in the treatment of respiratory disorders, e.g. asthma.

Priority: GB19960022173 Applic. Date: 1996-10-24; WO1997GB02929 Applic. Date: 1997-10-23

Inventor: COOPER SIMON MURRAY [GB]

Title: Benzene fused heterocyclic derivatives having thromboxane A2 receptor antagonistic activity and prostaglandin I2 Agonistic activity and application thereof

Applicant/Assignee: TORAY INDUSTRIES, INC

Application No.: 09/509909   Filing Date: 04/May/2000

Abstract:

Benzene fused derivatives represented by the following formula:having strong TXA2 receptor antagonistic action and PGI2 receptor agonistic action, and effective for treating or preventing diseases concerning TXA2.

Priority: JP19980220899 Applic. Date: 1998-08-04; WO1999JP04215 Applic. Date: 1999-08-04

Inventor: OHTAKE ATSUSHI [JP]; OHNO MICHIHIRO [JP]; HOSHI KAZUHIRO [JP]; TAKEDA TAKAHIRO [JP]; YAMADA NAOHIRO [JP]

Title: Spherical pharmaceutical granules comprising microcrystalline cellulose and a process for their production

Applicant/Assignee: NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD

Application No.: 09/626403   Filing Date: 26/Jul/2000

Abstract:

A high speed agitation granulator method of preparing a substantially spherical granule for pharmaceutical use comprising a medicament for pharmaceutical use, wherein the medicament has an aqueous solubility of 0.01 to 0.30 g/ml, which method comprises introducing a mixture of medicament and excipients comprising at least 5% crystalline cellulose into the granulator and spraying on water or a mixture of ethanol and water as binder solution

a substantially spherical granule for pharmaceutical use comprising famciclovir and 5% or more crystalline cellulose, together with an optional coating

and a sachet containing a unit dose of famciclovir in the form of such granules.

Priority: GB19950018465 Applic. Date: 1995-09-09

Inventor: AKIYAMA HIDERO [JP]; MATSUMOTO ZENE [JP]; UENO TAKASHI [JP]

Title: Herbal formulation of a combination of Piper betel and Murrya koenigii extracts for blocking 5 lipoxygenase activity

Applicant/Assignee: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH

Application No.: 09/925415   Filing Date: 10/Aug/2001

Abstract:

A pharmaceutical formulation is provided which is useful as a leukotrine synthesis and IL4 inhibitor and as a Th1 immunomodulator. The formulation comprises an effective amount of a combination of extracts and lyophilized extracts of Piper betel and Murrya koeniggi. The formulation can be formulated with pharmaceutically acceptable carriers. The formulation can be used in a method of treating humans for respiratory conditions.

Priority: WO2000IN00127 Applic. Date: 2000-12-18

Inventor: BANDYOPADHYAY SANTU [IN]; ROY KESHAB CHANDRA [IN]; ROY MITALI [IN]; PAL BIKASH CHANDRA [IN]; BHADRA RANJAN [IN]; DAS KRISHNA [IN]; BHATTACHARAYA SAMIR [IN]

Title: Pharmaceutical composition for treating viral diseases

Applicant/Assignee: UCB S.A

Application No.: 09/254548   Filing Date: 21/Apr/1999

Abstract:

Use of 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy-acetic-acid, an individual optical isomer or a pharmaceutically acceptable salt thereof as an active ingredient for the production of a pharmaceutical composition for the treatment of diseases induced by the respiratory-syncytial-virus.

Priority: EP19960870114 Applic. Date: 1996-09-11; WO1997EP04859 Applic. Date: 1997-09-08

Inventor: KOENIG BRIGITTE [DE]; RIHOUX JEAN-PIERRE [BE]; KOENIG WOLFGANG [DE]

Title: Aerosol formulations of albuterol and 1,1,1,2-tetrafluoroethane

Applicant/Assignee: SCHERING CORPORATION

Application No.: 09/651204   Filing Date: 30/Aug/2000

Abstract:

Aerosol formulations substantially free of chlorofluorocarbons, for oral and/or nasal administration are described. The formulations comprise 1,1,1,2 tetrafluoroethane, a medicament, optionally an excipient and optionally a surfactant. Methods of treatment utilizing the formulations also are described.

Priority: US1991-712789 Applic. Date: 1991-06-10

Inventor: FASSBERG JULIANNE [US]; SEQUEIRA JOEL A [US]; CHAUDRY IMTIAZ A [US]; KOPCHA MICHAEL [US]

Title: Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections

Applicant/Assignee: UMD, INC

Application No.: 09/613441   Filing Date: 11/Jul/2000

Abstract:

Devices, methods, and compositions for treating vaginal fungal, bacterial, viral and parasitic infections by intravaginal or transvaginal administration of therapeutic and/or palliative antifungal, antibacterial, antiviral or parasiticidal drugs to the vagina or to the uterus.

Priority: US1999-249963 Applic. Date: 1999-02-12; US1998-079897 Applic. Date: 1998-05-15; US19970049325P Applic. Date: 1997-06-11

Inventor: D AUGUSTINE MERIDA A [US]; LIU JAMES H [US]; HARRISON DONALD C [US]

Title: Sustained release tablet containing hydrocolloid and cellulose ether

Applicant/Assignee: NOSTRUM PHARMACEUTICALS, INC

Application No.: 09/459300   Filing Date: 10/Dec/1999

Abstract:

The present invention is directed to a solid sustained release pharmaceutical tablet for administering to a host, comprising a therapeutically effective amount of a pharmaceutically active ingredient and a sustained release carrier therefor, said sustained release carrier comprising (a) a hydrocolloid selected from the group consisting of xanthan gum, guar gum, and alginic acid or a pharmaceutically acceptable salt thereof, and (b) a cellulose ether, said hydrocolloid and cellulose ether being present in synergistic effective amounts to retard release of said pharmaceutically active ingredient, said hydrocolloid being present in amount ranging from about 0.3% to about 7.0% by weight of the tablet and said cellulose ether being present in an amount ranging from 3% to about 20% of said tablet, and said cellulose ether being present in said carrier in amounts equal to or greater than 33% by weight and said carrier being present in amounts less than 35% by weight of said tablet.

Priority: US19980111964P Applic. Date: 1998-12-11

Inventor: MULYE NIRMAL [US]; INAMDAR KAVITA [IN]

Title: QUICK RELEASE COMPOSITIONS

Applicant/Assignee: IMPLICO B.V

Application No.: 09/446957   Filing Date: 28/Feb/2000

Abstract:

A dosage form comprises a porous extrudate. The extrudate is obtained by extruding, at elevated temperature, a composition comprising a starch, water, a thermostable enzyme, and a pharmaceutically active agent. The porous extrudate is capable of disintegration when exposed to an aqueous environment.

Priority: WO1998EP04073 Applic. Date: 1998-07-01; ZA19970005853 Applic. Date: 1997-07-01

Inventor: TRUTER PATRICIA-ANN [ZA]; DILOVA EMILIA DIMITROVA [ZA]; VAN DER MERWE THILO LOTHAR [ZA]

Title: BETA-LACTAM ANTIBIOTIC-CONTAINING TABLET AND PRODUCTION THEREOF

Applicant/Assignee: FUJISAWA PHARMACEUTICAL CO., LTD

Application No.: 09/117295   Filing Date: 26/Aug/1998

Abstract:

This invention provides beta-lactam antibiotic-containing tablets capable of being orally taken either as such owing to their being small-sized, hence still easily swallowable, or, in the case of administration to the aged encountering some difficulty in swallowing, in the form of dispersions resulting from easy self-disintegration upon being dropped into water in a glass as well as a method of producing the same. The tablets of this invention comprise, on the per-tablet basis, 60-85% by weight of a beta-lactam antibiotic, 1-10% by weight of low-substituted hydroxypropylcellulose and/or crosslinked polyvinylpyrrolidone as a disintegrator, and 0.5-2% by weight of a binder. Granules to be compressed for tableting are prepared using water or an aqueous solution of ethanol or the like.

Priority: JP19960042743 Applic. Date: 1996-02-29; JP19960320264 Applic. Date: 1996-11-29; WO1997JP00509 Applic. Date: 1997-02-21

Inventor: YAMAGUCHI HISAMI [JP]

Title: Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent

Applicant/Assignee: MERCK PATENT GESELLSCHAFT MIT

Application No.: 09/622663   Filing Date: 22/Aug/2000

Abstract:

The present invention relates to an orally administrable galenic form allowing improved absorption by the transmembrane or paracellular route in the gastrointestinal tract of active ingredients which are hydrophilic or ionizable in physiol. media, comprising at least one such active ingredient, an absorption-promoting agent having an HLB>8, the the absorption-promoting agent consisting of one or more lipid substances chosen from: polysorbates

polyoxyethylene ethers

esters of polyoxyethylene and fatty acids

fatty acids

fatty alcs.

bile acids and their salts with pharmaceutically acceptable cations

esters of C1-C6 alkanol with fatty acids

esters of polyol with fatty acids, the polyol comprising from 2 to 6 hydroxyl functional groups

and polyglycolyzed glycerides

in combination with one or more pharmaceutically acceptable excipients, the pharmaceutical forms comprising captopril being excluded. A controlled-release tablet contained (1) cores contg. calcium acamprosate 50, Gelucire 44/14 10, Compritol 10, microcryst. cellulose 19, Povidone 10, and Mg stearate 1% and (2) a film-coating compn. contg. HPMC 64, PEG-4000 15, and talc 21%.

Priority: WO1999EP00994 Applic. Date: 1999-02-16; FR19980002143 Applic. Date: 1998-02-23

Inventor: SASLAWSKI OLIVIER [FR]; GIET PHILIPPE [FR]; MICHEL DOMINIQUE [FR]; HOLOT THIERRY [FR]

Title: Dry powder inhaler

Applicant/Assignee: DURA PHARMACEUTICALS, ICN

Application No.: 09/495494   Filing Date: 01/Feb/2000

Abstract:

A dry powder inhaler has a dispersion chamber containing beads. A dose of dry powder is released into the chamber, or into an inlet tangentially joining into the chamber. As the patient inhales on a nosepiece or mouthpiece, air moves circularly through the dispersion chamber to drive the beads. The beads roll, bounce, and collide repeatedly with the drug particles on the chamber surfaces or on the beads. The smaller active drug particles are separated from the larger carrier particles and from each other, and a powder aerosol is created and inhaled by the patient. The beads are preferably lightweight, so that they can be rapidly accelerated and moved, even with nominal inspiration. The flow resistance of the inhaler is also reduced via the beads, allowing greater air flow and powder dispersion, without any increased effort by the patient.

Priority:

Inventor: LIGOTKE MICHAEL [US]; GIESCHEN ANDREW W [US]; EISELE ROBERT F [US]; JACKSON THOMAS R [US]; CHEN JEFFREY [US]; GREENSPAN BERNARD [US]; WITHAM CLYDE [US]; WARD GARY [US]

Title: Plant extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis

Applicant/Assignee:

Application No.: 09/542237   Filing Date: 04/Apr/2000

Abstract:

The use of extracts from the plant Hypericum perforatum in the preparation of pharmaceutical compositions for the treatment of hepatitis C, chronic hepatitis C and related viruses, said pharmaceutical compositions comprising at least one extract of the plant Hypericum perforatum and optionally in addition, one or more pharmaceutically acceptable inactive components, selected from, carriers, coatings, diluents and adjuvants.

Priority: IL19960119833 Applic. Date: 1996-12-15; US1997-990340 Applic. Date: 1997-12-15

Inventor: LAVIE DAVID [IL]; STEINBECK-KLOSE ANNE [DE]

Title: Extracts of hypericum perforatum and formulations containing them

Applicant/Assignee: INDENA S.P.A

Application No.: 09/725938   Filing Date: 30/Nov/2000

Abstract:

The invention relates to a method for extracting Hypericum perforatum (St.-Johns-wort) by fractioning water-alcohol, alcohol extracts of the plant with esters of water-immiscible C1-C5 alcohols. The extracts have high activity and are stable over time. The invention also relates to formulations containing the extract.

Priority: WO1999EP03881 Applic. Date: 1999-06-04; IT1998MI01311 Applic. Date: 1998-06-10

Inventor: BOMBARDELLI EZIO [IT]; GABETTA BRUNO [IT]; MORAZZONI PAOLO [IT]

Title: Phospholipid complexes of proanthocyanidin A2 as antiatherosclerotic agents

Applicant/Assignee: INDENA S.P.A

Application No.: 09/857804   Filing Date: 11/Jun/2001

Abstract:

The present invention relates to complexes of proanthocyanidin A2 and one or more phospholipids, pharmaceutical compositions containing the complex of proanthocyanidin A2 and one or more phospholipids, and methods of treating or preventing atherosclerosis and myocardial and cerebral infarction in a patient by administering the complex of proanthocyanidin A2 and one or more phospholipids, as well as methods of forming such complexes

Priority: WO1999EP09854 Applic. Date: 1999-12-13; IT1998MI02732 Applic. Date: 1998-12-18

Inventor: BOMBARDELLI EZIO [IT]; MORAZZONI PAOLO [IT]

Title: Biodegradable sustained-release alginate gels

Applicant/Assignee: AMGEN INC

Application No.: 09/080832   Filing Date: 18/May/1998

Abstract:

The present invention relates to sustained-release formulations using biodegradable alginate delayed gels or particles and methods thereof.

Priority:

Inventor: GOLDENBERG MERRILL SEYMOUR [US]; GU JIAN HUA [US]

Title: Substituted N-benzylindol-3-ylglyoxylic acid derivatives having antitumor action

Applicant/Assignee: ZENTARIS AG

Application No.: 09/736431   Filing Date: 15/Dec/2000

Abstract:

The invention relates to novel, substituted N-benzyl-indol-3-ylglyoxylic acid derivatives of the following formula and their use for the treatment of oncosesThe invention further relates to their physiologically tolerable acid addition salts and if possible their N-oxides. In addition, the invention relates to pharmaceutical preparations containing at least one of the compounds of the abovementioned formula or their salts or N-oxides with physiologically tolerable inorganic or organic acids and, if appropriate, pharmaceutically utilizable vehicles and/or diluents or excipients and also administration forms of the compounds of the abovementioned formula containing at least one of the compounds of this formula or their salts in the form of tablets, coated tablets, capsules, solutions for infusion or ampoules, suppositories, patches,

powder preparations which can be employed by inhalation, suspensions, creams and ointments

Priority: DE19991062300 Applic. Date: 1999-12-23

Inventor: GUNTHER ECKHARD [DE]; EMIG PETER [DE]; REICHERT DIETMAR [DE]; LE BAUT GUILLAUME [FR]; NICKEL BERND [DE]; BACHER GERALD [DE]

Title: PEG-LHRH analog conjugates

Applicant/Assignee: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V

Application No.: 09/698134   Filing Date: 30/Oct/2000

Abstract:

PEG-LHRH analog conjugates, where a PEG moiety is covalently bound to a serine residue of a LHRH analog either directly or via a bifunctional linker molecule, such as an amino acid, and methods for producing these conjugates are provided in the present invention. Also provided are a pharmaceutical composition and a method for treating pathologies in which LHRH analog administration is beneficial.

Priority: WO1999US09160 Applic. Date: 1999-04-28; US19980083340P Applic. Date: 1998-04-28

Inventor: EL-TAYAR NABIL [US]; ZHAO XUAN [US]; BENTLEY MICHAEL D [US]

Title: Device and method for treating urinary incontinence in females

Applicant/Assignee: ENHANCE PHARMACEUTICALS, INC

Application No.: 09/531856   Filing Date: 21/Mar/2000

Abstract:

Provided herein is a novel and useful device and method for locally delivering and controllably releasing oxybutynin in the cervical region of a female. A device of the invention comprises a ring comprising trifluoropropylmethyl/dimethyl siloxane elastomer. A pharmaceutical composition comprising oxybutynin and an excipient is placed within a bore located in the ring, wherein the bore runs from the surface of the ring into the ring. The ring has a sufficient size such that it can be inserted into the vaginal canal of a female. A cap comprising is placed over the bore at the surface of the ring in order to contain the pharmaceutical composition within the bore. When the ring is inserted into the vaginal canal, the trifluoropropylmethyl/dimethyl siloxane elastomer controllably releases and locally delivers a therapeutically effective amount of oxybutynin to the detrusor muscle to treat the female's urinary incontinence.

Priority:

Inventor: MAHASHABDE ANU [US]; KAY MARTHA FRANCINE [US]; KOELMEL DONALD F [US]

Title: Controlled release oral dosage for suitable for oral administration

Applicant/Assignee: NORSTRUM PHARMACEUTICALS, INC

Application No.: 09/650837   Filing Date: 30/Aug/2000

Abstract:

The present invention is directed to a pharmaceutical composition, preferably in the form of a tablet comprising a therapeutically effective amount of a medicament in a carrier comprising a water insoluble polymer and a water-insoluble inorganic salt.

Priority: US19990152114P Applic. Date: 1999-09-02

Inventor: MULYE NIRMAL [US]

Title: Paroxetine maleate polymorph and pharmaceutical compositions containing it

Applicant/Assignee: MEDICHEM, S.A

Application No.: 09/743047   Filing Date: 04/Jan/2001

Abstract:

The form B of paroxetine maleate polymorph is characterized by determined data of X ray diffraction: it has a chemical stability which is superior to that of the form A of paroxetine maleate. This superior stability enables to use the new polymorph for the fabrication of medicaments intended to the treatment of troubles related to dysfunctions of the central nervous system. The process for producing the paroxetine maleate comprises the preparation of paroxetine maleate solution and a consequent precipitation.

Priority: ES19980001426 Applic. Date: 1998-07-07; WO1999ES00209 Applic. Date: 1999-07-05

Inventor: STAMPA DIEZ DEL CORRAL ALBERTO [ES]; BOSCH LLADO JORDI [ES]; MOLINS GRAU ELIAS [ES]; ONRUBIA MIGUEL MARIA DEL CARME [ES]

Title: Treatment of alzheimer disease by modulation of synapsins

Applicant/Assignee: THE ROCKEFELLER UNIVERSITY BRIGHAN AND WOMEN'S HOSPITAL

Application No.: 08/644433   Filing Date: 13/May/1996

Abstract:

The role of synapsin II in both the reformation and the maintenance of synaptic connections in cultured hippocampal neurons can be the basis of therapy for neurodegenerative disorder, particularly Alzheimer disease, which involve the disruption of synapses. When synapsin II expression in neurons is blocked by antisense synapsin II oligonucleotides, the ability of hippocampal neurons to reform as well as to maintain synapses is severely disrupted. Antisense suppression of synapsin II after axon formation but immediately before synaptogenesis prevents synapse formation. Suppression of synapsin II after synaptogenesis disrupts the majority of existing synapses. Re-expression of synapsin II in synapsin deficient neurons achieved after removing the antisense oligonucleotides leads to the re-establishment of synaptic connections, providing direct evidence that synapsin II is required for the maintenance and/or restoration of synapses. Thus, therapeutic methods based on the reformation and the maintenance of synapses, including delivery of the synapsin cDNAS or proteins into the patient's nervous system, use of the synapsin cDNAS to promote the synapse forming ability of cells for grafting, and use of agents that increase the expression of, enhancing the activity of, or mimic the activity of, the endogenous synapsins, can provide treatment of neurodegenerative disorders.

Priority: US1995-440561 Applic. Date: 1995-05-12

Inventor: HAN HUI-QUAN [US]; GREENGARD PAUL [US]; KOSIK KENNETH S [US]; FERREIRA ADRIANA [US]

Title: USE OF TRIAQUA-mu3-OXOHEXAKIS-mu-PROPIONATOTRICHROMIUM(1+), [CR3O(O2CCH2CH3)6(H2O)3]+, AS A NUTRITIONAL SUPPLEMENT OR IN TREATMENT OF MEDICAL CONDITIONS

Applicant/Assignee: UNIVERSITY OF ALABAMA

Application No.: 09/760856   Filing Date: 17/Jan/2001

Abstract:

Methods of using the chromium(III) complex represented by the formula [Cr3O(O2CCH2CH3)6(H2O)3]+ as a nutritional supplement, and for treating medical disorders associated with chromium deficiency. Nutritive and pharmaceutical compositions containing this chromium(III) complex are also provided.

Priority: US1998-163005 Applic. Date: 1998-09-30

Inventor: VINCENT JOHN B [US]; DAVIS CATHERINE M [US]

Title: Potassium (-)-hydroxycitric acid methods for pharmaceutical preparations for stable and controlled delivery

Applicant/Assignee:

Application No.: 09/661665   Filing Date: 14/Sep/2000

Abstract:

A method for making the potassium and sodium salts of (-)-hydroxycitric acid and mixtures thereof workable, non-hygroscopic and non-reactive in acidic media by encasement in hydrophobic and acidophobic polymers. The calcium and magnesium salts of (-)-hydroxycitric acid likewise can be rendered nonreactive in acidic media. The resulting products are suitable for tableting, encapsulation and use in other dry media for weight loss, appetite suppression, improvements in fat metabolism and postprandial lipemia and other pharmaceutical purposes. Further, the products of this invention can be made nonreactive as components of acidic liquid drink mixes and snack bars and can be used in the production of controlled release administration formats.

Priority: US19990153920P Applic. Date: 1999-09-14

Inventor: CLOUATRE DALLAS L [US]; DUNN JAMES M [US]

Title: Functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration

Applicant/Assignee: EURAND PHARMACEUTICALS LTD

Application No.: 09/506051   Filing Date: 17/Feb/2000

Abstract:

The present invention provides taste-masked microcapsules of Linezolid or the like (any member of the orally effective oxazolidinone or macrolide antibiotics), suitable for oral administration as a suspension, a fast-disintegrating, effervescent or chewable tablet, and more specifically relates to such oral dosage forms in which the bitter taste of Linezolid contained therein is masked by a combination of microencapsulation by solvent coacervation and subsequent functional membrane coating on said microcapsules. The taste-masked granules thus obtained release less than 5%, most preferably less than 3%, at a pH of 4.0 to 6.0 (pH of the saliva) but rapidly release (as a burst) at pHs of the upper intestinal tract. The taste-masked granules are optionally blended with other pharmaceutically acceptable excipients and filled into unit dose containers or compressed into fast-disintegrating/effervescent/chewable tablets. The contents of the Linezolid unit dose containers are suspended in an aqueous medium prior to oral administration to pediatric and geriatric patients, who are unwilling and/or find it difficult to swallow Linezolid tablets. In contrast, fast-disintegrating tablets on administration without water rapidly disperse into taste masked granules in the mouth.

Priority: US20000177233P Applic. Date: 2000-01-20

Inventor: PERCEL PHILLIP J [US]; VISHNUPAD KRISHNA S [US]; VENKATESH GOPI M [US]

Title: Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents

Applicant/Assignee: AMGEN INC

Application No.: 09/221178   Filing Date: 23/Dec/1998

Abstract:

The present invention relates generally to the development of pharmaceutical compositions which provide for sustained release of biologically active polypeptides. More specifically, the invention relates to the use of pH/thermosensitive biodegradable hydrogels, consisting of a A-B di block or A-B-A tri block copolymer of poly(d,l- or l-lactic acid) (PLA) or poly(lactide-co-glycolide) (PLGA) (block A) and polyethylene glycol (PEG) (block B), with ionizable functional groups on one or both ends of the polymer chains, for the sustained delivery of biologically active agents.

Priority:

Inventor: SHAH SUBODH [US]; DAI WEIGUO [US]

Title: Compositions and methods comprising morphine gluconate

Applicant/Assignee: NASTECH PHARMACEUTICAL COMPANY, INC

Application No.: 09/626942   Filing Date: 19/Oct/2000

Abstract:

The present invention relates to a pharmaceutical composition which includes morphine gluconate or chemical equivalent thereof. In one embodiment, the present invention includes a method of making morphine gluconate or chemical equivalent thereof by mixing morphine sulfate with sodium gluconate. The present invention also includes a method for eliciting an analgesic or anesthetic response in a mammal which includes administering a therapeutically effective amount of a pharmaceutical composition including morphine gluconate or chemical equivalent thereof.

Priority: US1999-334344 Applic. Date: 1999-06-16

Inventor: BEHL CHARANJIT R [US]; ROMEO VINCENT D [US]; SILENO ANTHONY P [US]

Title: PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION, COMPRISING AN ACTIVE SUBSTANCE AND A CYCLODEXTRIN

Applicant/Assignee: UCB, S.A

Application No.: 09/446735   Filing Date: 23/Dec/1999

Abstract:

The invention concerns pharmaceutical compositions for oral administration, comprising an active substance belonging to the family of substituted benzhydrylpiperazines and at least a cyclodextrin.

Priority: BE19970000572 Applic. Date: 1997-07-03; WO1998BE00100 Applic. Date: 1998-07-02

Inventor: FANARA DOMENICO [BE]; BERWAER MONIQUE [BE]; NOLF PHILIPPE [BE]; VRANCKX HENRI [BE]; DELEERS MICHEL [BE]

Title: Microgranules containing cisplatin

Applicant/Assignee: LABORATOIRES DES PRODUITS ETHIQUES ETHYPHARM

Application No.: 09/367270   Filing Date: 08/Sep/1999

Abstract:

The invention concerns an oral formulation of cisplatin, in the form of controlled-release microgranules, and its method of formulation by grossing in an aqueous medium. The invention also concerns a pharmaceutical preparation containing controlled-release cisplatin microgranules, optionally combined with an anticancer agent, to be used in anticancer therapy. The invention further provides a use for these microgranules for making orally administered medicaments for polychemotherapy or in combination with radiotherapy.

Priority: FR19970001545 Applic. Date: 1997-02-11; WO1998FR00251 Applic. Date: 1998-02-10

Inventor: DEBREGEAS PATRICE [FR]; LEDUC GERARD [FR]; OURY PASCAL [FR]; SUPLIE PASCAL [FR]

Title: GRF analogs with increased biological potency

Applicant/Assignee: THERATECHNOLOGIES INC

Application No.: 09/389486   Filing Date: 03/Sep/1999

Abstract:

The present invention relates to chimeric fatty body-GRF analogs with increased biological potency, their application as anabolic agents and in the diagnosis and treatment of growth hormone deficiencies. The chimeric fatty body-GRF analogs include an hydrophobic moiety (tail), and can be prepared, either by anchoring at least one hydrophobic tail to the GRF, in the chemical synthesis of GRF. The GRF analogs of the present invention are biodegradable, non-immunogenic and exhibit an improved anabolic potency with a reduced dosage and prolonged activity.

Priority: US1998-148982 Applic. Date: 1998-09-08; US1996-702113 Applic. Date: 1996-08-23; US1996-702114 Applic. Date: 1996-08-23; US1996-651645 Applic. Date: 1996-05-22; US1995-453067 Applic. Date: 1995-05-26

Inventor: GRAVEL DENIS [CA]; HABI ABDELKRIM [CA]; BRAZEAU PAUL [CA]

Title: Solid preparation

Applicant/Assignee: DAINIPPON PHARMACEUTICAL CO., LTD

Application No.: 09/661577   Filing Date: 14/Sep/2000

Abstract:

The present invention provides a solid preparation comprising a crystal of [3-[(2R)-[[(2R)-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1H-indol-7-yloxy]acetic acid (Compound A), especially a crystal of Compound A having a particle size of not larger than 100 mum at the cumulative weight distribution value of 50%, and not larger than 200 mum at the cumulative weight distribution value of 95%, preferably a solid preparation having the excellent stability and the content uniformity of Compound A, which is prepared by preparing granules of the crystal of Compound A with fillers, disintegrants and binders, and then followed by mixing said granules with external excipients.

Priority: JP19990339547 Applic. Date: 1999-11-30

Inventor: IWATA MOTOKAZU [JP]; KURIYAMA TERUAKI [JP]; FUJITA MEGUMI [JP]; FUJIWARA KEIICHI [JP]; KATO SHIRO [JP]; HARADA HIROSHI [JP]; FUJII AKIHITO [JP]; ODAI OSAMU [JP]; KAWASHIMA HITOSHI [JP]

Title: Process for the preparation of solid oral dosage forms comprising alendronic acid

Applicant/Assignee: UNIPHARM LTD

Application No.: 09/486425   Filing Date: 25/Feb/2000

Abstract:

The present invention relates to a process for preparing solid oral dosage forms e.g. tablets,capsules,coated tablets/capsules, etc. comprising as active ingredient 4-amino-1-hydroxybutylidene-1, 1-biphosphonic acid or one of its pharmaceutically acceptable salts ("Alendronic acid"). It comprises the free acid or one of its pharmaceutically acceptable salts. The process is characterized by granulating pharmaceutical carriers with an aqueous solution of Alendronic acid which is solubilized with the aid of alkaline hydroxides or alkaline salts. The oral dosage forms obtained by this process are less irritating to the digestive system than oral dosage forms obtained by conventional processes. The present invention also relates to tablets and to capsules prepared by said process.

Priority: IL19970121623 Applic. Date: 1997-08-26; WO1998IL00389 Applic. Date: 1998-08-18

Inventor: TOMER ZEVULUN [IL]; TOMER RON [IL]

Title: Solid compositions suitable for oral administration containing non-hydroscopic salts of L-carnitine and alkanoyl L-carnitines

Applicant/Assignee: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A

Application No.: 09/740786   Filing Date: 21/Dec/2000

Abstract:

Non-hygrocopic salts of L-carnitine and of the lower alkanoyl L-carnitines with pamoic acid are described, which are used to prepare solid compositions suitable for oral administration. Solid compositions containing such salts are also described.

Priority: IT1998RM00445 Applic. Date: 1998-07-03; WO1999IT00202 Applic. Date: 1999-07-02

Inventor: SANTANIELLO MOSE [IT]; SCAFETTA NAZARENO [IT]; TINTI MARIA ORNELLA [IT]

Title: Soft chewable tablets having convexed shaped face surfaces

Applicant/Assignee: MCNEIL-PPC, INC

Application No.: 09/880179   Filing Date: 13/Jun/2001

Abstract:

The present invention relates to a compressed, chewable tablet containing at least one active ingredient, a water-disintegratable, compressible carbohydrate and a binder. These components are dry blended and compressed into convex-shaped tablet having a hardness of about 2 to about 11 kp/cm2 and friability less than 1%.

Priority: US1998-135723 Applic. Date: 1998-08-18

Inventor: ROBINSON RONNI L [US]; DAMON JAMES R [US]; MOSSOP JAMES R [US]; PALMER MICHAEL D [US]

Title: Pharmaceutical excipient having improved compressibility

Applicant/Assignee: EDWARD MENDELL CO., INC

Application No.: 09/384130   Filing Date: 27/Aug/1999

Abstract:

A microcrystalline cellulose-based excipient having improved compressibility, whether utilized in direct compression, dry granulation or wet granulation formulations, is disclosed. The excipient is an agglomerate of microcrystalline cellulose particles and from about 0.1% to about 20% silicon dioxide particles, by weight of microcrystalline cellulose, wherein the microcrystalline cellulose and silicon dioxide are in intimate association with each other. The silicon dioxide utilized in the novel excipient has a particle size from about 1 nanometer to about 100 microns. Most preferably, the silicon dioxide is a grade of colloidal silicon dioxide. An extra low moisture excipient is provided which exhibits improved compressibility as compared to conventional microcrystalline cellulose, while providing a moisture content of from about 0.5 to 2.5% LOD, preferably between about 0.5 and about 1.8%, more preferably between 0.8 and 1.5%, and most preferably between about 0.8 and about 1.2 %.

Priority: US1997-992073 Applic. Date: 1997-12-17; US1996-724613 Applic. Date: 1996-09-30; US1995-370576 Applic. Date: 1995-01-09

Inventor: STANIFORTH JOHN N [GB]; SHERWOOD BOB E [US]; HUNTER EDWARD A [US]

Title: Anticancer compounds and methods

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Application No.: 09/373694   Filing Date: 13/Aug/1999

Abstract:

The testing of tumor cells, including human tumors capable of metastases, in assays employing fibronectin-depleted substrates is described. Ex vivo induction of cells, including biopsied human cells, is performed with invasion-inducing agents. Additionally, anti-cancer chemotherapeutics are described. Specifically, chemotherapeutic agents which have anti-metastatic and anti-growth properties are described including non-peptide compositions of matter.

Priority: US1997-915189 Applic. Date: 1997-08-20; US1996-754322 Applic. Date: 1996-11-21

Inventor: LIVANT DONNA [US]

Title: Process for manufacturing bite-dispersion tablets

Applicant/Assignee: SMITHKLINE BEECHAM CORPORATION

Application No.: 09/581334   Filing Date: 08/Jun/2000

Abstract:

This invention relates to a method for the manufacture of Bite-dispersion tablets which disperse easily and quickly in the oral cavity, after a gentle bite, without the aid of water, and if necessary includes masking the bitter taste of medicaments. The process comprises preparing a dry granulation of one or more of medicaments blended with suitable excipients, flavors and a combination of a waxy material and phospholipid (BMI-60) or an intense sweetener derived from fruit flavonoids (Neohesperidine) for taste-masking and compressing into tablets which can be packaged in bottles or blisters using conventional equipment.

Priority: US19970068258P Applic. Date: 1997-12-19; WO1998US27061 Applic. Date: 1998-12-17

Inventor: VENKATESH GOPADI M [US]; PALEPU NAGESWARA R [GB]

Title: Pharmaceutical composition with low toxicity for anti-inflammation and anti-exudation

Applicant/Assignee: SHANDONG LUYE PHARMACEUTICAL CO., LTD

Application No.: 09/787338   Filing Date: 16/Mar/2001

Abstract:

The present invention relates to a pharmaceutical composition with low toxicity for anti-inflammatory and anti-exudative which contains as active ingredients escin with general formula I and escin with general formula II as well as pharmaceutically acceptable carrier or excipient. In comparison with ESCIN, this pharmaceutical composition possesses the same anti-inflammatory and anti-exudative activity, but both toxicity and irritation lower remarkably.

Priority: WO1999CN00222 Applic. Date: 1999-12-30

Inventor: LIU WANHUI [CN]; ZHANG QINGCHUN [CN]; LI SHIXU [CN]; SU KAJIA [CN]; LIU SHUYAN [CN]; ZHU FABING [CN]

Title: Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates

Applicant/Assignee: TEVA PHARMACEUTICAL INDUSTRIES, LTD

Application No.: 09/770898   Filing Date: 26/Jan/2001

Abstract:

The present invention provides compacted pharmaceutical composition for oral administration to a patient which expands upon contact with gastric fluid to retain a dosage form in the patient's stomach for an extended period of time, the formulation comprising a non-hydrated hydrogel, a superdisintegrant and tannic acid. The present invention further provides a pharmaceutical dosage form containing an active ingredient, and the compacted pharmaceutical composition. The invention further provides a dosage form suitable for delivering a therapeutic bis-phosphonate such as alendronate to the stomach of a patient over and extended period.

Priority: US20000213832P Applic. Date: 2000-06-23; US20010260438P Applic. Date: 2001-01-09

Inventor: FLASHNER-BARAK MOSHE [IL]; ROSENBERGER VERED [IL]; DAHAN MAZAL [IL]; LERNER YITZHAK [IL]

Title: Medicaments containing doxazosin mesylate of crystalline modification D

Applicant/Assignee: CHEMISCHE FABRIK BERG GMBH

Application No.: 09/936792   Filing Date: 18/Sep/2001

Abstract:

Drugs comprising modification D of doxazosin mesylate are described. They are suitable for treating high blood pressure.

Priority: DE19991012573 Applic. Date: 1999-03-19; WO2000EP01938 Applic. Date: 2000-03-06

Inventor: THYES MARCO [DE]; EINIG HEINZ [DE]; KLEIN PETER [DE]; HIX DIETER [DE]

Title: Aerosol formulations and method

Applicant/Assignee: SMITHKLINE BEECHAM CORPORATION

Application No.: 09/467486   Filing Date: 20/Dec/1999

Abstract:

A hand held apparatus and method for creating an aerosolized mist of particles is described. The apparatus comprises a high pressure vessel containing a solution or suspension of the substance to be aerosolized in a high pressure liquefied gas, a manually actuatable valve and a spray nozzle. The high pressure liquefied gas is in a sub-critical state.

Priority: GB19950007768 Applic. Date: 1995-04-13

Inventor: HISCOCKS PETER GERARD [GB]; GEE DAVID LAURENCE [GB]

Title: Taste masked pharmaceutical liquid formulations

Applicant/Assignee: ORTHO-MCNEIL PHARMACEUTICAL, INC

Application No.: 09/598157   Filing Date: 21/Jun/2000

Abstract:

A liquid composition for oral administration comprising a pharmaceutically active medicament coated with a taste masking effective amount of a polymer blend of (a) dimethylaminoethyl methacrylate and neutral methacrylic acid ester (MM/MAE) and (b) a cellulose ester, in an aqueous vehicle, wherein the polymer weight ratio of the cellulose ester to the MM/MAE is about 40:60 to about 90:10, preferably about 60:40. The liquid composition utilizes a "reverse enteric coating" which is soluble in the acid pH's of the stomach, generally about 1.0 to 4.0, but relatively insoluble at the non-acidic pH's of the mouth. The coatings provide for rapid release and absorption of the drug, which is generally desirable in the case of liquid dosage forms.

Priority: US19990143019P Applic. Date: 1999-07-09

Inventor: YU DANNY [US]; ROCHE EDWARD [US]

Title: MIXTURE OF PRIMARY FATTY ACIDS OBTAINED FROM SUGAR CANE WAX

Applicant/Assignee: LABORATORIOS DALMER SA

Application No.: 09/402292   Filing Date: 19/Jan/2000

Abstract:

A new natural mixture of primary fatty acids of high molecular weight ranging from 24 to 38 carbon atoms, especially those ranging between 26 and 36 carbon atoms and more especially those of straight chain of 26, 28, 29, 30, 31, 32, 33, 34, 35 and 36 carbon atoms. This mixture has a relative composition of each fatty acid that is highly reproducible batch to batch and it is extracted from sugar cane (Saccharum officinarum, L.) wax. This mixture of fatty acids has specific pharmacological properties that supports its use as an active component of pharmaceutical formulations used as hypocholesterolemic and against hypercholesterolaemia type II, as antiplatelet, anti-thrombotic and anti-ischemic. This mixture of primary fatty acids is also effective in the inhibition of the development of gastric ulcers induced by different agents.

Priority: CU19970000035 Applic. Date: 1997-04-02; WO1998IB00870 Applic. Date: 1998-04-01

Inventor: GONZALES BRAVO LUIS [CU]; MARRERO DELANGE DAVID [CU]; LAGUNA GRANJA ABILO [CU]; MAS FERREIRO ROSA MARIA [CU]; DE LOURDES ARRUZAZABALA VALMAN [CU]; CARBAJAL QUINTANA DAYSI [CU]; CORA MEDINA MIRIAN [CU]; MENENDEZ SOTO DEL VALLE ROBERT [CU]

Title: Substituted benzimidazole dosage forms and method of using same

Applicant/Assignee: THE CURATORS OF THE UNIVERSITY OF MISSOURI

Application No.: 09/481207   Filing Date: 11/Jan/2000

Abstract:

There is provided a solid pharmaceutical composition in a dosage form that is not enteric-coated, having active ingredients including a non-enteric coated proton pump inhibitor and at least one buffering agent. The proton pump inhibitor is omeprazole, lansoprazole, rabeprazole, esomeprazole, pantoprazole, pariprazole, and leminoprazole, or an enantiomer, isomer, derivative, free base, or salt thereof, in an amount of approximately 5 mg to approximately 300 mg

and the buffering agent is in an amount of approximately 0.1 mEq to approximately 2.5 mEq per mg of proton pump inhibitor. The dosage form includes a suspension tablet, a chewable tablet, an effervescent powder, or an effervescent tablet. Also provided is a method for treating an acid-related gastrointestinal disorder in a subject in need thereof by administering to the subject a solid pharmaceutical composition.

Priority: US1998-183422 Applic. Date: 1998-10-30; US1996-680376 Applic. Date: 1996-07-15; US19960009608P Applic. Date: 1996-01-04

Inventor: PHILLIPS JEFFREY OWEN [US]

Title: Osmotic device within an osmotic device

Applicant/Assignee: OSMOTICA CORP

Application No.: 09/755827   Filing Date: 04/Jan/2001

Abstract:

The delivery devices described herein are capable of delivering one or more active substances by osmotic pumping through preformed passageways. An osmotic device according to the invention includes a first osmotic device enclosed within a second osmotic device. In some embodiments, the semipermeable membrane of one or both of the osmotic devices completely dissolves or degrades during use. This delivery device can include an immediate release outer coat.

Priority: US20000176081P Applic. Date: 2000-01-14

Inventor: FAOUR JOAQUINA [AR]; COPPARI MARCELO A [AR]

Title: Use of a farnesyl transferase inhibitor in the manufacture of a medicament for local administration to the vascular wall in the prevention of restenosis

Applicant/Assignee: UNIVERSITY OF STRATHCLYDE

Application No.: 09/674584   Filing Date: 21/Dec/2000

Abstract:

The present invention relates to the prevention of restenosis of vascular passages following surgical removal of obstructions, by means of local administration of farnesyl transferase inhibitors to the vascular wall. This allows effective use of particularly low dosages with minimal side effects.

Priority: GB19980009889 Applic. Date: 1998-05-11; WO1999GB01266 Applic. Date: 1999-05-11

Inventor: WAINWRIGHT CHERRY LINDSEY [GB]; WADSWORTH ROGER MARTIN [GB]; PYNE NIGEL JOHN [GB]; PYNE SUSAN [GB]; WORK LORRAINE MARGARET [GB]

Title: Controlled onset and sustained release dosage forms and the preparation thereof

Applicant/Assignee:

Application No.: 09/358732   Filing Date: 21/Jul/1999

Abstract:

A pharmaceutical composition for controlled onset and sustained release of an active ingredient, said composition comprising:(i) a core comprising:(a) an active ingredient

(b) a hydrophilic carrier

(c) a hydrodynamic diffusion enhancer

and optionally(d) conventional pharmaceutically acceptable excipients selected from the group consisting of binders, fillers and lubricants and combinations thereof

and(ii) a functional coating membrane surrounding said core.

Priority:

Inventor: CHHABRA HARINDERPAL [US]; SARKAR SHYAMAL K [US]

Title: Coloring substance composition and a method of manufacturing same

Applicant/Assignee: CHR. HANSEN A/S

Application No.: 09/555738   Filing Date: 20/Jul/2000

Abstract:

A composition comprising coloring substance bodies that are at least partially coated with beet pectin, chicory pectin and/or Jerusalem artichoke pectin or other pectin types having a high degree of acetylation. The composition which may be water dispersible is useful for preparation of health improving products and/or coloring products for use in the coloring of edible products including food products and nutraceuticals, and for coloring of pharmaceutical products.

Priority: WO2000DK00270 Applic. Date: 2000-05-18; US1999-315955 Applic. Date: 1999-05-21

Inventor: KOEHLER KLAUS [DK]; JACOBSEN SOEREN JAN [DK]; SOENDERGAARD CLAUS [DK]; KENSOE MARTIN [DK]

Title: Pharmaceutical composition comprising entacapone, levodopa, and carbidopa

Applicant/Assignee: ORION CORPORATION

Application No.: 09/605529   Filing Date: 29/Jun/2000

Abstract:

An oral solid fixed dose composition comprising pharmacologically effective amounts of entacapone, levodopa, and carbidopa, or pharmaceutically acceptable salts or hydrates thereof, and comprising at least one pharmaceutically acceptable excipient. The composition can be used, e.g., for the treatment of Parkinson's disease.

Priority: FI19990001485 Applic. Date: 1999-06-30

Inventor: VIRKKI MATTI [FI]; VAHERVUO KARI [FI]; RITALA MARJA [FI]; PARTANEN MARJA [FI]; NISKANEN MERVI [FI]; LINTULAAKSO JARMO [FI]; LAAKSONEN MARJA [FI]; KERVINEN LASSE [FI]; KALLIOINEN SARI [FI]

Title: Non-chlorofluorocarbon aerosol formulations

Applicant/Assignee: SCHERING CORPORATION

Application No.: 08/157188   Filing Date: 09/Dec/1993

Abstract:

Aerosol formulations substantially free of chlorofluorocarbons, for oral and/or nasal administration, are described. The formulations comprise 1,1,1,2-tetrafluoroethane, a medicament, optionally an excipient and optionally a surfactant. Methods of treatment using the formulations also are described.

Priority: WO1992US04618 Applic. Date: 1992-06-08; US1991-712789 Applic. Date: 1991-06-10

Inventor: FASSBERG JULIANNE [US]; SEQUEIRA JOEL A [US]; CHAUDRY IMTIAZ A [US]; KOPCHA MICHAEL [US]

Title: Effervescent drug delivery system for oral administration

Applicant/Assignee: CIMA LABS INC

Application No.: 10/021486   Filing Date: 29/Oct/2001

Abstract:

The pharmaceutical compositions of the present invention comprise orally administerable dosage forms that use effervescence as a penetration enhancer for drugs known, or suspected, of having poor bioavailability. Effervescence can occur in the stomach, once the tablet or other dosage form is ingested. In addition to effervescence in the stomach, or as alternative technique, by the use of appropriate coatings and other techniques, the effervescence can occur in other parts of the gastrointestinal tract, including, but not limited to, the esophagus, duodenum, and colon. The site of effervescence and drug release is chosen to correspond with the segment of the gastrointestinal tract displaying maximal absorption of the formulated drug, or to gain some other therapeutic advantage.

Priority: US2000-613270 Applic. Date: 2000-07-10; US1999-302105 Applic. Date: 1999-04-29; US19980083391P Applic. Date: 1998-04-29

Inventor: PATHER S INDIRAN [US]; ROBINSON JOSEPH R [US]; EICHMAN JONATHAN D [US]; KHANKARI RAJENDRA K [US]; HONTZ JOHN [US]; GUPTE SANGEETA V [US]

Title: Sustained release pharmaceutical matrix tablet of pharmaceutically acceptable salts of diclofenac and process for preparation thereof

Applicant/Assignee:

Application No.: 09/945056   Filing Date: 31/Aug/2001

Abstract:

The present invention provides a novel sustained release composition and method for making such a composition of diclofenac and its pharmaceutically acceptable salts. The composition of the present invention provides a sustained release formulation of diclofenac and pharmaceutically acceptable salts thereof which is suitable for once daily administration and provides controlled and long lasting in vivo release. The composition comprises: (a) about 5-25% by weight of hydroxyethyl cellulose

(b) about 5-75% by weight of lactose

(c) about 0-3% by weight of silicone dioxide

(d) about 0.5-5% by weight of PVP

(e) about <3% by weight of talc

and f) about <3% by weight of magnesium stearate.

Priority: US1998-054942 Applic. Date: 1998-04-03; US19970036550P Applic. Date: 1997-04-04

Inventor: ODIDI ISA [CA]; ODIDI AMINA [CA]

Title: PHARMACEUTICAL COMPOSITIONS FOR TOPICAL USE CONTAINING HYALURONIC ACID AND ITS DERIVATIVES

Applicant/Assignee: FIDIA ADVANCED BIOPOLYMERS S.R.L

Application No.: 09/290873   Filing Date: 14/Apr/1999

Abstract:

The present invention is drawn to a pharmaceutical composition, comprising a pharmaceutically effective amount of an acidic polysaccharide and/or a derivative thereof, a gaseous vehicle, and a pharmaceutically acceptable carrier or excipient. Said acidic polysaccharide or derivative thereof can be hyaluronic acid, a pharmaceutically acceptable salt of hyaluronic acid, a partial or total ester of hyaluronic acid with an alcohol, a partial or total intermolecular ester of hyaluronic acid, a partial or total intramolecular ester of hyaluronic acid, a cross-linked ester of hyaluronic acid, an alginic acid ester, an ester of carboxymethylcellulose, an ester of carboxymethylchitin, an ester of carboxymethyl starch, a gellan ester, a cross-linked gellan ester, a pectic acid ester, and a pectinic acid ester.

The composition can contain one or more topical drugs, and can be in the form of an aerosol or liquid spray, a foam, or a dry spray. The composition is useful in the treatment of a variety of pathological situations requiring the acceleration of tissue repair, for example in the treatment of burns, sores, ulcerations, and wounds. Also provided is a therapeutic method, comprising topically administering a pharmaceutical composition comprising a pharmaceutically effective amount of an acidic polysaccharide and/or a derivative thereof in association with a gaseous vehicle and a pharmacologically acceptable excipient, and optionally, one or more topical drugs.

Priority: WO1994EP02536 Applic. Date: 1994-07-29; IT1993PD00165 Applic. Date: 1993-07-30; US1996-591673 Applic. Date: 1996-04-17

Inventor: BENEDETTI LUCA [IT]; CALLEGARO LANFRANCO [IT]

Title: Anti-inflammatory pharmaceutical formulations

Applicant/Assignee: NORTON HEALTHCAR LTD NORTON HEALTHCARE LTD

Application No.: 10/045406   Filing Date: 19/Nov/2001

Abstract:

A pharmaceutical dosage form comprising a tablet containing a non-steroidal anti inflammatory drug and misoprostol, wherein the non-steroidal anti inflammatory drug is in the form of coated pellets.

Priority: US2001-789365 Applic. Date: 2001-02-20; US1999-346122 Applic. Date: 1999-07-01; US19980091960P Applic. Date: 1998-07-07

Inventor: WOOLFE AUSTEN JOHN [GB]; MCINTYRE GORDON [GB]; SHETH NITIN VADILAL [US]

Title: Taste masking of oral quinolone liquid preparations using ion exchange resins

Applicant/Assignee: SCHERING-PLOUGH VETERINARY CORPORATION

Application No.: 09/614523   Filing Date: 12/Jul/2000

Abstract:

This invention relates to the formulation of oral liquid products of quinolones or derivatives thereof using ion exchange resins, such as methacrylic acid polymer crosslinked with divinylbenzene, as the carrier, thereby eliminating the extreme bitterness of the quinolones oral liquid formulation.

Priority: US19990143819P Applic. Date: 1999-07-14

Inventor: GAO RONG [US]; SHAO ZEZHI JESSE [US]; FAN ALLAN CHOR-LUN [US]; WITCHEY-LAKSHMANAN LEONORE CAT [US]; STEWART DANIEL CHARLES [US]

Title: Anti-inflammatory pharmaceutical formulations

Applicant/Assignee: NORTON HEALTHCARE LTD

Application No.: 09/841881   Filing Date: 24/Apr/2001

Abstract:

An oral pharmaceutical dosage form including a mixture of a delay release formulation of a non-steroidal anti-inflammatory drug (NSAID) and a mixture containing a prostaglandin and one or more excipients.

Priority: US1999-394179 Applic. Date: 1999-09-10; US19980099814P Applic. Date: 1998-09-10

Inventor: WOOLFE AUSTEN JOHN [GB]; MCINTYRE GORDON [GB]; SHETH NITIN VADILAL [US]

Title: Controlled-release dosage forms comprising zolpidem or a salt thereof

Applicant/Assignee: SANOFI-SYNTHELABO

Application No.: 09/857154   Filing Date: 16/Jul/2001

Abstract:

The present invention relates to controlled-release dosage forms of zolpidem or salts thereof adapted to release zolpidem over a predetermined time period, according to a biphasic profile of dissolution, where the first phase is an immediate release phase and the second phase is a prolonged release phase and particular embodiments thereof intended to avoid abuse.

Priority: EP19980403037 Applic. Date: 1998-12-04; WO1999EP10454 Applic. Date: 1999-12-01

Inventor: ALAUX GERARD [FR]; LEWIS GARETH [FR]; ANDRE FREDERIC [FR]

Title: Formulations and methods for treating chronic migraine

Applicant/Assignee:

Application No.: 09/935945   Filing Date: 24/Aug/2001

Abstract:

A prophylactic treatment for the human malady clinically described as migraine headache comprising daily administration in unit dosage form of a first formulation which comprises a major amount of bioactive peptides and a minor amount of probiotics. Concurrently, daily administration in dosage form of a second formulation of a major amount of active components like malic acid, sylibum marianum, acetyl-L-cysteine, copper chelate, zinc gluconate, aspartate and bromelain. A minor amount of plant derivatives excipients comprise the balance of the second formulation. Preferably, these plant derivatives include beet root, powder, watercress, celery, dandelion, capsicum and artichoke extract.

Priority:

Inventor: MARRONGELLE JEFFREY L [US]; STAVEROSKY THOMAS J [US]

Title: Dry mix formulation for bisphosphonic acids

Applicant/Assignee: MERCK & CO., INC

Application No.: 09/999312   Filing Date: 19/Oct/2001

Abstract:

Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by direct compression/dry mix tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease.

Priority: US2000-690540 Applic. Date: 2000-10-17; US1999-432859 Applic. Date: 1999-11-02; US1998-141782 Applic. Date: 1998-08-28; US1997-946849 Applic. Date: 1997-10-08; US1995-454100 Applic. Date: 1995-07-26; US1992-984399 Applic. Date: 1992-12-02

Inventor: BECHARD SIMON R [CA]; KRAMER KENNETH A [US]; KATDARE ASHOK V [US]

Title: Pharmaceutical excipient having improved compressibility

Applicant/Assignee: EDWARD MENDELL CO., INC

Application No.: 09/981319   Filing Date: 16/Oct/2001

Abstract:

A microcrystalline cellulose-based excipient having improved compressibility, whether utilized in direct compression, dry granulation or wet granulation formulations, is disclosed. The excipient is an agglomerate of microcrystalline cellulose particles and from about 0.1% to about 20% silicon dioxide particles, by weight of the microcrystalline cellulose, wherein the microcrystalline cellulose and silicon dioxide are in intimate association with each other. The silicon dioxide utilized in the novel excipient has a particle size from about 1 nanometer to about 100 microns. Most preferably, the silicon dioxide is a grade of colloidal silicon dioxide.

Priority: US2001-754760 Applic. Date: 2001-01-04; US1999-438646 Applic. Date: 1999-11-12; US1997-992073 Applic. Date: 1997-12-17; US1996-724613 Applic. Date: 1996-09-30; US1995-370576 Applic. Date: 1995-01-09

Inventor: SHERWOOD BOB E [US]; STANIFORTH JOHN H [GB]; HUNTER EDWARD A [US]

Title: Synthetic polysaccharides, their method of production and pharmaceutical compositions containing same

Applicant/Assignee: SANOFI-SYNTHELABO AKZO NOBEL N.V

Application No.: 09/600506   Filing Date: 05/Sep/2000

Abstract:

Novel synthetic polysaccharides for use in the treatment of pathologies associated with a coagulation dysfunction.

Priority: FR19980000515 Applic. Date: 1998-01-19; WO1999FR00044 Applic. Date: 1999-01-13

Inventor: BASTEN JOHANNES [NL]; DREEF-TROMP CORNELIA [NL]; DRIGUEZ PIERRE ALEXANDRE [FR]; DUCHAUSSOY PHILIPPE [FR]; HERBERT JEAN MARC [FR]; PETITOU MAURICE [FR]; VAN BOECKEL CONSTANT [NL]

Title: Taste masking of phenolics using citrus flavors

Applicant/Assignee: PFIZER INC

Application No.: 10/033852   Filing Date: 28/Dec/2001

Abstract:

An oral rinse, dentifrice, or oral gel composition comprising:a) about 0.01 weight % to about 5 weight % of a citrus flavor, citrus flavor ingredient, or mixtures thereof

b) about 0.01 weight % to about 5 weight % of a phenolic, said phenolic selected from the group consisting of menthol, eucalyptol, methyl salicylate, thymol, triclosan, and mixtures thereof

andc) an orally acceptable carrier.The claimed composition is useful in retarding the development of plaque, treating gingivitis, and reducing the viable population of micro-organisms in the oral cavity of a mammal.

Priority: US2001-772682 Applic. Date: 2001-01-30; US1999-298675 Applic. Date: 1999-04-23; US1998-047741 Applic. Date: 1998-03-25; US19970042874P Applic. Date: 1997-03-31

Inventor: DELLI SANTI PATRICIA A [US]; NELSON DENNIS G A [US]

Title: Process for preparing a pharmaceutical composition

Applicant/Assignee: HOFFMANN-LA ROCHE INC

Application No.: 09/891069   Filing Date: 25/Jun/2001

Abstract:

A method for the preparation of compositions, preferably pharmaceutical compositions, in form of expanded, mechanically stable, lamellar, porous, sponge-like or foam structures out of solutions and dispersions results in a favored pharmaceutical product. This method comprises the steps of a) preparing a solution or a homogeneous dispersion of a liquid and a compound selected from the group consisting of one or more pharmaceutically active compounds, one or more pharmaceutically suitable excipients, and mixtures thereof, followed by b) the expansion of the solution or the homogeneous dispersion without boiling.

Priority: EP20000113535 Applic. Date: 2000-06-27

Inventor: BUSSON PATRICK [DE]; SCHROEDER MARCO [DE]

Title: Fibrate-statin combinations with reduced fed-fasted effects

Applicant/Assignee: SKYEPHARMA CANADA INC

Application No.: 09/838583   Filing Date: 20/Apr/2001

Abstract:

This invention discloses an orally administered pharmaceutical composition for the treatment of elevated levels of cholesterol and related conditions comprising a statin and fenofibrate in the form of microparticles of solid fenofibrate that are stabilized by phospholipid as a surface active substance, wherein a therapeutically effective amount of the composition provides the statin and a quantity of fenofibrate to a fasted human patient that is greater than 80% of the quantity of fenofibrate provided by the same amount of the composition when administered to the same patient who has been fed a high fat meal.

Priority: US20010270157P Applic. Date: 2001-02-22

Inventor: GUIVARC H POL-HENRI W [CA]; PARIKH INDU [US]; SNOW ROBERT A [US]

Title: Microfabricated devices for the delivery of molecules into a carrier fluid

Applicant/Assignee: MICROCHIPS, INC

Application No.: 10/195338   Filing Date: 15/Jul/2002

Abstract:

Apparatus and methods are provided for the delivery of molecules to a site via a carrier fluid. The apparatus include microchip devices which have reservoirs containing the molecules for release. The apparatus and methods provide for active or passive controlled release of the molecules. Embodiments include systems for release of fragrance molecules and beverage additives.

Priority: US2000-715493 Applic. Date: 2000-11-17; US19990166370P Applic. Date: 1999-11-17

Inventor: SANTINI JR JOHN T [US]; HUTCHINSON CHARLES E [US]; UHLAND SCOTT A [US]; CIMA MICHAEL J [US]; LANGER ROBERT S [US]; AUSIELLO DENNIS [US]

Title: Anti-inflammatory pharmaceutical formulations

Applicant/Assignee: NORTON HEALTHCARE LTD

Application No.: 10/002411   Filing Date: 14/Nov/2001

Abstract:

An oral pharmaceutical dosage form including a mixture of a delay release formulation of a non-steroidal anti-inflammatory drug (NSAID) and a mixture containing a prostaqlandin and one or more excipients.

Priority: US2000-479430 Applic. Date: 2000-01-07; US1999-414673 Applic. Date: 1999-10-07; US1999-394179 Applic. Date: 1999-09-10; US19980099814P Applic. Date: 1998-09-10

Inventor: WOOLFE AUSTEN JOHN [GB]; GREENE SIOBHAN [IE]; MCINTYRE GORDON [GB]; SHETH NITIN VADILAL [US]

Title: Thermosensitive biodegradable hydrogels for sustained delivery of leptin

Applicant/Assignee: AMGEN INC

Application No.: 09/107603   Filing Date: 30/Jun/1998

Abstract:

The present invention relates generally to the development of pharmaceutical compositions which provide for sustained release of biologically active polypeptides. More specifically, the invention relates to the use of thermosensitive, biodegradable hydrogels, consisting of a block copolymer of poly(d,l- or l-lactic acid)(PLA) or poly(lactide-co-glycolide)(PLGA) and polyethylene glycol (PEG), for the sustained delivery of biologically active agents, such as leptin.

Priority:

Inventor: SHAH SUBODH [US]

Title: Nanosheres comprising a biocompatible polysaccharide

Applicant/Assignee: FIDIA ADVANCED BIOPOLYMERS S.R.L

Application No.: 09/558801   Filing Date: 26/Apr/2000

Abstract:

Microspheres, having a size lower than 1mu and comprising a biocompatible polysaccharidic polymer, are prepared with a process comprising the precipitation of polymer induced by means of a supercritical antisolvent (SAS). These microspheres are used as vehicling agents or carriers in the preparation of pharmaceutical compositions administrable by oral, nasal, pulmonary, vaginal or rectal route. These microspheres can also be advantageously used as vehicling agent or carriers in the preparation of pharmaceutical compositions for the treatment of human diseases associated with genic defects, for the preparation of diagnostics and in the agro-alimentary industry.

Priority: IT1995PD00065 Applic. Date: 1995-03-28; IT1996PD00021 Applic. Date: 1996-02-05; US1997-938288 Applic. Date: 1997-09-26

Inventor: PALLADO PAOLO [IT]; BENEDETTI LUCA [IT]; CALLEGARO LANFRANCO [IT]

Title: Fusion proteins comprising tumor necrosis factor receptor

Applicant/Assignee: IMMUNEX CORPORATION

Application No.: 08/406824   Filing Date: 20/Mar/1995

Abstract:

Fusion proteins having a tumor necrosis factor receptor (TNF-R) polypeptide and at least one additional polypeptide covalently fused thereto and selected from an interleukin-1 receptor (IL-1R) and a second TNF-R polypeptide. The receptor polypeptides are preferably fused together by a peptidyl linker. Suitable fusions include, for example, TNF-R-linker-TNF-R

TNF-R-linker-IL-1R

and TNF-R-linker-TNF-R-linker-L-1R molecules.

Priority: US1994-255849 Applic. Date: 1994-06-08; US1990-523635 Applic. Date: 1990-05-10; US1989-421417 Applic. Date: 1989-10-13; US1989-405370 Applic. Date: 1989-09-11; US1989-403241 Applic. Date: 1989-09-05; US1992-860710 Applic. Date: 1992-03-30

Inventor: SMITH CRAIG A [US]

Title: Keratin-based powders and hydrogel for pharmaceutical applications

Applicant/Assignee: KERAPLAST TECHNOLOGIES, LTD

Application No.: 09/638643   Filing Date: 14/Aug/2000

Abstract:

A hydratable, highly absorbent keratin solid fiber or powder capable of absorbing a large weight excess of water may be produced by partially oxidizing hair keratin disulfide bonds to sulfonic acid residues and reacting the sulfonic acid residues with a cation. The neutralized suspension can be filtered, washed, and dried, leaving keratin solid which can be shredded into fibers and further ground into powder. Addition of water to the solid produces a hydrogel. The powder or hydrogel may be useful as an absorbent material, as a therapeutic for skin, or as an excipient. The keratin materials can be incorporated into nonwoven films. The hydrogel can be used as a biocompatible viscoelastic filler for implant applications. Another use for the absorbent keratin and keratin hydrogel is as an excipient in pharmaceutical and cosmetic applications.

Priority: US2000-587157 Applic. Date: 2000-06-05; US2000-528893 Applic. Date: 2000-03-20; US2000-512918 Applic. Date: 2000-02-25; US1999-394782 Applic. Date: 1999-09-13

Inventor: SILLER-JACKSON ARLENE J [US]; VAN DYKE MARK E [US]; TIMMONS SCOTT F [US]; BLANCHARD CHERYL R [US]; SMITH ROBERT A [US]

Title: Medicaments for gastrointestinal disorders

Applicant/Assignee: GLAXO GROUP LIMITED

Application No.: 08/156727   Filing Date: 24/Nov/1993

Abstract:

The invention relates to the co-administration in human or veterinary medicine of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one or a physiologically acceptable salt or solvate thereof and dexamethasone or a physiologically acceptable salt or ester thereof. The two active ingredients, which may be administered separately either simultaneously or sequentially, or may be combined in a single pharmaceutical preparation, are useful in the relief and/or prevention of nausea and vomiting.

Priority: GB19880005269 Applic. Date: 1988-03-04; US1992-984737 Applic. Date: 1992-12-02; US1991-739613 Applic. Date: 1991-08-02; US1989-318683 Applic. Date: 1989-03-03

Inventor: TYERS MICHAEL BRIAN [GB]; CHALLONER TERESA ELIZABETH [GB]

Title: Solid pharmaceutical compositions containing hexedecylphosphocholine (miltefosine) for oral administration in the treatment of leishmaniasis

Applicant/Assignee: ZENTARIS AG

Application No.: 09/624890   Filing Date: 24/Jul/2000

Abstract:

The present invention relates to new solid pharmaceutical compositions containing hexadecylphosphocholine (miltefosine) for oral administration in the treatment of leishmaniasis, a process for the manufacture of said pharmaceutical composition, a dosage scheme for oral administration of said pharmaceutical composition in the treatment of leishmaniasis, and finally a combination comprising said solid pharmaceutical composition, antiemeticum, and/or an antidiarrhoeal.

Priority: WO1998EP00345 Applic. Date: 1998-01-22

Inventor: ENGEL JUERGEN [DE]; SARLIKIOTIS WERNER [DE]; KLENNER THOMAS [DE]; HILGARD PETER [DE]; SAUERBIER DIETER [DE]; MILSMANN ECKHARD [DE]

Title: Method of producing porous tablets with improved dissolution properties

Applicant/Assignee: PARTICLE AND COATING TECHNOLOGIES, INC

Application No.: 09/757426   Filing Date: 11/Jan/2001

Abstract:

A method of producing a fast-dissolving pharmaceutical delivery device of moderate strength. The delivery device is a fully formed tablet composed of readily available sugars, strength polymers and a volatilizable excipient along with an active ingredient and optional flavorings. The tablet as made will disintegrate in an aqueous medium such as saliva in under 15 seconds, making mastication unnecessary or at least requiring only one or two bites on the tablet. Essential to the invention is the easily obtainable particle size ranges of the sugars and the volatilizable excipient which promotes optimum release and tablet strength. The invention also allows for effective taste masking of the active ingredient with standard particle coating techniques.

Priority:

Inventor: SPARKS ROBERT E [US]; JACOBS IRWIN C [US]; MASON NORBERT S [US]

Title: Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol

Applicant/Assignee: PROTEIN TECHNOLOGIES INTERNATIONAL, INC

Application No.: 09/298528   Filing Date: 23/Apr/1999

Abstract:

A composition is provided comprising a plant sterol and a soy protein material and/or and isoflavone selected from genistein, daidzein, glycitein, biochanin A, formononetin, and their naturally occurring glycosides, where the plant sterol comprises at least 0.49% of the composition, by weight. The present invention is also a method for decreasing the blood concentration of total and LDL cholesterol in a human in which the plant sterol and a soy protein material and/or an isoflavone are co-administered to the human, where the plant sterol comprises at least 0.49%, by weight, of the combined weight of the plant sterol and the soy protein material and/or the isoflavone. Also provided is also a method for preventing or minimizing the development of atherosclerosis in a human in which a plant sterol and a soy protein material and/or an isoflavone are co-administered to the human, where the plant sterol comprises at least 0.49%, by weight, of the combined weight of the plant sterol and the soy protein material and/or the isoflavone. A preferred method involves co-administering to a human a plant sterol and a soy protein material containing at least 49% by weight soy protein and containing the isoflavone glycoside, glycitin. The plant sterol is at least 0.49% by combined weight of the co-administered plant sterol and soy protein material. The plant sterol can be B-sitosterol, campesterol, stigmasterol, sitostanol, or campestanol. Also an isoflavone can be administered in combination with the plant sterol and soy protein material. This isoflavone can be genistein, daidzein, glycitein, biochanin A, formononetin, and their naturally occurring glycosides and glycoside conjugates.

Priority:

Inventor: WAGGLE DOYLE H [US]; POTTER SUSAN M [US]; HENLEY E C [US]

Title: Treated water-insoluble solid particles, preparation and use

Applicant/Assignee: COLETICA

Application No.: 09/909438   Filing Date: 19/Jul/2001

Abstract:

The present invention relates to water-insoluble solid particles, especially pigments, which characteristically are coated with at least one layer of at least one product resulting from the reaction between at least one molecule capable of becoming hydrated in contact with water and at least one lipophilic molecule. It further relates to cosmetic, pharmaceutical and agricultural compositions comprising such particles and to the manufacture and use of said particles.

Priority: FR20010007336 Applic. Date: 2001-06-05

Inventor: PERRIER ERIC [FR]; THOLON LYSIANE [FR]; ABDUL MALAK NABIL [FR]

Title: Pharmaceutical compositions containing N-palmitoylethanolamide and use thereof in the veterinary field

Applicant/Assignee: INNOVET ITALIA S.R.L

Application No.: 10/030060   Filing Date: 04/Jan/2002

Abstract:

The present invention relates to a method for treating eosinophilic granuloma in a Feline comprising administering a pharmaceutical composition, the composition comprising N-palmitoylethanolamide. The present invention also relates to said pharmaceutical composition and the process for the preparation thereof.

Priority: WO1999IT00259 Applic. Date: 1999-08-06

Inventor: COMELLI CRISTINA [IT]; DELLA VALLE MARIA FEDERICA [IT]; DELLA VALLE FRANCESCO [IT]; MARCOLONGO GABRIELE [IT]

Title: Taste masking coating composition

Applicant/Assignee: BRISTOL-MYERS SQUIBB COMPANY

Application No.: 09/553513   Filing Date: 20/Apr/2000

Abstract:

There is provided a coating composition that masks the undesirable taste of a pharmaceutically active ingredient, i.e. drug or medicine, that is consumed orally. The coating composition has polyvinyl acetate, and a dimethylaminoethyl methacrylate and neutral methacrylic acid ester. Optionally, an alkaline modifier may be included in the coating composition to enhance release of the active ingredient.

Priority:

Inventor: CORBO MICHAEL [US]; DESAI JATIN [US]; PATELL MAHESH [US]; WARRICK RONALD [US]

Title: Compositions and methods for mucosal delivery

Applicant/Assignee: LAVIPHARM LABORATORIES INC

Application No.: 09/434878   Filing Date: 05/Nov/1999

Abstract:

Mucosal surface-coat-forming film dosage units containing a water-soluble hydrocolloid, an effective dose of an active agent and a mucosal adhesion enhancer

wherein the active agent is encapsulated within a polymer which is chemically or physically distinct from the hydocolloid

wherein the mucosal adhesion enhancer is a starch graft copolymer

wherein the film exhibits a dry tack value of less than 3.5 g, a wet tack of greater than 35 g, a gelation temperature that is greater than 70 DEG C. for a 2% polymer solution, a dry film thickness of less than 20 mil, a water content of 0.5 to 10%, a tensile strength greater than 1500 psi, a modulus in the range of 35,000 to 300,000 psi, a % elongation of less than 20%, a tear probagation resistance of 0.001 to 1 N, and a dissolution time in the range of 1 to 600 seconds upon application to an oral mucosal surface.

Priority: US19990116823P Applic. Date: 1999-01-21

Inventor: CHEN LI-LAN H [US]; PFISTER WILLIAM R [US]; RENN DONALD W [US]; BURANACHOKPAISAN THITIWAN [US]; OSBORNE JAMES [US]; TAN HOCK SENG [US]; TAO LI [US]

Title: Multi-spike release formulation for oral drug delivery

Applicant/Assignee: PHARMACEUTICAL DISCOVERY CORPORATION

Application No.: 09/766394   Filing Date: 19/Jan/2001

Abstract:

Methylphenidate or other drugs are provided in a formulation for oral administration that releases the drug in two or more pharmacokinetic spikes, by combining different release forms in a single formulation. In a preferred embodiment for methylphenidate, the first pharmacokinetic spike is achieved by the release of taste-masked methylphenidate which is not enterically coated, while a second pharmacokinetic spike is achieved by the release of methylphenidate in a finely divided form from enterically coated pellets or microparticles formulated for rapid release following dissolution of the enteric coating. A critical aspect of the formulation is the inclusion of excipients that create a burst release following the initial rapid release and uptake. The formulation can be administered as a paste, jelly, suspension, or fast dissolving wafer.

To manipulate the dose, the formulation can be provided, for example, as a paste packaged in a tube similar to those used to dispense toothpaste.

Priority: US20000176853P Applic. Date: 2000-01-19

Inventor: STEINER SOLOMON S [US]

Title: Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants

Applicant/Assignee: BRISTOL-MYERS SQUIBB COMPANY

Application No.: 09/824071   Filing Date: 02/Apr/2001

Abstract:

The present invention provides improved oral dosage form formulations of efavirenz that are useful in the inhibition of human immunodeficiency virus (HIV), the prevention or treatment of infection by HIV, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS). In particular, the present invention relates to compressed tablets or capsules comprising efavirenz that contain one or more disintegrants that enhance the dissolution rate of the efavirenz in the gastrointestinal tract thereby improving the rate and extent of absorption of efavirenz in the body. The present invention also relates to the process of making such tablets or capsules.

Priority: US1999-286902 Applic. Date: 1999-04-06; US19980080925P Applic. Date: 1998-04-07

Inventor: MAKOOI-MOREHEAD WILLIAM T [US]; BUEHLER JOHN D [US]; LANDMANN BRIAN R [US]

Title: Synergistic mixtures of garlic and lycopene for preventing LDL oxidation

Applicant/Assignee: LYCORED NATURAL PRODUCTS INDUSTRIES LTD

Application No.: 09/601403   Filing Date: 11/Oct/2000

Abstract:

The present invention provides a synergistic pharmaceutical or dietary composition containing lycopene and garlic. The present invention also provides an improved method to block the oxidation of LDL in order to arrest the process of therapeutic agent and a method for the prevention or treatment of atheroscelerosis using and/or applying said compositions.

Priority: IL19980123132 Applic. Date: 1998-02-01; WO1999IL00062 Applic. Date: 1999-01-31

Inventor: AVIRAM MICHAEL [IL]; FUHRMAN BIANCA [IL]; NIR ZOHAR [IL]; GRUENWALD JEORG [DE]

Title: Pharmaceutical compositions comprising co-micronized fenofibrate

Applicant/Assignee:

Application No.: 09/544498   Filing Date: 07/Apr/2000

Abstract:

A pharmaceutical composition for oral administration comprising a co-micronized mixture of fenofibrate and a solid excipient that is not a surfactant.

Priority: CA19992270306 Applic. Date: 1999-04-27

Inventor: SHERMAN BERNARD CHARLES [CA]

Title: PREPARATION OF MICRON-SIZE PHARMACEUTICAL PARTICLES BY MICROFLUIDIZATION

Applicant/Assignee: WOCKHARDT EUROPE LIMITED

Application No.: 09/340917   Filing Date: 28/Jun/1999

Abstract:

The present invention relates to a process of microfluidization or wet-micronization of hydrophobic drugs in combination with dextrins such as beta-cyclodextrin. The microfluidized particles are useful in controlled swellability, erosion rate-controlled drug delivery systems. The process of microfluidization facilitates reduction of mean particle size of slightly soluble but highly permeable drugs and creates a smooth, latex-like micro-suspension. A blend of swellable polymer and insoluble, hydrophilic excipients granulated with the micro-suspension create a swellable matrix that after compaction erodes uniformly over a 24-hour period. Optimization of drug release is achieved by modification of the geometry of the drug delivery system.

Priority:

Inventor: SHARMA VINAY K [US]

Title: Therapies for treating pulmonary diseases

Applicant/Assignee: SMITHKLINE BEECHAM CORPORATION

Application No.: 09/933455   Filing Date: 20/Aug/2001

Abstract:

This invention relates to treating pulmonary diseases such as chronic obstructive pulmonary disease or asthma by administering a phosphodiesterase 4 inhibitor in combination with beta adrenergic bronchodilator.

Priority: US2001-763516 Applic. Date: 2001-02-23; US19980097973P Applic. Date: 1998-08-26

Inventor: NIEMAN RICHARD [US]; REBUCK ANTHONY S [US]; TORPHY THEODORE J [US]

Title: Over-coated chewing gum formulations

Applicant/Assignee: WM. WRIGLEY JR. COMPANY

Application No.: 09/759561   Filing Date: 11/Jan/2001

Abstract:

Methods and products for delivering a medicament or agent to an individual are provided. The product includes a coating having a medicament or agent. The medicament or agent is present within the coating that surrounds a gum center (the water soluble portion and a water insoluble base portion). By chewing the gum, the medicament or agent is released from the product. Continuing to chew the chewing gum creates a pressure within the buccal cavity forcing the agent or medicament directly into the systemic system of the individual through the oral mucosa contained in the buccal cavity. This greatly enhances the absorption of the drug into the systemic system as well as the bioavailability of the drug within the system.

Priority: US2000-510878 Applic. Date: 2000-02-23; US1999-286818 Applic. Date: 1999-04-06; WO1999US29742 Applic. Date: 1999-12-14

Inventor: REAM RONALD L [US]; GREENBERG MICHAEL J [US]; WOKAS WILLIAM J [US]; CORRIVEAU CHRISTINE L [US]

Title: Delivery system for pharmaceutical, nutritional and cosmetic ingredients

Applicant/Assignee: NATREON INC INDIAN HERBS RESEARCH & SUPPLY COMPANY LTD

Application No.: 09/957797   Filing Date: 21/Sep/2001

Abstract:

A stable, water-soluble delivery system of a purified Shilajit composition obtained by extraction of native Shilajit, containing at least 40% by weight of a carrier which is purified fulvic acid, characterized by having a sponge-like structure punctured by voids of about 200-1000 AA in diameter, and a {overscore (Mn molecular weight of about 700-2500

and an effective amount of an active pharmaceutical, nutritional or cosmetic ingredient added to said carrier and filling voids therein.

Priority:

Inventor: GHOSAL SHIBNATH [IN]

Title: EXTRACT OF NERIUM SPECIES, PHARMACEUTICAL COMPOSITION THEREOF AND METHODS FOR PREPARATION THEREOF

Applicant/Assignee: OZELLE PHARMACEUTICALS, INC

Application No.: 09/401494   Filing Date: 22/Sep/1999

Abstract:

A substantially sterile extract of Nerium species is described, together with a method for production thereof. A pharmaceutical composition comprising the extract is also described, together with a method for production thereof. The pharmaceutical composition is useful for the treatment of cell-proliferative and immune deficient diseases in mammals, including cancer and AIDS, respectively.

Priority: US19980101622P Applic. Date: 1998-09-24

Inventor: SELVARAJ ULAGARAJ [US]; SINGH CHANDRA U [US]; OZEL HUSEYIN Z [TK]

Title: Method for treatment of bacterial infections with once or twice-weekly administered rifalazil

Applicant/Assignee: KANEKA CORPORATION

Application No.: 09/972320   Filing Date: 05/Oct/2001

Abstract:

A method for treatment of bacterial infections with rifalazil administered once-weekly or twice-weekly. A method for treatment of tuberculosis caused by Mycobacterium tuberculosis, infections caused by Mycobacterium avium complex, infections caused by Chlamydia pneumoniae and infections caused by Helicobacter pylori by administering to a patient suffering from the bacterial infection 1-100 mg of rifalazil once or twice a week. In this dose regimen, the treatment is fast, efficacious and eliminates undesirable secondary symptoms observed with daily doses of 1-50 mg of rifalazil.

Priority: US1999-464353 Applic. Date: 1999-12-15; US19980112921P Applic. Date: 1998-12-18

Inventor: ROSE LYNN M [US]; PORUBEK DAVID J [US]; MONTGOMERY ALAN B [US]

Title: Combination of acid protease enzymes and acidic buffers and uses thereof

Applicant/Assignee: ACTIVE ORGANICS

Application No.: 09/354687   Filing Date: 16/Jul/1999

Abstract:

Novel compositions comprising one or more of an acid protease and an acidic buffer, the acidic buffer comprising an acid and a pharmaceutically or cosmetically 5 acceptable carrier, vehicle or excipient, useful for treating or preventing abnormal biological conditions, diseases or disorders, and/or for improving the texture or appearance of the skin, and/or for enhancing epidermal exfoliation and/or for enhancing epidermal cell renewal and to methods for the use of the compositions. The acid protease comprises one or more proteolytic enzymes that exhibit proteolytic activity at pH values below that of the surface of the skin, i.e., approximately pH 5.5. The acidic buffer comprises inorganic and/or organic acids or mixtures thereof with a pharmaceutically or cosmetically acceptable carrier, vehicle or excipient. The buffer is capable of reducing the pH of the surface of the skin to less than pH 5.5 and is susceptible to neutralization by normal epidermal processes.

Priority: US1996-664056 Applic. Date: 1996-06-13

Inventor: BISHOP MICHAEL [US]; GILLIS GLEN [US]; NORTON SCOTT J [US]

Title: PROCESS FOR MAKING PERSONAL CARE COMPOSITIONS COMPRISING TITANIUM DIOXIDE AND PERSONAL CARE COMPOSITIONS MADE BY THE PROCESS

Applicant/Assignee: NOVILLE INC

Application No.: 10/010362   Filing Date: 13/Nov/2001

Abstract:

The invention concerns a process for making personal care compositions and opacifying agents, and corresponding products, having a stable cloudy and milky appearance. The components are processed in a specific sequence in which titanium dioxide is added after thickening agent which comprises a hydrophilic colloid. The composition may, optionally, comprise calcium lactate, calcium lactate salts and combinations thereof. The products, and process, may also comprise the addition of other components such as filler, additives, colorants, cooling agents, warming agents, numbing agents, additional flavorings, active compounds, pharmaceutical actives and excipients or finished bases.

Priority:

Inventor: STIER ROGER E [US]

Title: Pharmaceutical formulations in hydroxypropylmethylcellulose capsules

Applicant/Assignee: PHARMACIA ITALIA S.P.A

Application No.: 09/857188   Filing Date: 20/Jun/2001

Abstract:

An oral pharmaceutical formulation, which comprises, in a hydroxypropylmethylcellulose capsule, a camptothecin analogue dispersed or solubilized in a semi-solid matrix of a polyethyleneglycol with a molecular weight ranging from 400 to 20000.

Priority: WO2000EP06590 Applic. Date: 2000-07-11; GB19990018885 Applic. Date: 1999-08-10

Inventor: CIVAROLI PAOLA [IT]; MUGGETTI LORENA [IT]; MARTINI ALESSANDRO [IT]

Title: Osmotic device containing diltiazem and an ACE inhibitor or diuretic

Applicant/Assignee: OSMOTICA CORP

Application No.: 09/755371   Filing Date: 05/Jan/2001

Abstract:

The present invention provides an osmotic device containing controlled release diltiazem in the core in combination with a rapid release ACE inhibitor, or diuretic, in an external coat. The delivery device of the invention can also be a chronotherapeutic osmotic device that provides a delayed and controlled release of diltiazem and a delay and rapid release of an ACE inhibitor or diuretic. A wide range of ACE inhibitors or diuretics can be used in this device. Particular embodiments of the invention provide osmotic devices having predetermined release profiles. One specific embodiment of the osmotic device includes an external coat that has been spray coated rather than compression coated onto the device. The device with spray coated external core is smaller and easier to swallow than the similar device having a compression coated external coat.

The device is useful for the treatment of blood pressure or hypertension related disorders.

Priority: US20000176174P Applic. Date: 2000-01-13

Inventor: FAOUR JOAQUINA [AR]; VERGEZ JUAN A [AR]

Title: Enteric coated pharmaceutical tablet and method of manufacturing

Applicant/Assignee: BRISTOL-MYERS SQUIBB COMPANY

Application No.: 09/866501   Filing Date: 25/May/2001

Abstract:

A high drug load enteric coated pharmaceutical composition is provided which includes a core in the form of a tablet and which is comprised of a medicament which is sensitive to a low pH environment of less than 3, such as ddl, and having an enteric coating formed of methacrylic acid copolymer and a plasticizer. The tablets may be of varying sizes and may be orally ingested individually or a plurality of tablets sufficient to attain a desired dosage may be encapsulated in a dissolvable capsule. The tablets have excellent resistance to disintegration at pH less than 3 but have excellent drug release properties at pH greater than 4.5. A novel method of making said pharmaceutical composition is also disclosed.

Priority: US2000-549455 Applic. Date: 2000-04-14; US1998-118418 Applic. Date: 1998-07-17

Inventor: ULLAH ISMAT [US]; WILEY GARY J [US]

Title: Layering process for multiparticulate dosage form

Applicant/Assignee: EURAND INTERNATIONAL S.P.A

Application No.: 09/701233   Filing Date: 16/Jan/2001

Abstract:

The present invention relates to a new layering process, in particular to a process for the manufacture of multiparticulate solid oral dosage forms based on a dry spray layering technique optionally with electrostatic attraction. The invention also relates to an apparatus for use in the process.

Priority: EP19980109349 Applic. Date: 1998-05-22; WO1999EP03512 Applic. Date: 1999-05-21

Inventor: CORNELLI LIVIO MARIA [IT]; LA GRASTA GIOVANNI [IT]; MARCONI MARCO GIUSEPPE RAFFAEL [IT]

Title: Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications

Applicant/Assignee:

Application No.: 09/961194   Filing Date: 20/Sep/2001

Abstract:

Self-preserved nasal, inhalable and topical ophthalmic preparations and medications which destroy, inhibit or therapeutically significantly limit microbial growth within said preparations or medications. The nasal, inhalable, and topical ophthalmic preparations and medications are mildly buffered and maintain a stable pH at pH 3.5 or lower.

Priority: US20000234319P Applic. Date: 2000-09-20

Inventor: SHAHINIAN JR LEE [US]

Title: Polysaccharide material for direct compression

Applicant/Assignee: NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION

Application No.: 09/804666   Filing Date: 12/Mar/2001

Abstract:

This invention relates to a method of using compressible polysaccharides having a tap density of less than 0.4 g/ml as a filler/binder for tablets prepared by direct compression, excipient blends including said polysaccharides, a method of tableting an active ingredient therein from the excipient blends and the tablets produced therefrom. More particularly, this invention relates to the use of low-density starches as binders for tablets prepared by direct compression, excipient blends, and methods of tableting an active ingredient therein from such starches. Further, this invention describes a starch-based excipient composition having a tap density of less than 0.4 g/ml, which has excellent moisture resistance.

Priority: US20000233210P Applic. Date: 2000-09-15; US20000200858P Applic. Date: 2000-05-01

Inventor: WEISSER ERIC M [US]; WHALEY JUDITH K [US]; ENABOSI AMOS E [US]; SHAH HIMANSHU [US]; REGE PANKAJ [US]

Title: Food bars containing nutritional supplements

Applicant/Assignee: PBM PHARMACEUTICALS, INC

Application No.: 10/078814   Filing Date: 19/Feb/2002

Abstract:

The present invention provides food bars for consumption by pregnant women, lactating women or women of childbearing potential that are attempting to become pregnant containing one or more vitamins and/or minerals, DHA, one or more DHA taste-masking agents and, optionally, one or more anti-constipation and regularity-maintaining agents, methods for preparing these food bars, and methods for supplementing the dietary requirements of pregnant women, lactating women or women of childbearing potential that are attempting to become pregnant.

The food bars of the invention generally comprise one or more vitamins and minerals recommended for consumption by pregnant women, lactating women or women of childbearing potential that are attempting to become pregnant in an amount that is effective for enhancing the nutrition of pregnant women, lactating women or women of childbearing potential that are attempting to become pregnant, and that is not harmful to developing fetuses or breast-feeding babies, including calcium in an amount above 1,000 mg, DHA in an amount that is effective for providing, or increasing the supply of, DHA to a developing fetus or baby through a placenta or breast milk, one or more DHA taste-masking agents in an amount that is effective for masking the taste of DHA, and that is not harmful to developing fetuses or breast-feeding babies and, optionally,

one or more anti-constipation and regularity-maintaining agents in an amount that is effective for reducing or eliminating constipation, and that is not harmful to developing fetuses or breast-feeding babies, from about 0 to about 99 weight percent of carbohydrates, from about 0 to about 80 weight percent of proteins, and from about 0 to about 60 weight percent of fats.

Priority: US2000-730194 Applic. Date: 2000-12-05

Inventor: MANNING PAUL B [US]; SCHRAMM JACK H [US]; MCGRATH JR JAMES W [US]

Title: APPLICATION OF WATER-SOLUBLE OR WATER-DISPERSIBLE POLYMERIZATES WHICH CONTAIN POLY-ETHER AND WHICH ARE USED AS A COATING AGENT, A BINDING AGENT AND/OR AS A FILM-FORMING AUXILIARY AGENT IN PHARMACEUTICAL FORMS OF ADMINISTRATION

Applicant/Assignee: BASF AKTIENGESELLSCHAFT

Application No.: 09/787956   Filing Date: 23/Mar/2001

Abstract:

The use of polymers which are obtainable by polymerization ofa) at least one vinyl ester of aliphatic C1-C24-carboxylic acids in the presence ofb) polyethers of the general formula I, in which the variables have, independently of one another, the meanings mentioned in the description, as coating agent, binder and/or film-forming excipient in pharmaceutical presentations.

Priority: DE19981044903 Applic. Date: 1998-09-30; DE19991005906 Applic. Date: 1999-02-11; DE19991031667 Applic. Date: 1999-07-08; WO1999EP07123 Applic. Date: 1999-09-24

Inventor: GOTSCHE MICHAEL [DE]; KOLTER KARL [DE]; SANNER AXEL [DE]; ANGEL MAXIMILIAN [DE]; LEINENBACH ALFRED [DE]

Title: Medicinal compositions adhering to stomach/duodenum

Applicant/Assignee: KOWA CO., LTD

Application No.: 09/600885   Filing Date: 07/Sep/2000

Abstract:

The present invention provides a gastric and/or duodenal adhesive pharmaceutical composition obtained by coating a composition, which comprises a medicament acting at the stomach and/or duodenum and one or more of ingredients selected from water insoluble polymers, polyglycerin fatty acid esters, lipids and waxes, with a polymer having adhesive capacity onto the surface of the mucosa of a digestive tract under acid conditions and separates from the mucosa of the digestive tract in neutral or alkaline conditions. This composition adheres only to the mucosa of the stomach and/or duodenum and releases the medicament over long hours so that sufficient effects are available by a small amount of the medicament.

Priority: JP19980072098 Applic. Date: 1998-03-20; JP19980072099 Applic. Date: 1998-03-20; WO1999JP01311 Applic. Date: 1999-03-17

Inventor: INAGI TOSHIO [JP]; SHIRAI HIROYUKI [JP]; YAMAGUCHI NORIKAZU [JP]; NISHINO TAKESHI [JP]

Title: Extended release formulation of etodolac

Applicant/Assignee: RANBAXY LABORATORIES LIMITED

Application No.: 09/648949   Filing Date: 25/Aug/2000

Abstract:

A sustained release formulation of etodolac for once daily administration is described.A sustained release formulation of etodolac for once daily administration is described

Priority: IN1999DE01210 Applic. Date: 1999-09-10

Inventor: RAGHUVANSHI RAJEEV S [IN]; RAMPAL ASHOK [IN]; SEN HIMADRI [IN]

Title: Taste masked pharmaceutical liquid formulations

Applicant/Assignee: ORTHO-MCNEIL PHARMACEUTICAL, INC

Application No.: 10/253683   Filing Date: 24/Sep/2002

Abstract:

A liquid composition for oral administration comprising a pharmaceutically active medicament coated with a taste masking effective amount of a polymer blend of (a) dimethylaminoethyl methacrylate and neutral methacrylic acid ester (MM/MAE) and (b) a cellulose ester, in an aqueous vehicle, wherein the polymer weight ratio of the cellulose ester to the MM/MAE is about 40:60 to about 90:10, preferably about 60:40. The liquid composition utilizes a "reverse enteric coating" which is soluble in the acid pH's of the stomach, generally about 1.0 to 4.0, but relatively insoluble at the non-acidic pH's of the mouth. The coatings provide for rapid release and absorption of the drug, which is generally desirable in the case of liquid dosage forms.

Priority: US2000-598157 Applic. Date: 2000-06-21; US19990143019P Applic. Date: 1999-07-09

Inventor: YU DANNY [US]; ROCHE EDWARD [US]

Title: Porous celecoxib matrices and methods of manufacture thereof

Applicant/Assignee: ACUSPHERE, INC

Application No.: 09/881289   Filing Date: 14/Jun/2001

Abstract:

Celecoxib is provided in a porous matrix form wherein the dissolution rate of the drug is enhanced when the matrix is contacted with an aqueous medium. The porous matrix yields upon contact with an aqueous medium nanoparticles and microparticles of celecoxib having a mean diameter between about 0.01 and 5 mum and a total surface area greater than about 0.5 m2/mL. The dry porous matrix preferably is in a dry powder form having a TAP density less than or equal to 1.0 g/mL.

The porous celecoxib matrices preferably are made using a process that includes (i) dissolving celecoxib in a volatile solvent to form a drug solution, (ii) combining at least one pore forming agent with the drug solution to form an emulsion, suspension, or second solution, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the dry porous matrix of celecoxib. The resulting porous matrix has a faster rate of dissolution following administration to a patient, as compared to non-porous matrix forms of the drug.

Priority: US20000211723P Applic. Date: 2000-06-15

Inventor: STRAUB JULIE [US]; BERNSTEIN HOWARD [US]; CHICKERING III DONALD E [US]; RANDALL GREG [US]

Title: Nanoparticulate dispersions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 10/075443   Filing Date: 15/Feb/2002

Abstract:

Disclosed are solid dose nanoparticulate compositions comprising a poorly soluble active agent, at least one polymeric surface stabilizer, and dioctyl sodium sulfosuccinate (DOSS). The solid dose compositions exhibit superior redispersibility of the nanoparticulate composition upon administration to a mammal, such as a human or animal. The invention also describes methods of making and using such compositions.

Priority: US2000-666539 Applic. Date: 2000-09-21

Inventor: RYDE NIELS P [US]; RUDDY STEPHEN B [US]

Title: Pharmaceutical compositions of O-desmethyl-N-mono-desmethyl-tramadol

Applicant/Assignee: GRUENENTHAL GMBH

Application No.: 09/974886   Filing Date: 12/Oct/2001

Abstract:

A method of producing pharmaceutical compositions using O-desmethyl-N-mono-desmethyl-tramadol for the treatment of pain and various related indications, pharmaceutical compositions containing O-desmethyl-N-mono-desmethyl-tramadol, and a method of treating pain, urinary incontinence, diarrhea or pruritus using O-desmethyl-N-mono-desmethyl-tramadol.

Priority: JP20000043446 Applic. Date: 2000-02-21; DE20002002943U Applic. Date: 2000-02-21; US2000-642152 Applic. Date: 2000-08-21

Inventor: KOEGEL BABETTE [DE]; ENGLBERGER WERNER [DE]; HENNIES HAGEN-HEINRICH [DE]; FRIDERICHS ELMAR [DE]

Title: Tumor necrosis factor receptor releasing enzyme

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Application No.: 09/081385   Filing Date: 14/May/1998

Abstract:

The present invention relates to methods of regulating TNF receptor releasing enzyme (TRRE) activity. Composition altering TRRE activity, including a family of proteins and the genes encoding these proteins having TRRE activity, are provided. These proteins, RNA products, or DNA sequences can be administered to individuals suffering from a disease characterized by abnormal TRRE activity. In the case of diseases associated with elevated levels of TNF, such as rheumatoid arthritis, an inhibitor of TRRE is administered to the disease site to decrease the local levels of TNF. Methods of isolating other compositons which increase or decrease TRRE activity are also provided.

Priority: US1997-964747 Applic. Date: 1997-11-05; US19960030761P Applic. Date: 1996-11-06

Inventor: GATANAGA TETSUYA [US]; GRANGER GALE A [US]

Title: Promotion of wound healing utilizing steroids having reduced deteriorous systemic side effects typical of glucocorticoids, mineralocorticoids and sex steroids

Applicant/Assignee: JAGOTEC AG

Application No.: 08/893620   Filing Date: 11/Jul/1997

Abstract:

A pharmaceutical composition utilized for increasing neovascularization and angiogenesis during wound healing in a mammal beyond the level of neovascularization and angiogenesis which would occur at the wound site without any treatment, said composition comprising an effective amount of any angiostatic steroid which has reduced or no deteriorative or detrimental side effects combined with an effective amount of a form of hyaluronan such as hyaluronic acid and pharmaceutically acceptable salts thereof.

Priority:

Inventor: SEED MICHAEL P [GB]; ALAM CHANDAN [GB]; WILLOUGHBY DEREK A [GB]

Title: High molecular weight primary aliphatic alcohols obtained from natural products and uses thereof

Applicant/Assignee: HAUSER, INC

Application No.: 10/133986   Filing Date: 25/Apr/2002

Abstract:

The present invention relates to a naturally obtained mixture of higher molecular weight primary aliphatic alcohols which contain 20 to 34 carbon atoms. This invention also relates to the process for obtaining the alcohol mixture by extraction and purification with organic solvents from a natural product, such as beeswax with and without saponification of the natural product. The alcohol mixture obtained from beeswax has enhanced purity and contains a mixture of alcohols having 20, 22, 24, 26, 27, 28, 30, 32 and 34 carbon atoms. The alcohol mixture is useful in pharmaceutical compositions, foodstuffs and dietary supplements and is effective for lowering cholesterol and LDL-cholesterol and increasing HDL-cholesterol levels so that it is effective in treating hypercholesterolemia.

Consequently the composition may be used to reduce the risk of coronary heart disease, to inhibit the atherosclerotic process (platelet hyperaggregability, ischemia and thrombosis) and also to act as an anti-inflammatory and anti-thrombotic agent. The composition also possesses neurotrophic properties and is useful for improving male sexual activity.

Priority: US2001-949285 Applic. Date: 2001-09-07; US2001-845043 Applic. Date: 2001-04-27; US1999-337339 Applic. Date: 1999-06-21; US20000236515P Applic. Date: 2000-09-29

Inventor: GAMBLE WILLIAM R [US]; LIU ZHENGJIE [US]; BAILEY DAVID T [US]; PEREZ PEDRO P [US]; STULL DEAN P [US]; RICHHEIMER STEVEN L [US]; NICHOLS REBECCA L [US]; LENOBLE ROD [US]

Title: Osmotic device having a preformed passageway that increases in size

Applicant/Assignee: OSMOTICA CORP

Application No.: 09/728859   Filing Date: 30/Nov/2000

Abstract:

The present invention provides a simple and improved osmotic device (1) that is capable of providing a controlled release of active agent contained in the core (4) through a preformed passageway (5) into an environment of use. The preformed passageway (5) increases in size during use of the osmotic device (1) thereby increasing the release rate of the active agent, enabling the release of large particles containing active agent, and enabling the release of active agents that are substantially insoluble in the environment of use.

Priority: US20000177427P Applic. Date: 2000-01-21

Inventor: FAOUR JOAQUINA [AR]

Title: Mechanically stable pharmaceutical presentations form containing liquid or semisolid surface-active substances

Applicant/Assignee: ABBOTT GMBH & CO. KG

Application No.: 09/936349   Filing Date: 11/Sep/2001

Abstract:

The present invention relates to mechanically stable pharmaceutical presentations for oral administration, comprising in addition to one or more active ingredients and at least one melt-processable matrix-forming excipient more than 10 and up to 40% by weight of a surface-active substance with an HLB of from 2 to 18, which is liquid at 20 DEG C. or has a drop point in the range from 20 to 50 DEG C.

Priority: DE19991013692 Applic. Date: 1999-03-25; WO2000EP02381 Applic. Date: 2000-03-17

Inventor: ROSENBERG JOERG [DE]; BERNDL GUNTHER [DE]; LIEPOLD BERND [DE]; BREITENBACH JOERG [DE]

Title: Method of making ibuprofen and narcotic analgesic compositions

Applicant/Assignee: BASF CORPORATION KNOLL PHARMACEUTICAL COMPANY

Application No.: 10/028939   Filing Date: 21/Dec/2001

Abstract:

Provided herein are compositions and methods of making compositions of ibuprofen in combination with a narcotic analgesic. Specifically provided is a pharmaceutical tablet composition comprising ibuprofen

a narcotic analgesic

colloidal silicon dioxide

a filler selected from the group consisting of microcrystalline cellulose and powdered cellulose

a disintegrant selected from the group consisting of croscarmellose sodium, crospovidone, and sodium starch glycolate

a binder consisting of an akylhydroxy methylcellulose

a starch

and a lubricant. Also provided herein is a method of preparing a pharmaceutical tablet composition comprising: (a) Granulating ibuprofen, a narcotic analgesic, a first glidant, a first disintegrant, a binder, and starch to form granules wherein said granulating step comprises a wet granulation process

(b) blending the granules with extra-granular material comprised of a second glidant, a second disintegrant, a filler and starch to form a blend of granules and extra-granular material

and (c) compressing the blend into a tablet.

Priority: US1997-872217 Applic. Date: 1997-06-10; US19960020973P Applic. Date: 1996-06-12

Inventor: KUSHLA GREGORY P [US]; LAI JIN-WANG [US]; POLLI GERALD P [US]

Title: Masking agent in powder form for pharmaceutical tastes

Applicant/Assignee: PANCOSMA SOCIETE ANONYME POUR L'INDUSTRIE DES PRODUITS

Application No.: 10/003569   Filing Date: 24/Oct/2001

Abstract:

A masking agent for pharmaceutical tastes comprises a mixture of a sapid agent and an enhancer, in the form of an intimate mixture. The sapid agent/enhancer distribution is substantially homogeneous and non-statistical. The proportion of sapid agent relative to the enhancer is substantially constant and equal in all powder particles. The masking agent can have a grain size comprised between 10 and 100 mum, with a Gaussian distribution. The proportion of sapid agent/enhancer is comprised between 97/3 and 90/10, expressed in parts by weight. The sapid agent comprises a sweetener selected from the group comprising sodium saccharinates, calcium saccharinates, saccharine, aspartyl-phenylalanine, acesulfam, cyclamates, stevioside, and mixtures thereof

and the enhancer is selected from the group comprising thaumatin, neohesperidin dihydrochalcone (NHDC), glycyrrhizin, and mixtures thereof.

A method of producing a masking agent is also disclosed.

Priority: EP19970810941 Applic. Date: 1997-12-03; US2000-555813 Applic. Date: 2000-07-24

Inventor: FELISAZ DENIS [FR]; JACQUIER YVAN [CH]

Title: Nasal delivery of xylitol

Applicant/Assignee: NASTECH PHARMACEUTICAL COMPANY, INC

Application No.: 09/429255   Filing Date: 29/Oct/1999

Abstract:

The present invention is a method and pharmaceutical composition for prevention and/or treatment of upper respiratory infections including otitis media by nasal administration of xylitol.

Priority: US19980106388P Applic. Date: 1998-10-30

Inventor: ROMEO VINCENT D [US]; BEHL CHARANJIT R [US]

Title: Method for producing quickly decomposable solid pharmaceutical preparations

Applicant/Assignee: BAYER AG

Application No.: 10/030456   Filing Date: 03/Jan/2002

Abstract:

Rapidly disintegrating preparations containing at least one active pharmaceutical ingredient and at least one excipient can be obtained by a simple process in which at least the predominant part of the complete composition of the ingredients for the preparation to be produced is granulated, the resulting granules and, where appropriate, the remainder of the ingredients are shaped in the presence of liquid virtually without pressure, and the resulting shaped articles are dried.

Priority: DE19991031708 Applic. Date: 1999-07-08; WO2000EP05938 Applic. Date: 2000-06-27

Inventor: SCHROEDER MARCO [DE]; STEFFENS KLAUS-JUERGEN [DE]

Title: Drug delivery device containing oseltamivir and an H1 antagonist

Applicant/Assignee: OSMOTICA CORP

Application No.: 09/907486   Filing Date: 17/Jul/2001

Abstract:

The present invention provides a dual release solid dosage form containing a first composition that releases oseltamivir in a controlled manner and a second composition that releases an H1 antagonist in a rapid and/or immediate manner. A wide range of H1 antagonist antihistamines, especially fexofenadine and loratadine, can be used in this device. Particular embodiments of the invention provide osmotic devices having predetermined release profiles. The device is useful for the treatment of respiratory congestion and other viral infection associated symptoms.

Priority:

Inventor: FAOUR JOAQUINA [AR]; VERGEZ JUAN A [AR]

Title: Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture

Applicant/Assignee:

Application No.: 09/606399   Filing Date: 29/Jun/2000

Abstract:

The present invention relates to a novel form of cross-linked high amylose starch and processes for its manufacture. Such cross-linked high amylose starch is useful as an excipient in a controlled-release pharmaceutical formulation when compressed with pharmaceutical agent(s) in a tablet. Such cross-linked high amylose starch is prepared by (a) cross-linking and chemical modification of high amylose starch, (b) gelatinization, and (c) drying to obtain a powder of said controlled release excipient. In a preferred embodiment, such cross-linked high amylose starch is prepared in the following steps: (1) granular cross-linking and additional chemical modification (e.g., hydroxypropylation) of high-amylose starch

(2) thermal gelatinization of the starch from step (1)

and (3) drying the starch from step (2) to yield a powder capable of being used as a controlled release excipient.

Priority:

Inventor: LENAERTS VINCENT [CA]; BECK ROLAND HERWIG FRIEDRICH [US]; VAN BOGAERT ELSIE [BE]; CHOUINARD FRANCOIS [CA]; HOEPCKE REINER [DE]; DESEVAUX CYRIL [CA]

Title: Lipstatin derivative-soluble fiber tablets

Applicant/Assignee: SMITHKLINE BEECHAM CORPORATION

Application No.: 09/786518   Filing Date: 06/Mar/2001

Abstract:

The present invention relates to a novel pharmaceutical composition and process for preparing swallowable rapidly disintegrating methylcellulose and lipstatin derivatives together in combination with a suitable diluent and excipients.

Priority: US19980099399P Applic. Date: 1998-09-08; WO1999US20744 Applic. Date: 1999-09-08

Inventor: DAGGY BRUCE P [US]; MANDEL KENNETH G [US]

Title: CALCIUM METASILICATES AND METHODS FOR MAKING

Applicant/Assignee:

Application No.: 10/156890   Filing Date: 29/May/2002

Abstract:

Disclosed is calcium metasilicate having an aspect ratio (average major axial diameter/average minor axial diameter) of from about 1:1 to about 2.5:1, and an oil absorption of from about 20 ml/100 g to about 220 ml/100.

Priority: US20010333899P Applic. Date: 2001-11-28

Inventor: WITHIAM MICHAEL C [US]; CONLEY DONALD P [US]; YANNUL EDWARD T [US]

Title: Porous paclitaxel matrices and methods of manufacture thereof

Applicant/Assignee: ACUSPHERE, INC

Application No.: 09/798824   Filing Date: 02/Mar/2001

Abstract:

Paclitaxel is provided in a porous matrix form, which allows the drug to be formulated without Cremophor and administered as a bolus. The paclitaxel matrices preferably are made using a process that includes (i) dissolving paclitaxel in a volatile solvent to form a paclitaxel solution, (ii) combining at least one pore forming agent with the paclitaxel solution to form an emulsion, suspension, or second solution, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of paclitaxel. The pore forming agent can be either a volatile liquid that is immiscible with the paclitaxel solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent.

In a preferred embodiment, microparticles of the porous paclitaxel matrix are reconstituted with an aqueous medium and administered parenterally, or processed using standard techniques into tablets or capsules for oral administration.

Priority: WO2000US14578 Applic. Date: 2000-05-25; US20000186310P Applic. Date: 2000-03-02; US19990136323P Applic. Date: 1999-05-27; US19990158659P Applic. Date: 1999-10-08

Inventor: STRAUB JULIE [US]; BERNSTEIN HOWARD [US]; CHICKERING III DONALD E [US]; KHATTAK SARWAT [US]; RANDALL GREG [US]

Title: Divalproex sodium tablets

Applicant/Assignee: ANDRX CORPORATION

Application No.: 09/785069   Filing Date: 16/Feb/2001

Abstract:

A process for preparing divalproex sodium tablets is provided. The process comprises preparing a neutralized divalproex sodium solution by combining divalproex sodium, having a sodium valproate and a valproic acid moiety, with an aqueous solvent and a base, e.g., sodium hydroxide, the base being in sufficient amount to ensure neutralization of the valproic acid moiety of the divalproex sodium. The neutralized divalproex sodium solution is sprayed onto a pharmaceutically acceptable carrier, and processed to obtain divalproex sodium tablets.

Priority:

Inventor: CHEN CHIH-MING [US]; LI BOYONG [US]

Title: Anti-diabetic agent obtained from the plant humboldtia decurrens and a process for preparing the same

Applicant/Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES & TECHNOLOGY KERALA INSTITUTE FOR RESEARCH TRAINING AND DEVELOPMENT STUDIES OF SCHEDULED CASTES AND SCHEDULED TRI

Application No.: 09/993028   Filing Date: 06/Nov/2001

Abstract:

The invention relates to an anti-diabetic agent obtained from the plant Humboldtia decurrens, an anti-diabetic formulation comprising an effect amount of the extract obtained from the plant Humboldtia decurrens optionally together with additives, a process for obtaining the anti-diabetic agent, and a method for treatment of diabetes.

Priority: US2001-790793 Applic. Date: 2001-02-22

Inventor: RAO JANASWAMY MADHUSUDANA [IN]; SUMATHYKUTTY MANGATTU ACHUTANK [IN]; NAIR GOPALAN VIJAY [IN]; DAMODARAN ALATHUR DAMODARAN [IN]; RATHINAM KODANDARAMAN [IN]; SIVAKUMAR RAJAGOPAL [IN]; DAS KOTTILIL MOHAN [IN]; NAIR NARAYANAPILLAI VISWANATHA [IN]

Title: Anti-leishmanial activity of betel leaf extract

Applicant/Assignee: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH

Application No.: 10/124459   Filing Date: 18/Apr/2002

Abstract:

This invention relates to method of treating visceral leishmaniasis or kala-azar by administering effective amount of betel leaf extract or lyophilized extract together with or associated with an additive and a composition comprising betel leaf extract with a pharmaceutically acceptable additive.

Priority: WO2000IN00119 Applic. Date: 2000-12-04; US2001-772031 Applic. Date: 2001-01-30

Inventor: BANDYOPADHYAY SANTU [IN]; PAL BIKASH [IN]; BHATTACHARYA SAMIR [IN]; RAY MITALI [IN]; ROY KESHAB CHANDRA [IN]

Title: Processes for making- and a new crystalline form of- leflunomide

Applicant/Assignee: TEVA PHARMACEUTICAL INDUSTRIES LTD

Application No.: 09/736727   Filing Date: 14/Dec/2000

Abstract:

New leflunomide Form III is disclosed, along with processes for preparing it. The present invention also provides an economic process for preparing leflunomide Form II and a process for preparing leflunomide Form I from leflunomide Form III. Pharmaceutical compositions and dosage forms containing the new form and methods of using them for the treatment of rheumatoid arthritis are also disclosed.

Priority: US19990171228P Applic. Date: 1999-12-16; US20000202416P Applic. Date: 2000-05-08; US19990171237P Applic. Date: 1999-12-16; US20000182647P Applic. Date: 2000-02-15

Inventor: AVRUTOV ILYA [IL]; GERSHON NEOMI [IL]; ARONHIME JUDITH [IL]

Title: Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID

Applicant/Assignee: ASTRAZENECA AB

Application No.: 10/090882   Filing Date: 04/Mar/2002

Abstract:

An oral pharmaceutical dosage form comprising an acid susceptible proton pump inhibitor and one or more NSAIDs in a fixed formulation, wherein the proton pump inhibitor is protected by an enteric coating layer. The fixed formulation is in the form of an enteric coating layered tablet, a capsule or a multiple unit tableted dosage form. The multiple unit dosage forms are most preferred. The new fixed formulation is especially useful in the treatment of gastrointestinal side-effects associated with NSAID treatment.

Priority: SE19960000070 Applic. Date: 1996-01-08; US1999-471958 Applic. Date: 1999-12-23; US1997-793078 Applic. Date: 1997-02-13

Inventor: DEPUI HELENE [SE]; LUNDBERG PER [SE]

Title: Process for the purification of a new motility-promoting protein from buffalo serum: a slaughter house waste

Applicant/Assignee: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH

Application No.: 09/037409   Filing Date: 10/Mar/1998

Abstract:

The present invention relates to a new motility-promoting protein macromolecule and a process for the isolation of the motility promoting protein from buffalo serum/plasma, a slaughter house waste. The new motility promoting protein macromolecule preferably has a molecular mass of 66 kda. The process for preparation of a new motility-promoting protein from buffalo serum/plasma includes purifying the motility-promoting protein from the above fractionated serum/plasma by chromatography and electrophoresis methods.

Priority: EP19980301431 Applic. Date: 1998-02-26; JP19980054925 Applic. Date: 1998-03-06

Inventor: MAJUMDER GOPAL CHANDRA [IN]; MANDAL MAHITOSH [IN]; BANERJEE SASWATI [IN]

Title: Sustained release ranolazine formulations

Applicant/Assignee: CV THERAPEUTICS, INC SYNTEX (USA), LLC

Application No.: 10/259143   Filing Date: 27/Sep/2002

Abstract:

A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.

Priority: US2001-041521 Applic. Date: 2001-10-19; US2000-538337 Applic. Date: 2000-03-29; US1999-321522 Applic. Date: 1999-05-27; US19980099804P Applic. Date: 1998-09-10

Inventor: WOLFF ANDREW A [US]; BAKER FIONA [GB]; LANGRIDGE JOHN [GB]

Title: Phenytoin sodium pharmaceutical compositions

Applicant/Assignee: MYLAN PHARMACEUTICALS INC

Application No.: 09/852761   Filing Date: 11/May/2001

Abstract:

A pharmaceutical composition is provided containing an admixture of phenytoin sodium and an erodible matrix which extends the release of the phenytoin sodium over about a two hour period. The erodible matrix comprises binder(s) and diluent(s) which control the release of drug from the pharmaceutical composition. The erodible matrix can further comprise an alkaline pH modifier.

Priority: US1999-255705 Applic. Date: 1999-02-23

Inventor: ADDICKS WILLIAM J [US]; DUDA JOSEPH P [US]; SNIDER DANIEL A [US]; BENSON KERRY R [US]

Title: Edible compositions containing trehalose

Applicant/Assignee: BRITISH SUGAR PLC

Application No.: 10/048049   Filing Date: 16/Apr/2002

Abstract:

The invention provides edible compositions such as solid particulate sweeteners, boiled sweets, chocolate and chewing gum, wherein the compositions comprise at least 10% on a dry weight basis of one or more substances having an endothermic heat of solution of at least -30 kJ/kg and at least 10% on a dry weight basis of a substantially amorphous solid trehalose. The one or more substances having an endothermic heat of solution may comprise dextrose monohydrate or a crystalline sugar alcohol. The invention also provides processes suitable for the production of such edible compositions, wherein the processes comprise the step of dry mixing amorphous trehalose particles in an amount of at least 10% based on the dry weight of the composition with one or more other edible ingredients to form a dry mixture.

Priority: GB19990011783 Applic. Date: 1999-05-20; WO2000GB01914 Applic. Date: 2000-05-18

Inventor: COOPER JULIAN MICHAEL [GB]; TIAN WEI [GB]

Title: Pharmaceutical tablets

Applicant/Assignee: MERCK & CO., INC

Application No.: 10/099672   Filing Date: 15/Mar/2002

Abstract:

The present invention relates to novel pharmaceutical tablets useful for administering pharmaceutical active ingredients, such as bisphosphonates. These tablets have improved surface properties which can aid esophageal transit, thereby reducing the potential for adverse gesture intestinal effects. The present invention also relates to processes for making said novel pharmaceutical tablets.

Priority: US2001-881285 Applic. Date: 2001-06-14; US2000-605513 Applic. Date: 2000-06-28; US19990141987P Applic. Date: 1999-07-01

Inventor: CHEN TZYY-SHOW H [US]; NYAIRO THOMAS G [US]; KATDARE ASHOK V [US]

Title: Coating and excipient agent for oral or dermal dosage forms

Applicant/Assignee: ROEHM GMBH & CO. KG

Application No.: 09/764993   Filing Date: 23/Jan/2001

Abstract:

The invention relates to a method for the production of a coating and excipient agent for oral or dermal dosage forms, consisting of (a) 35-98% by weight of a copolymer consisting of radically polymerized C1-C4 esters of acrylic or methacrylic acid and additional (meth)acrylate monomers having functional tertiary ammonium groups and (b) 1-50% by weight of a softener and 1-15% by weight of an emulgator with an HLB value of less than 14, wherein constituents (a), (b) and (c) are mixed with or without adding water and optionally adding a pharmaceutical active substance and other conventional additives and the coating and excipient agent is produced by melting, casting, spreading or spraying. The invention is characterized in that the copolymer (a) is applied in powder form with a mean particle size of 1-40 mum.

Priority: DE19981033016 Applic. Date: 1998-07-23; DE19991018435 Applic. Date: 1999-04-23; WO1999EP04620 Applic. Date: 1999-07-02

Inventor: PETEREIT HANS-ULRICH [DE]; MEIER CHRISTIAN [DE]; ROTH ERNA [DE]

Title: Stabilized thyroxine compounds

Applicant/Assignee: NEW RIVER PHARMACEUTICALS INC

Application No.: 09/440635   Filing Date: 16/Nov/1999

Abstract:

Throxinyldimethylphosphinate was invented as a prodrug to stabilize thyroxine, a drug widely used to treat hypothyroidism. The presence of the dimethylphosphinate group at the phenolic hydroxyl of thyroxine is key to preventing thyroxine from decomposing through the proposed pathway. The prodrug will be hydrolyzed in the stomach or the gut into thyroxine and the biologically inert dimethylphosphinic acid. Related products may be stabilized with the same or similar protecting groups.

Priority:

Inventor: PICCARIELLO THOMAS [US]; LECLERCQ ANNE F [US]

Title: AMORPHOUS COMPOUND

Applicant/Assignee: ASTRAZENECA AB

Application No.: 09/891190   Filing Date: 25/Jun/2001

Abstract:

The present invention relates to a novel form of (S)-1-[N<2>-(1-carboxy-3-phenylpropyl]-L-lysyl]-L-proline known under the generic name lisinopril. Further, the present invention also relates to the use of the novel amorphous form of lisinopril for the treatment of hypertension and other cardiovascular diseases, pharmaceutical compositions containing it as well as processes for the preparation of the novel amorphous form of lisinopril.

Priority:

Inventor: ROBERTS RONALD JOHN [GB]

Title: Compositions for conjugated estrogens and associated methods

Applicant/Assignee: WATSON PHARMACEUTICALS, INC

Application No.: 10/076046   Filing Date: 12/Feb/2002

Abstract:

Oral conjugated estrogen formulations are disclosed and described. In one aspect, the oral formulation may be a tablet having a core and one or more coatings thereon. In addition to conjugated estrogen ingredients, the core may include one or more organic excipients and one or more inorganic excipients. In one aspect, the organic excipients may include less than about 20% w/w of a cellulose ingredient, and less than about 50% w/w of a sugar ingredient. In another aspect, the inorganic excipients may include less than about 10% w/w of a calcium phosphate tribasic ingredient. In yet another aspect, the formulation does not crack when stored at about 40 DEG C. and about 75% relative humidity for about 2 months.

Priority: US20010268177P Applic. Date: 2001-02-12

Inventor: HO THOMAS [US]

Title: Compositions of optically pure (+) norcisapride

Applicant/Assignee: SEPRACOR INC

Application No.: 09/809165   Filing Date: 16/Mar/2001

Abstract:

Compositions and methods utilizing the optically pure (+) isomer of norcisapride are disclosed. This compound has surprisingly been found to be a potent drug for the treatment of disorders of the central nervous system. The compound, (+) norcisapride, has also been found to be a potent antiemetic agent. Finally, the (+) isomer of norcisapride also avoids certain adverse side effects and certain adverse drug interactions.

Priority: US1996-684753 Applic. Date: 1996-07-19; US1997-905941 Applic. Date: 1997-08-05; US1998-123892 Applic. Date: 1998-07-28; US2000-573423 Applic. Date: 2000-05-18

Inventor: MCCULLOUGH JOHN R [US]; JERUSSI THOMAS P [US]

Title: Milled particles

Applicant/Assignee: RTP PHARMA INC

Application No.: 09/940864   Filing Date: 29/Aug/2001

Abstract:

A process for milling a solid substrate in the milling chamber of a dispersion or media mill in the presence of a two or more compositions of milling media bodies is disclosed wherein all milling media bodies contribute to the grinding of the solid substrate and wherein at least one composition of media bodies provides fragments of milling media bodies that are retained with the milled solid substrate particles in the form of a synergetic commixture produced in the milling process. More specifically, a process is disclosed for preparing a synergetic commixture comprising small particles of a solid substrate and small particulates of a first material of a desired size comprising the steps of (a) providing to the milling chamber of a media mill a contents comprising a pre-mix of a solid substrate, a fluid carrier, a plurality of milling bodies of a first material having a fracture toughness Kc1, and a plurality of milling bodies of a second material having a fracture toughness Kc2

(b) operating the media mill to grind the solid substrate and degrade at least a portion of the milling bodies of first material to produce a dispersion in the fluid carrier comprising a synergetic commixture of small particulates of the first material and small particles of the solid substrate having a desired size equal to or less than a size Sp

(c) separating the dispersion from any milling bodies and solid substrate particles having a size larger than Sp

and (d) optionally removing the fluid carrier from the dispersion to form a synergetic commixture free of fluid and comprising the particles and the small particulates, wherein KC2 is greater than KC1.

Priority: US20000229042P Applic. Date: 2000-08-31

Inventor: VERHOFF FRANK [US]; PACE GARY W [US]; SNOW ROBERT A [US]; MILLAR FAY [US]

Title: Pharmaceutical composition based on cocaethylene and use thereof for treating psychoactive substance dependence

Applicant/Assignee: DEBUSSY HOLDING SA

Application No.: 10/049061   Filing Date: 10/Jun/2002

Abstract:

The present invention relates to a pharmaceutical composition comprising cocaethylene as active ingredient and to its use in treating dependence on psychoactive substances, in particular on cocaine.

Priority: FR20000009408 Applic. Date: 2000-07-18; WO2001FR01544 Applic. Date: 2001-05-18

Inventor: LOWENSTEIN WILLIAM [FR]; SANCHEZ MARIO [FR]; LEPERE-PREVOT BENEDICTE [FR]; DE ROTHSCHILD BENJAMIN [CH]

Title: Active ingredient-containing floating forms comprising polyvinyl acetate and polyvinylpyrrolidone, their use and production

Applicant/Assignee: BASF AKTIENGESELLSCHAFT

Application No.: 09/811434   Filing Date: 20/Mar/2001

Abstract:

The present invention relates to oral dosage forms comprisinga) one or more active ingredientsb) a formulated mixture of polyvinyl acetate and polyvinylpyrrolidonec) where appropriate other excipients customary for producing the dosage form,wherein they float on gastric fluid and display delayed release of active ingredient, and to the use and production thereof.

Priority: DE20001014588 Applic. Date: 2000-03-27

Inventor: KOLTER KARL [DE]; SCHOENHERR MICHAEL [DE]; ASCHERL HERMANN [DE]

Title: MODIFIED AVIDIN-TYPE MOLECULES AS TARGETING AGENTS FOR THE LIVER AND CELLS OF THE RETICULOENDOTHELIAL SYSTEM

Applicant/Assignee: YEDA RESEARCH AND DEVELOPMENT CO., LTD

Application No.: 09/100015   Filing Date: 19/Jun/1998

Abstract:

The present invention relates to avidin-type molecules having 2,4,6-trinitrophenyl or lactosyl groups or being complexed with an antibody specific to the avidin-type molecule, which shifts the biodistribution pattern in tissues and organs to the liver, where these molecules accumulate at high levels over several days. These modified avidin-type molecules provide a means for delivery of diagnostic and therapeutic agents, including radionuclides to the liver and cells of the reticuloendothelial system (RES) for diagnosing and treating hepatic disorders and disorders of the RES.

Priority: IL19950116500 Applic. Date: 1995-12-21; WO1996US20333 Applic. Date: 1996-12-20

Inventor: SCHECHTER BILHA [IL]; ARNON RUTH [IL]; WILCHEK MEIR [IL]

Title: Antimicrobial peptides

Applicant/Assignee: BARNAUX HEALTHCARE B.V

Application No.: 09/601124   Filing Date: 13/Oct/2000

Abstract:

The present invention relates to peptides with antimicrobial activity, consisting of an amino acid chain which contains a domain of 10 to 25 amino acids, wherein the majority of the amino acids of the one half of the domain is positively charged amino acids and the majority of the amino acids of the other half of the domain is uncharged amino acids.

Priority: NL19981008139 Applic. Date: 1998-01-27; WO1999NL00045 Applic. Date: 1999-01-26

Inventor: VAN NIEUW AMERONGEN ARIE [NL]; VEERMAN ENGELMUNDUS CORNELIS I [NL]; VAN T HOF WILLEM [NL]; HELMERHORST EVA JOSEPHINE [NL]

Title: Modified release formulations containing a hypnotic agent

Applicant/Assignee: SYNTHON BV

Application No.: 09/833662   Filing Date: 13/Apr/2001

Abstract:

Hypnotic pharmaceutical compositions are made from pellets and exhibit a modified release. Zolpidem or a pharmaceutically acceptable salt thereof is a typical hypnotic. The pellets are preferably spherical and exhibit a dissolution profile that includes 60% of the hypnotic agent being release from the pellet not earlier than 5 minutes from the start of a specified in vitro dissolution test. Although the modified release profile can include 50% of the hypnotic agent being released not earlier than 15 minutes after the start of the dissolution test, the pellet preferably does not contain a release rate controlling excipient or coating. Instead, microcrystalline cellulose and the active constitute the majority of the pellet, e.g. 90% or more. Spherical pellets are also made by a convenient method that is applicable to any pharmaceutically active agent.

Priority: US20000196939P Applic. Date: 2000-04-13

Inventor: LEMMENS JACOBUS M [NL]; VAN DEN HEUVEL DENNIE J M [NL]; PLATTEEUW JOHANNES J [NL]; VAN DALEN FRANS [NL]

Title: Paroxetine compositions and processes for making the same

Applicant/Assignee: SYNTHON BCT TECHNOLOGIES, LLC

Application No.: 09/939561   Filing Date: 28/Aug/2001

Abstract:

Paroxetine salt compositions having improved stability are formed by controlling the pH to 6.5 or less. The compositions can be made with the aide of water without significant coloration problems. The paroxetine salts include paroxetine hydrochloride salts but preferably use paroxetine sulfonate salts such as paroxetine methane sulfonate.

Priority: US20000228110P Applic. Date: 2000-08-28; US20000234936P Applic. Date: 2000-09-26

Inventor: LEMMENS JACOBUS M [NL]; PETERS THEODORUS H A [NL]; PICHA FRANTISEK [CZ]; PLATTEEUW JOHANNES J [NL]; VAN DALEN FRANS [NL]

Title: Stabilized sustained release tramadol formulations

Applicant/Assignee: EURO-CELTIQUE S.A

Application No.: 10/052844   Filing Date: 19/Oct/2001

Abstract:

A stabilized sustained release oral solid dosage form which includes an effective amount of tramadol or a pharmaceutically acceptable salt thereof dispersed in a matrix of a hydrophobic material comprising a wax-like substance which was melted or softened during the preparation of the matrix, is cured at a temperature from about 35 DEG C. to about 65 DEG C. for a time period from about 4 to about 72 hours, such that the formulation, when subjected to in-vitro dissolution after exposure to accelerated storage conditions of at least one month at 40 DEG C./75% RH, releases an amount of tramadol which does not vary at any given dissolution time point by more than about 20% of the total amount of tramadol released when compared to in-vitro dissolution conducted prior to subjecting the dosage form to the accelerated storage conditions.

Priority: US1998-109615 Applic. Date: 1998-07-02; US19970051602P Applic. Date: 1997-07-02

Inventor: OSHLACK BENJAMIN [US]; HUANG HUA-PIN [US]; CHASIN MARK [US]; GOLDENHEIM PAUL [US]

Title: Porous drug matrices and methods of manufacture thereof

Applicant/Assignee: ACUSPHERE, INC

Application No.: 09/694407   Filing Date: 23/Oct/2000

Abstract:

Drugs, especially low aqueous solubility drugs, are provided in a porous matrix form, preferably microparticles, which enhances dissolution of the drug in aqueous media. The drug matrices preferably are made using a process that includes (i) dissolving a drug, preferably a drug having low aqueous solubility, in a volatile solvent to form a drug solution, (ii) combining at least one pore forming agent with the drug solution to form an emulsion, suspension, or second solution, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of drug. The pore forming agent can be either a volatile liquid that is immiscible with the drug solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent. The resulting porous matrix has a faster rate of dissolution following administration to a patient, as compared to non-porous matrix forms of the drug. In a preferred embodiment, microparticles of the porous drug matrix are reconstituted with an aqueous medium and administered parenterally, or processed using standard techniques into tablets or capsules for oral administration.

Priority: US1999-433486 Applic. Date: 1999-11-04; US19990136323P Applic. Date: 1999-05-27; US19990158659P Applic. Date: 1999-10-08

Inventor: STRAUB JULIE [US]; BERNSTEIN HOWARD [US]; CHICKERING III DONALD E [US]; KHATTAK SARWAT [US]; RANDALL GREG [US]

Title: Dry granulation formulation for an HIV protease inhibitor

Applicant/Assignee: MERCK & CO., INC

Application No.: 09/045885   Filing Date: 04/Mar/1998

Abstract:

This invention relates to a dry granulation capsule formulation of the HIV protease inhibitor, indinavir sulfate, which is useful in the treatment of AIDS, ARC or HIV infection. Processes for making the oral formulation are also disclosed.

Priority: US19970040158P Applic. Date: 1997-03-07

Inventor: LUI CHUNG Y [US]; OSTOVIC DRAZEN [US]; KATDARE ASHOK V [US]; STELMACH CHRISTINE [US]

Title: Substituted benzimidazole dosage forms and method of using same

Applicant/Assignee: CURATORS OF THE UNIVERSITY OF MISSOURI

Application No.: 09/901942   Filing Date: 09/Jul/2001

Abstract:

The present invention relates to pharmaceutical preparations comprising substituted benzimidazole proton pump inhibitors. There is provided a liquid or solid pharmaceutical dosage form that is not enteric coated or delayed released containing a proton pump inhibitor and a Primary Essential Buffer. When the dosage form is placed in a liquid phase the Primary Essential Buffer maintains the pH of the environment at a value greater than the pKa of the proton pump inhibitor for a time sufficient to substantially avoid acid degradation of the proton pump inhibitor in the environment. Also provided is a method for treating acid-related gastrointestinal disorders by administering a solid pharmaceutical dosage form

and a kit for the preparation of a liquid oral pharmaceutical composition.

Priority: US2000-481207 Applic. Date: 2000-01-11; US1998-183422 Applic. Date: 1998-10-30; US1996-680376 Applic. Date: 1996-07-15; US19960009608P Applic. Date: 1996-01-04

Inventor: PHILLIPS JEFFREY O [US]

Title: Method for administration of active substances to the olfactory region

Applicant/Assignee:

Application No.: 09/446931   Filing Date: 11/Feb/2000

Abstract:

The present invention relates to a method for administering a pharmaceutical preparation comprising at least one active substance to the olfactory region of a human. The method comprises administering a unit dose of the preparation by ejection from a nasal spray device (1) through a nostril of a human, the device and the pharmaceutical preparation being adapted so that the spray angle (3) is at the most 35 DEG . The method is useful for the treatment of diseases affecting the olfactory organ, the brain and the central nervous system. The present invention also relates to a nasal spray device (1) comprising a pharmaceutical preparation. The pharmaceutical preparation preferably contains a viscosity enhancing agent and the pharmaceutical preparation preferably has a dynamic viscosity in the range of 5-300 cP.

Priority: WO1998DK00297 Applic. Date: 1998-07-01; IS19970004516 Applic. Date: 1997-07-01

Inventor: GIZURARSON SVEINBJOERN [IS]

Title: Use of polyalkylamine polymers in controlled release devices

Applicant/Assignee: BRISTOL-MYERS SQUIBB PHARMA COMPANY

Application No.: 10/074385   Filing Date: 12/Feb/2002

Abstract:

The invention provides a method and device for administering an amine drug, such as [S-(R,S)]-2-[4-[[(4-methyl)piperazin-1-yl]carbonyl]phenoxy]-3,3-diethyl-N-[1-(3,4-methylenedioxyphenyl)butyl]-4-oxo-1-azetidinecarboxamide), in a sustained release dosage form. The invention includes a pharmaceutical composition and dosage form containing a polyalkylamine polymer and an amine drug. The polyalkylamine polymer is a hydrogel that forms hydrated particles when exposed to an aqueous environment. When mixed with the amine drug in the core of a coated tablet, the polyalkylamine polymer controls the release of the amine drug into an aqueous environment of use. The hydrated particles of the polymer together with the amine drug are released from the tablet core through plural apertures in the surrounding coat.

Priority: US20010269243P Applic. Date: 2001-02-16

Inventor: HUSSAIN MUNIR A [US]; REPTA ARNOLD J [US]

Title: Controlled release formulation containing bupropion

Applicant/Assignee: INTELLIPHARMACEUTICS CORP

Application No.: 09/166365   Filing Date: 05/Oct/1998

Abstract:

The present invention relates to a controlled release pharmaceutical formulation comprising an effective amount of an active ingredient and from about 1% to about 70% by weight of an uncrosslinked polymer, a crosslinked insoluble polymer or a mixture of uncrosslinked and crosslinked polymers.

Priority: US19970061121P Applic. Date: 1997-10-06

Inventor: ODIDI ISA [CA]; ODIDI AMINA [CA]

Title: Granulated pharmaceutical formulations and methods for making the same

Applicant/Assignee:

Application No.: 10/439865   Filing Date: 16/May/2003

Abstract:

Compounds represented by formula (Ia) are disclosed by the invention, along with compositions and complexes thereof, optionally in combination with compounds of formula (Ib). Pharmaceutical formulations and methods of making and using such compounds are also disclosed.

Priority: US2002-189659 Applic. Date: 2002-07-03; US2002-057659 Applic. Date: 2002-01-25; US2000-645145 Applic. Date: 2000-08-24; US2000-519976 Applic. Date: 2000-03-07; US19990150878P Applic. Date: 1999-08-26

Inventor: WHITTLE ROBERT R [US]; SANCILIO FREDERICK D [US]; STOWELL GRAYSON WALKER [US]; JENKINS DOUGLAS JOHN [US]; WHITTALL LINDA B [US]

Title: Vaccinal preparations

Applicant/Assignee: MITSUBISHI CHEMICAL CORPORATION

Application No.: 09/147773   Filing Date: 03/Jul/1999

Abstract:

Vaccinal preparations comprising an antigen such as tumor-associated antigens and viral antigens, together with a hydrophobized polysaccharide as adjuvant, e.g., hydrophobized polysaccharides containing a saccharide unit whose primary hydroxyl group is represented by the following formula: -O-(CH2)mCONH(CH2)nNH-CO-O-R wherein R represents an alkyl group or a sterol residue

m represents 0 or 1

and n represents an arbitrary positive integer, at a ratio of one to five units per 100 saccharide units that constitute the polysaccharide, preferably comprising an antigen encapsulated in microparticles of aggregated hydrophobized polysaccharide.

Priority: JP19960236937 Applic. Date: 1996-09-06; WO1997JP03123 Applic. Date: 1997-09-05

Inventor: SHIKU HIROSHI [JP]; SUNAMOTO JUNZO [JP]; NAKAMURA HIDEO [JP]

Title: Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LTD

Application No.: 09/392557   Filing Date: 09/Sep/1999

Abstract:

Nanoparticulate amorphous cyclosporine formulations, and nanoparticulate cyclosporine formulations comprising a mixture of amorphous and crystalline cyclosporine, having effective average particle sizes of less than about 2000 nm are described. The compositions exhibit increased bioavailability and increased consistency of bioavailability as compared to prior macro-sized cyclosporine and formulations. Methods of making and using the compositions are also described.

Priority:

Inventor: BOSCH H WILLIAM [US]; OSTRANDER KEVIN D [US]; HOVEY DOUGLAS C [US]

Title: Combination of acid protease enzymes and acidic buffers and uses thereof

Applicant/Assignee: ACTIM ORGANICS, INC

Application No.: 10/059790   Filing Date: 29/Jan/2002

Abstract:

Novel compositions comprising one or more of an acid protease and an acidic buffer, the acidic buffer comprising an acid and a pharmaceutically or cosmetically acceptable carrier, vehicle or excipient, useful for treating or preventing abnormal biological conditions, diseases or disorders, and/or for improving the texture or appearance of the skin, and/or for enhancing epidermal exfoliation and/or for enhancing epidermal cell renewal and to methods for the use of the compositions. The acid protease comprises one or more proteolytic enzymes which exhibit proteolytic activity at pH values below that of the surface of the skin, i.e., approximately pH 5.5.

The acidic buffer comprises at least one acidic buffering component that can reversibly disassociate hydrogen ions and has buffering capacity at pH values below that of the surface of the skin, i.e., approximately pH 5.5. or mixtures thereof with a pharmaceutically or cosmetically acceptable carrier, vehicle or excipient. The buffer is capable of reducing the pH of the surface of the skin to less than pH 5.5 and is susceptible to neutralization by normal epidermal processes.

Such types of abnormal biological conditions, diseases or disorders include skin atrophy, i.e., the thinning and/or general degradation of the dermis often characterized by a decrease in collagen and/or elastin as well as decreased number, size and doubling potential of fibroblast cells, and other maladies including, but are not limited to dry skin, severe dry skin, dandruff, acne, keratoses, psoriasis, eczema, skin flakiness, pruritus, age spots, lentigines, melasmas, wrinkles, warts, blemished skin, hyperpigmented skin, hyperkeratotic skin, inflammatory dermatoses, age-related skin changes and skin in need of cleansers.

Priority: US1999-354687 Applic. Date: 1999-07-16; US1999-664056 Applic. Date: 1999-11-02

Inventor: BISHOP MICHAEL [US]; GILLIS GLEN [US]; NORTON SCOTT J [US]

Title: Pharmaceutical composition with a synthetic natural progesterone and oestradiol base and its preparation process

Applicant/Assignee: LABORATOIRES BESINS ISCOVESCO

Application No.: 09/268353   Filing Date: 16/Mar/1999

Abstract:

The object of this invention is a pharmaceutical composition with a synthetic natural progesterone and oestradiol base coming in the form of a tablet, characterised by the fact that it has a disintegration time of less than 15 minutes, preferably less than 10 minutes, and more preferably still less than 5 minutes.

Priority: FR19980002830 Applic. Date: 1998-03-09; WO1999FR00515 Applic. Date: 1999-03-08

Inventor: AGNUS BENOIT [FR]; BESINS ANTOINE [FR]

Title: Modified release pharmaceutical formulation comprising amoxycillin

Applicant/Assignee: BEECHAM PHARMACEUTICALS (PTE) LIMITED BEECHAM PHARMACEUTICALS LIMITED

Application No.: 09/911905   Filing Date: 24/Jul/2001

Abstract:

Bacterial infections may be treated using a high dosage regimen of amoxycillin. Preferably, the dosage is provided by a bilayer tablet.

Priority: US2000-544417 Applic. Date: 2000-04-06; US19990129074P Applic. Date: 1999-04-13; US19990150727P Applic. Date: 1999-08-25; US19990159813P Applic. Date: 1999-10-15; US19990159838P Applic. Date: 1999-10-15

Inventor: CONLEY CREIGHTON P [US]; ROUSH JOHN A [US]; STORM KEVIN H [US]

Title: Use of 2-amino-1-(4-hydroxy-2-methanesulfonamidophenyl)ethanol for treating urinary incontinence

Applicant/Assignee: BOEHRINGER INGELHEIM PHARMA KG

Application No.: 10/060492   Filing Date: 30/Jan/2002

Abstract:

A method of treating urinary incontinence in a patient in need thereof, the method comprising administering to the patient an effective amount of 2-amino-1-(4-hydroxy-2-methanesulfonamidophenyl)ethanol or a pharmacologically acceptable salt thereof, and pharmaceutical compositions.

Priority: DE20011004369 Applic. Date: 2001-02-01; US20010270303P Applic. Date: 2001-02-20

Inventor: POUZET PASCALE [DE]; ESSER FRANZ [DE]; KITAGAWA HISATO [JP]; ISHIGURO NAOKI [JP]; MURAMATSU IKUNOBU [JP]

Title: Ambroxol-containing lozenge

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 10/031580   Filing Date: 23/Apr/2002

Abstract:

The present invention relates to a new tablet for sucking containing the active substance ambroxol and having improved properties.

Priority: DE19991033148 Applic. Date: 1999-07-20; WO2000EP06437 Applic. Date: 2000-07-07

Inventor: MAERZ FRIEDER ULRICH [DE]; VON DER HEYDT HOLGER HANS-HERM [DE]; SCHMITT HORST [DE]

Title: Multiple portion tablet

Applicant/Assignee: L. PERRIGO COMPANY

Application No.: 10/223127   Filing Date: 19/Aug/2002

Abstract:

A solid orally administrable pharmaceutical dosage form for the treatment of gastric disorders includes a first portion containing a therapeutically effective amount of a histamine H2-receptor antagonist, and a second portion immediately adjacent the first portion without an intervening barrier disposed between the first portion and the second portion, the second portion containing a therapeutically effective amount of an antacid. Physical separation of the active ingredients into two different portions without a separating barrier has been found sufficient to prevent degradation of the histamine H2-receptor antagonist due to contact with the antacid. The invention therefore provides stabilization of a histamine H2-receptor antagonist-antacid combination tablet which is comparable to known multiple portion tablets, but without an intervening barrier between the antacid portion and the histamine H2-receptor antagonist portion. Therefore, the benefits of the prior art are achieved at a reduced cost by eliminating a barrier and manufacturing steps associated with the provision of a barrier, as is conventional.

Priority:

Inventor: THASSU DEEPAK K [US]

Title: Taste masking coating composition

Applicant/Assignee: BRISTOL-MYERS SQUIBB CO

Application No.: 10/067724   Filing Date: 05/Feb/2002

Abstract:

There is provided a coating composition that masks the undesirable taste of a pharmaceutically active ingredient, i.e. drug or medicine, that is taken orally. The coating composition is comprised of dimethylaminoethyl methacrylate and neutral methacrylic acid ester, a cellulose ester polymer, and an alkaline modifier.

Priority: US2000-557924 Applic. Date: 2000-04-20

Inventor: CORBO MICHAEL [US]; DESAI JATIN [US]; PATELL MAHESH [US]; WARRICK RONALD [US]

Title: Pharmaceutical compositions containing an effervescent acid-base couple

Applicant/Assignee: CHIESI FARMACEUTICI S.P.A

Application No.: 09/932097   Filing Date: 20/Aug/2001

Abstract:

A pharmaceutical formulation in the form of a fast dissolving tablet comprising an active ingredient, sodium glycine carbonate and an acid capable of reacting rapidly with sodium glycine carbonate to release carbon dioxide.

Priority: IT1997MI01746 Applic. Date: 1997-07-23; US2000-463224 Applic. Date: 2000-03-21

Inventor: CHIESI PAOLO [IT]; VENTURA PAOLO [IT]; MEZZADRI ROSA [IT]; BRAMBILLA GAETANO [IT]; ACERBI DANIELA [IT]

Title: Pharmaceutical compositions and treatment methods

Applicant/Assignee: HOLLIS-EDEN PHARMACEUTICALS, INC

Application No.: 09/535675   Filing Date: 23/Mar/2000

Abstract:

The invention provides compositions comprising, 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen (viral) replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using certain steroids and steroid analogs. The invention also provides methods to make and use these immunomodulatory compositions and formulations.

Priority: US20000190140P Applic. Date: 2000-03-16

Inventor: AHLEM CLARENCE NATHANIEL [US]; DE CARVALHO LUIS DANIEL DOS AN [PT]; HEGGIE WILLIAM [PT]

Title: DRY BLEND PHARMACEUTICAL FORMULATIONS

Applicant/Assignee:

Application No.: 10/439438   Filing Date: 16/May/2003

Abstract:

Compounds represented by formula (Ia) are disclosed by the invention, along with compositions and complexes thereof, optionally in combination with compounds of formula (Ib). Pharmaceutical formulations and methods of making and using such compounds are also disclosed.

Priority: US2002-189659 Applic. Date: 2002-07-03; US2002-057659 Applic. Date: 2002-01-25; US2000-645145 Applic. Date: 2000-08-24; US2000-519976 Applic. Date: 2000-03-07; US19990150878P Applic. Date: 1999-08-26

Inventor: WHITTLE ROBERT R [US]; SANCILIO FREDERICK D [US]; STOWELL GRAYSON WALKER [US]; JENKINS DOUGLAS JOHN [US]; WHITTALL LINDA B [US]

Title: Composition containing isoflavone material and plant sterol for reducing LDL-cholesterol

Applicant/Assignee: PROTEIN TECHNOLOGIES INTERNATIONAL, INC SOLAE, LLC

Application No.: 09/821860   Filing Date: 30/Mar/2001

Abstract:

A composition is provided comprising a plant sterol and a soy protein material and/or and isoflavone selected from genistein, daidzein, glycitein, biochanin A, formononetin, and their naturally occurring glycosides, where the plant sterol comprises at least 0.49% of the composition, by weight. The present invention is also a method for decreasing the blood concentration of total and LDL cholesterol in a human in which the plant sterol and a soy protein material and/or an isoflavone are co-administered to the human, where the plant sterol comprises at least 0.49%, by weight, of the combined weight of the plant sterol and the soy protein material and/or the isoflavone.

Also provided is a method for preventing or minimizing the development of atherosclerosis in a human in which a plant sterol and a soy protein material and/or an isoflavone are co-administered to the human, where the plant sterol comprises at least 0.49%, by weight, of the combined weight of the plant sterol and the soy protein material and/or the isoflavone. A preferred composition contains an isoflavone material free of soy bean protein and at least 0.49% by weight of plant sterol. The isoflavone can be genistein, daidzein, glycitein, biochanin A, formononetin, and their naturally occurring glycosides and glycoside conjugates. The plant sterol can be B-sitosterol, campesterol, stigmasterol, sitostanol, or campestanol.

Priority: US1999-298528 Applic. Date: 1999-04-23

Inventor: WAGGLE DOYLE H [US]; POTTER SUSAN M [US]; HENLEY E C [US]

Title: Galenic formulations fast disintegrating in the mouth and method for preparing same

Applicant/Assignee: CLL PHARMA

Application No.: 09/831711   Filing Date: 05/Sep/2001

Abstract:

The invention relates to pharmaceutical dosage forms with rapid disintegration in the mouth and to their process of preparation.These pharmaceutical dosage forms comprise at least one active principle dispersed in a mixture of excipients and are characterized in that the mixture of excipients comprises at least one weakly compressible diluting agent other than trehalose and a copolymer of 1-vinylpyrrolidin-2-one and of vinyl acetate.Applications: oral administration of a great many active principles (analgesics, antispasmodics, agents used in gastroenterology, agents for combating motion sickness, antimigraines, beta-blockers, antihistaminics, antibiotics or antibacterials, antivertigos, hypnotics, and the like).

Priority: FR19990011513 Applic. Date: 1999-09-15; WO2000FR02563 Applic. Date: 2000-09-15

Inventor: LARUELLE CLAUDE [FR]; ZAKARIAN NOEL [FR]; GIMET RENE [FR]; TOSELLI DOMINIQUE [FR]

Title: Method of depositing particles with an electrostatic chuck

Applicant/Assignee: DELSYS PHARMACEUTICAL CORPORATION DELSYS PHARMACEUTICAL

Application No.: 10/174301   Filing Date: 17/Jun/2002

Abstract:

The present invention is directed to electrostatic chucks, methods for their use, the electrostatic deposition of objects, such as particles in a dry powder, onto recipient substrates, and the recipient substrates themselves that have been subjected to electrostatic deposition. In one aspect, the present invention provides an electrostatic chuck for electrostatically attracting an object or objects wherein the object is used in chemical or pharmaceutical assaying or manufacturing. The objects can be pharmaceutical substrates, for example, such as a pharmaceutical tablet. Additional embodiments of the invention provide chucks and their use to electrostatically attract particles, such as a pharmaceutically active ingredient, to a substrate, such as a tablet.

In one aspect, the electrostatic chuck comprises a floating electrode, and is used to selectively attract particles to a substrate above the floating electrode, thereby providing for charge imaging for the deposition of particles in a selected image. Additionally, the invention provides comprising a sensing electrode, optionally for use with an electrostatic chuck, for sensing the number of particles attracted to the objects on the chuck or other substrate, thereby providing for deposition of an accurate amount of particles. Furthermore, the present invention provides objects having selected areas in which particles are applied to the object via electrostatic means.

Priority: US2000-740123 Applic. Date: 2000-12-19; US1998-175287 Applic. Date: 1998-10-20; US1996-661210 Applic. Date: 1996-06-10; US1996-630050 Applic. Date: 1996-04-09

Inventor: SUN HOI CHEONG STEVE [US]; PLETCHER TIMOTHY ALLEN [US]

Title: Pentasaccharides processes for their preparation and pharmaceutical compositions containing them

Applicant/Assignee: SANOFI-SYNTHELABO

Application No.: 09/600516   Filing Date: 16/Jul/2001

Abstract:

Pentasaccharides in acidic form and their pharmaceutically acceptable salts, the anionic form thereof having the formula:wherein:R represents hydrogen or an -SO3<->, (C1-C3)alkyl or (C2-C3)acyl group

T represents hydrogen or an ethyl group

andn represents 1 or 2 for use in the treatment of pathologies associated with a clotting dysfunction.

Priority: FR19980000514 Applic. Date: 1998-01-19; WO1999FR00045 Applic. Date: 1999-01-13

Inventor: PETITOU MAURICE [FR]

Title: Controlled release formulation

Applicant/Assignee: RANBAXY LABORATORIES LIMITED

Application No.: 10/054077   Filing Date: 22/Jan/2002

Abstract:

The present invention relates to a controlled release pharmaceutical composition comprising amounts ranging from about 0.1 to about 4.5% w/w, of one or more of rate controlling cellulosic ether polymers.

Priority: WO2001IB01564 Applic. Date: 2001-08-29

Inventor: RAMPAL ASHOK [IN]; RAGHUVANSHI RAJEEV S [IN]; KUMAR MANOJ [IN]

Title: Nicotine-containing pharmaceutical compositions giving a rapid transmucosal absorption

Applicant/Assignee: PHARMACIA AB

Application No.: 09/856522   Filing Date: 11/Jul/2001

Abstract:

Formulations of nicotine for use in nicotine replacement therapy. The formulations are intended for application in the oral cavity where upon the uptake of nicotine mainly takes place through the buccal mucosa. The formulations essentially comprise apolar, polar and surface-active components. The formulations may be administered in combination with other nicotine formulations.

Priority: SE19980003986 Applic. Date: 1998-11-23; WO1999SE01983 Applic. Date: 1999-11-04

Inventor: ANDERSSON SVEN BOERJE [SE]; LANDH TOMAS [SE]; JONN STEFAN [SE]; GRUDEN STEFAN [SE]; LINDBERG NILS-OLOF [SE]

Title: Extended release metformin hydrochloride formulations

Applicant/Assignee: INTELLIPHARMACEUTICS CORP

Application No.: 09/845496   Filing Date: 01/May/2001

Abstract:

An extended release formulation of metformin hydrochloride is disclosed. The metformin hydrochloride is encased within polymeric film layers providing for gradual release of the metformin hydrochloride for over 12 and even 24 hours in the gastrointestinal tract and the blood plasma.

Priority: US20000202768P Applic. Date: 2000-05-09

Inventor: ODIDI AMINA [CA]; ODIDI ISA [CA]

Title: Methods comprising intranasal morphine

Applicant/Assignee: NASTECH PHARMACEUTICAL COMPANY INC

Application No.: 09/594916   Filing Date: 15/Jun/2000

Abstract:

The present invention relates to a pharmaceutical formulation for intranasal administration comprising morphine or pharmaceutically acceptable salt thereof at a pH from about 3.0 to about 7.0. Such formulations provide enhanced absorption of morphine or pharmaceutically acceptable salts thereof. In one embodiment, the present invention provides a method for eliciting an analgesic or anesthetic response in a mammal which includes nasally administering a therapeutically effective amount of morphine or pharmaceutically acceptable salt thereof at a pH from about 3.0 to about 7.0.

Priority: US1999-334537 Applic. Date: 1999-06-16

Inventor: ACHARI RAJA G [US]; BEHL CHARANJIT R [US]; DEMEIRELES JORGE C [US]; DUA RAMNEIK [US]; ROMEO VINCENT D [US]; SILENO ANTHONY P [US]

Title: Controlled-release pharmaceutical preparation containing nalbuphine and a process for preparing the same

Applicant/Assignee:

Application No.: 09/991608   Filing Date: 26/Nov/2001

Abstract:

A controlled-release pharmaceutical preparation containing an oil suspension which comprises an analgesic and an injectable oil. The analgesic is either a nalbuphine free base or a pharmaceutical salt of nalbuphine such as nalbuphine HCl. The injectable oil is preferably sesame oil. The oil suspension contains microparticles in the size range of 1 to 100 mum, preferably less than 50 mum, which is produced by treating the analgesic and injectable oil in an ultra high energy mixing equipment. The controlled-release preparation permits nalbuphine free base or nalbuphine HCl to have a longer duration of action in relieving pain, and allows the administration of lower doses. A process for preparing the injectable oil suspension is also disclosed.

Priority:

Inventor: HU OLIVER YOA-PU [TW]; HSIONG CHENG-HUEI [TW]

Title: Particulate blends and compacted products formed therefrom, and the preparation thereof

Applicant/Assignee: ALBEMARLE CORPORATION

Application No.: 09/487816   Filing Date: 18/Jan/2000

Abstract:

The dry blends comprise a powdery or finely-divided active ingredient such as a pharmaceutical, dietary supplement, agricultural chemical, water-treating agent or biocidal agent, and a micronized synthetic polyolefin-based hydrocarbon wax and/or a micronized synthetic polyfluorocarbon wax that is compatible with the active ingredient. Shape-retentive compacted compositions are formed by pressure compacting such blends. Preferred active ingredients are 1,3-dihalo-5,5-dialkylhydantoins and profen pharmaceuticals such as naproxen.

Priority:

Inventor: HOWARTH JONATHAN N [US]; PETERS BRUCE C [US]

Title: Pharmaceutical compositions comprising 2-isoxazoles-8-aminotetralin derivatives

Applicant/Assignee: SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.)

Application No.: 10/069804   Filing Date: 30/Jan/2002

Abstract:

The invention relates to novel pharmaceutical compositions comprising 2-isoxazole-8-aminotetralin derivatives. The invention more specifically relates to compositions in the form of a patch comprising a therapeutically efficacious amount of a derivative of 2-isoxazole-8-aminotetraline, especially 1,2,3,4-tetrahydro-8(5-isoxazolyl)N-N-diisopropyl-2-naphtalenamine. The invention also relates to a 2-isoxazole-8-aminotetralin derivative, especially 1,2,3,4-tetrahydro-8-(5-isoxazolyl)-N,N-diisopropyl-2-naphtalenamine, which is used to produce a medicament which can be administered transdermally to treat irritable bowel syndrome.

Priority: FR19990005268 Applic. Date: 1999-04-26; WO2000FR01099 Applic. Date: 2000-04-26

Inventor: MOREAU JACQUES PIERRE [US]; GUIMBERT BEATRICE [FR]; PELLET MARC [FR]

Title: Formulation of adenovirus for gene therapy

Applicant/Assignee: INTROGEN THERAPEUTICS, INC

Application No.: 09/441410   Filing Date: 16/Nov/1999

Abstract:

The present invention addresses the need to improve the long-term storage stability (i.e. infectivity) of vector formulations. In particular, it has been demonstrated that for adenovirus, the use of bulking agents, cryoprotectants and lyoprotectants imparts desired properties that allow both lyophilized and liquid adenovirus formulations to be stored at 4 DEG C. for up to 6 months and retain an infectivity between 60-100% of the starting infectivity.

Priority: US19980108606P Applic. Date: 1998-11-16; US19990133116P Applic. Date: 1999-05-07

Inventor: WU ZHENG [US]; ZHANG SHUYUAN [US]

Title: Treatment of hyperproliferative skin disorders and diseases

Applicant/Assignee: NUCRYST PHARMACEUTICALS CORP

Application No.: 09/916757   Filing Date: 27/Jul/2001

Abstract:

The invention relates to the use of one or more noble metals selected from silver, gold, platinum, and palladium but most preferably silver, in a nanocrystalline form, for the treatment of a hyperproliferative skin disorder or disease such as psoriasis. Among the noble metals, silver is preferred for such treatment. The nanocrystalline noble metal of choice may be used in the form of a nanocrystalline coating of one or more noble metals, a nanocrystalline powder of one or more noble metals, or a solution containing dissolved species from a nanocrystalline powder or coating of one or more noble metals.

Priority: US2000-628735 Applic. Date: 2000-07-27

Inventor: BURRELL ROBERT EDWARD [CA]; WRIGHT JOHN BARRYMORE [CA]; LAM KAN [CA]

Title: Spray drying process and compositions of fenofibrate

Applicant/Assignee: RTP PHARMA INC

Application No.: 09/838593   Filing Date: 20/Apr/2001

Abstract:

The present invention relates to a novel spray drying process for the preparation of pharmaceutical compositions containing small particles of phospholipid-stabilized fenofibrate. This invention also relates to spray dried powdered compositions prepared according to this process, and to dosage forms of fenofibrate (capsules, tablets, powders, granules, and dispersions) prepared from these powdered compositions. The powdered compositions and dosage forms are useful in the treatment of dyslipidemia and dyslipoproteinemia and have the advantage that they provide reduced in vivo variability in the bioavailability of fenofibrate active species among fed and fasted patients when administered orally.

Priority: US20000234186P Applic. Date: 2000-09-20; US20000241761P Applic. Date: 2000-10-20; US20010270157P Applic. Date: 2001-02-22

Inventor: PACE GARY W [US]; MISHRA AWADESH K [CA]; SNOW ROBERT A [US]; PARIKH INDU [US]; GUIVARC H POL-HENRI W [CA]

Title: Electro-powder

Applicant/Assignee: MICRODRUG AG

Application No.: 09/636548   Filing Date: 11/Aug/2000

Abstract:

A method and a process are disclosed for preparation of medical electro-powders. The electro-powder results from preparations of chemical and biological substances to form electro-powders suitable for electrostatic charging and dosing for functionality in a dry powder inhaler device. The electro-powder resulting from the method and process forms an active powder substance or a dry powder medical formulation with a fine particle fraction representing of the order 50% or more of the content having a size ranging between 0.5-5 mum and provides electrostatic properties with an absolute specific charge per mass after charging of the order 0.1x10<-6 >to 25x10<-6 >C/g and presenting a charge decay rate constant Q50>0.1 sec with a tap density of less than 0.8 g/ml and a water activity aw of less than 0.5. In the processing the active substance is a generally pharmaceutical active chemical or biological substance, for instance a polyeptide or any other corresponding substance selected alone or mixed or blended together with one or more excipients being a compound to improve electrostatic properties of the medical dry powder substance or dry powder medical formulation. Further the electro-powder may even be formed as a micro-encapsulation by coating micronized powder with the excipient in such a way that the active substance is capsulated, whereby the powder electrostatic properties mainly comes from the excipient.

Priority: SE20000002822 Applic. Date: 2000-08-04

Inventor: NILSSON THOMAS [SE]; NILSSON LARS-GUNNAR [SE]

Title: PHARMACEUTICAL COMPOSITION OF TOPIRAMATE

Applicant/Assignee: ORTHO-MCNEIL PHARMACEUTICAL, INC

Application No.: 09/259718   Filing Date: 01/Mar/1999

Abstract:

The invention is directed to a pharmaceutical composition of topiramate an anticonvulsant which is useful for treating epilepsy. More specifically, the present invention provides a solid dosage formulation of topiramate intended primarily for use by pediatric patients, or for patients who have difficulty swallowing tablets. Processes for preparing the pharmaceutical composition are also described.

Priority: US19980076770P Applic. Date: 1998-03-04

Inventor: THAKUR MADHAV S [US]; KOTWAL PRAMOD M [US]; GIBBS IRWIN S [US]

Title: SALT OF PERINDOPRIL AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT

Applicant/Assignee: LES LABORATOIRES SERVIER

Application No.: 10/371865   Filing Date: 21/Feb/2003

Abstract:

The present invention relates to a new salt of perindopril and to pharmaceutical compositions containing it, and Medicaments for treatment of hypertension and heart failure.

Priority: FR20020004847 Applic. Date: 2002-04-18

Inventor: DAMIEN GERARD [FR]; LEFOULON FRANCOIS [FR]; MARCHAND BERNARD [FR]

Title: Method and compositions for regulation of 5-alpha reductase activity

Applicant/Assignee: UNIVERSITY OF CHICAGO OFFICE OF TECHNOLOGY AND INTELLECTUAL PROPERTY

Application No.: 10/132050   Filing Date: 24/Apr/2002

Abstract:

Pharmaceutical compositions and methods for treating androgen related disorders. The pharmaceutical compositions may include a 5alpha-reductase inhibitor, such as natural and synthetic flavanoids, catechols, curcumin-related substances, quinones, catechins, particularly epigallocatechin derivatives, fatty acids, and the salts, esters, analogues, pro-drugs, isomers, racemic mixtures, or derivatives of any of the foregoing. The use of testosterone (or DHT) combinations with the aforementioned 5alpha-reductase inhibitor compounds is also contemplated.

Priority: US2000-530443 Applic. Date: 2000-04-28; US19970063770P Applic. Date: 1997-10-31

Inventor: LIAO SHUTSUNG [US]; HIIPAKKA RICHARD [US]

Title: Treating irritable bowel syndrome or disease

Applicant/Assignee: MERACOL CORPORATION LIMITED

Application No.: 10/275270   Filing Date: 27/Mar/2003

Abstract:

A treatment for humans or other mammals for irritable bowel syndrome (IBS) or irritable bowel disease (IBD) is disclosed using dosage forms or compositions that comprise cetyl myristate alone or (in admixture or serially) both cetyl myristate and cetyl palmitate.

Priority: NZ20000504524 Applic. Date: 2000-05-12; WO2001NZ00084 Applic. Date: 2001-05-11

Inventor: MEAKIN TIMOTHY DAVID [NZ]; CADWALLADER DIANNE [NZ]; HEATLEY CRAIG LEONARD [NZ]

Title: Pharmaceutical compositions for controlled release of active substances

Applicant/Assignee: UCB, S.A

Application No.: 09/381044   Filing Date: 29/Sep/1999

Abstract:

The present invention is directed a pharmaceutical composition which can be administered orally, allowing for the controlled release of at least one active substance. The composition includes at least one active substance, between 5 and 60% by weight, relative to the total weight of the composition, of at least one excipient, selected from inert matrices, hydrophilic matrices, lipid matrices, mixtures of inert matrices and of lipid matrices, and mixtures of hydrophilic matrices and of inert matrices, with the exception of mixtures including a polyacrylic acid and at least one hydrophilic matrix of the cellulose type

and between 5 and 50% by weight, relative to the total weight of the composition, of at least one alkalinizing agent soluble in an aqueous phase under physiological pH conditions, selected from alkali or alkaline-earth metal hydroxides, carbonates, bicarbonates, phosphates, sodium borate and basic salts of organic acids. The invention further includes a process for preparation of the composition, multi-layered pharmaceutical compositions including at least one layer of the inventive composition, and processes for producing same.

Priority: BE19970000225 Applic. Date: 1997-03-14; WO1998BE00033 Applic. Date: 1998-03-13

Inventor: FANARA DOMENICO [BE]; BERWAER MONIQUE [BE]; BOUQUELLE ANNE [BE]; DELEERS MICHEL [BE]

Title: Excipient

Applicant/Assignee: ASAHI KASEI KABUSHIKI KAISHA

Application No.: 09/759104   Filing Date: 12/Jan/2001

Abstract:

An excipient comprising trehalose having a purity of 99.0% or more, a proportion of particles of 75 mum or more of 2 to 90 wt %, an average particle size of 10 to 250 mum, an apparent specific volume of 1.5 to 3.5 ml/g, and a whiteness of 90% or more.

Priority: JP19980200295 Applic. Date: 1998-07-15; JP19980323560 Applic. Date: 1998-11-13; WO1999JP03775 Applic. Date: 1999-07-13

Inventor: OOBAE KAZUHIRO [JP]; KAMADA ETSUO [JP]; GOMI SHUN ICHI [JP]

Title: Substituted benzimidazole dosage forms and methods of using same

Applicant/Assignee: THE CURATORS OF THE UNIVERSITY OF MISSOURI

Application No.: 10/054350   Filing Date: 19/Jan/2002

Abstract:

Disclosed herein are methods, kits, combinations, and compositions for treating gastric acid disorders employing pharmaceutical compositions comprising a proton pump inhibiting agent (PPI) and a buffering agent in a pharmaceutically acceptable carrier.

Priority: US2001-901942 Applic. Date: 2001-07-09; US2000-481207 Applic. Date: 2000-01-11; US1998-183422 Applic. Date: 1998-10-30; US1996-680376 Applic. Date: 1996-07-15; US19960009608P Applic. Date: 1996-01-04

Inventor: PHILLIPS JEFFREY O [US]

Title: Lipase inhibiting compositions

Applicant/Assignee: HOFFMAN-LA ROCHE INC

Application No.: 09/660700   Filing Date: 13/Sep/2000

Abstract:

A pharmaceutical composition contains at least one inhibitor of lipases and at least one fatty acid ester of polyol. In this composition, the fatty acid ester has a melting point above the body temperature and the polyols are chosen from the group consisting of sugars, sugar derivatives, and mixtures thereof.

Priority: EP19990118179 Applic. Date: 1999-09-13

Inventor: DE SMIDT PASSCHIER CHRISTIAAN [ES]; HADVARY PAUL [CH]; LENGSFELD HANS [CH]; SCHMID MARCEL [CH]; SMALL DONALD MACFARLAND [US]; STEFFEN HANS [CH]; TARDIO JOSEPH [FR]

Title: Process for the preparation of granular and porous sucralfate dry gel

Applicant/Assignee: LABORATORIO ITALIANO BIOCHIMICO FARMACEUTICO LISAPHARMA S.P.A

Application No.: 09/744869   Filing Date: 29/Jan/2001

Abstract:

Sucralfate gel in the dry state in porous granular form having a particle-size distribution of between 100 and 1000 mum, an apparent density of the powder bed of between 0.7 and 0.9 g/ml, a settling index of between 5 and 15%, and a residual humidity of between 5 and 15%, and the corresponding process of preparation, which comprises a treatment with microwaves of a diluted solution of powdered sucralfate gel, with a sucralfate titre of between 20 and 70 wt. %. This solid product may be advantageously used in the preparation of solid pharmaceutical compositions that contain it as single active principle, or else as coating of solid compositions that contain, as active principle, a substance that may cause lesions to the gastric mucosa.

Priority: WO1999EP03879 Applic. Date: 1999-06-04; IT1998MI01785 Applic. Date: 1998-07-30

Inventor: ZAGNOLI GIORGIO [IT]; COLOMBO PAOLO [IT]; MAGGI LORETTA [IT]; CUDAZZO FABRIZIO [IT]

Title: Quick release pharmaceutical compositions of drug substances

Applicant/Assignee: NYCOMED DANMARK A/S

Application No.: 09/786864   Filing Date: 10/Jul/2001

Abstract:

The present invention relates to an oral modified release pharmaceutical composition for the administration of a therapeutically and/or prophylactically effective amount of an active substance (a drug substance), to obtain a relatively fast or quick onset of the therapeutic and/or prophylactic effect. The drug substances contained in a modified release pharmaceutical composition according to the invention are suitably a drug substance which has a pKa value below about 5, such as in a range of from about 4 to about 5. The composition is based on a powder comprising a therapeutically and/or prophylactically active substance and has such a particle size that: when the powder is subjected to a sieve analysis, then at least about 90% w/w of the particles pass through a 180 micron sieve, and when the powder is contacted with an aqueous medium to form a particulate composition, which as such a particle size that when the particulate composition is subjected to a sieve analysis, then at least about 50% w/w of the particles passes through a 180 micron sieve. Further more, the composition, when tested in accordance with the dissolution method (I) defines herein, employing 0.07 HCl as dissolution medium, release at least about 50% w/w of the active substance within the first 20 minutes of the test.

Priority: DK19980001143 Applic. Date: 1998-09-10; WO1999DK00480 Applic. Date: 1999-09-10

Inventor: BERTELSEN POUL [DK]; HANSEN NIELS GJOERLOEV [DK]; RUCKENDORFER HERMANN [AT]; ITAI SHIGERU [JP]

Title: Pharmaceutical complex

Applicant/Assignee: PFIZER INC

Application No.: 09/606508   Filing Date: 29/Jun/2000

Abstract:

This invention relates to a complex of eletriptan and a sulphobutylether-beta-cyclodextrin, or a pharmaceutically acceptable salt thereof, and to processes for the preparation of, pharmaceutical formulations including, and the uses of, such a complex.

Priority: GB19990015231 Applic. Date: 1999-06-29

Inventor: BILLOTTE ANNE [GB]

Title: Controlled release formulation for treating COPD

Applicant/Assignee: SMITHKLINE BEECHAM CORPORATION

Application No.: 09/913997   Filing Date: 22/Aug/2001

Abstract:

This invention relates to a controlled or sustained release formulation designed to deliver a PDE4 inhibitor for treating an inflammatory disease such as asthma or COPD and the like.

Priority: US19990121291P Applic. Date: 1999-02-23; WO2000US04713 Applic. Date: 2000-02-22

Inventor: FAULKNER PATRICK G [US]; LUCCA JAIME J [US]; WRZOSEK THOMAS J [US]

Title: Method for increasing the active loading of compressible composition forms

Applicant/Assignee: VERION, INC

Application No.: 09/576356   Filing Date: 22/May/2000

Abstract:

A process for increasing the percentage of active ingredient relative to non-active excipient in a compressible formulation, and also for reducing tablet size, by excluding an amount of the excipient and including in its place a reduced amount of a polysaccharide material.

Priority: US19990134977P Applic. Date: 1999-05-20

Inventor: HARDEN JEROME W [US]; GLOVER DUANE [US]; REDDING JR BRUCE K [US]

Title: Inhalatory compositions of formoterol

Applicant/Assignee: CHEMO HEALTHCARE S.A

Application No.: 10/086868   Filing Date: 04/Mar/2002

Abstract:

Inhalatory pharmaceutical compositions containing Formoterol as active ingredient, comprising:a vial containing a sterile liquid vehicle suitable for inhalation

a reservoir chamber cap containing a powder mixture consisting of Formoterol or a related salt in micronized form and one or more excipients, soluble in the vehicle and suitable for respiratory use.

Priority: IT2001MI00428 Applic. Date: 2001-03-02

Inventor: MEOLI ANDREA [CH]; CAGNONI ALESSANDRO [IT]; VANOSSI SERENO [CH]

Title: Serotonin reuptake inhibitor formulations

Applicant/Assignee: ANDRX CORPORATION

Application No.: 09/785040   Filing Date: 16/Feb/2001

Abstract:

A process for preparing amorphous paroxetine hydrochloride or sertraline hydrochloride is provided, which comprises preparing a solution in which paroxetine hydrochloride or sertraline hydrochloride and a water-soluble polymer are dissolved in a co-solvent of a volatile organic solvent and water. Said solution is dried to obtain a composition comprising amorphous paroxetine hydrochloride or sertraline hydrochloride and the water-soluble matrix.

Priority:

Inventor: CHEN CHIH-MING [US]; LI BOYONG [US]; CACACE JANICE [US]

Title: Pharmaceutical tramadol salts

Applicant/Assignee: GRUENENTHAL GMBH

Application No.: 10/084682   Filing Date: 28/Feb/2002

Abstract:

Disclosed are a compound of tramadol and a sugar substitute, pharmaceutical compositions and sustained-release formulations comprising the compound, and methods of treatment using the compound. The tramadol compound according to the present invention has reduced bitter taste of tramadol and is more acceptable to the patient.

Priority: DE19991040740 Applic. Date: 1999-08-31; WO2000EP07526 Applic. Date: 2000-08-03

Inventor: KUGELMANN HEINRICH [DE]

Title: Compositions comprising cefuroxime axetil

Applicant/Assignee: BIOCHEMIE GESELLSCHAFT M.B.H

Application No.: 09/445741   Filing Date: 10/Dec/1999

Abstract:

Cefuroxime axetil in a non-gelatinous form on contact with an aqueous liquid, e.g., in the form of a solid dispersion on a carrier, e.g., useful for the production of pharmaceutical compositions comprising cefuroxime axetil as an active ingredient and use of cefuroxime axetil in the manufacture of an oral dosage form which does not exhibit an adverse food effect.

Priority: AT19980001989 Applic. Date: 1998-11-26; WO1999EP09096 Applic. Date: 1999-11-24

Inventor: JENNEWEIN HERWIG [AT]; RANEBURGER JOHANNES [AT]

Title: Taste masking rapid release coating system

Applicant/Assignee: CIMA LABS INC

Application No.: 09/449851   Filing Date: 24/Nov/1999

Abstract:

The present invention relates to a core containing a drug encased in a spacing layer and a taste masking layer which provides effective taste masking for in-mouth disintegrable dosage forms containing highly objectionable tasting drugs, as well as dosage forms containing these cores.

Priority: US19980110032P Applic. Date: 1998-11-25

Inventor: HOLT KRIS E [US]; KHANKARI RAJENDRA K [US]; HONTZ JOHN [US]

Title: Modified release pharmaceutical formulation comprising amoxycillin

Applicant/Assignee: BEECHAM PHARMACEUTICALS (PTE) LIMITED

Application No.: 10/115700   Filing Date: 04/Apr/2002

Abstract:

Bacterial infections may be treated using a high dosage regimen of amoxycillin and potassium clavulanate. Preferably, the dosage is provided by a bilayer tablet.

Priority: US2000-544019 Applic. Date: 2000-04-06; US19990129074P Applic. Date: 1999-04-13; US19990150727P Applic. Date: 1999-08-25; US19990159813P Applic. Date: 1999-10-15

Inventor: CONLEY CREIGHTON P [US]; ROUSH JOHN A [US]; STORM KEVIN H [US]

Title: Pharmaceutical excipient having improved compressibility

Applicant/Assignee: J. RETTENMAIER & SOEHNE GMBH + CO. KG

Application No.: 10/266518   Filing Date: 08/Oct/2002

Abstract:

A microcrystalline cellulose-based excipient having improved compressibility, whether utilized in direct compression, dry granulation or wet granulation formulations, is disclosed. The excipient is an agglomerate of microcrystalline cellulose particles and from about 0.1% to about 20% silicon dioxide particles, by weight of microcrystalline cellulose, wherein the microcrystalline cellulose and silicon dioxide are in intimate association with each other. The silicon dioxide utilized in the novel excipient has a particle size from 1 nanometer to about 100 microns. Most preferably, the silicon dioxide is a grade of colloidal silicon dioxide.

An extra low moisture excipient is provided which exhibits improved compressibility as compared to conventional microcrystalline cellulose, while providing a moisture content of of from about 0.5 to 2.5% LOD, preferably between about 0.5 and about 1.8%, more preferably between 0.8 and 1.5%, and most preferably between about 0.8 and about 1.2%.

Priority: US1999-384130 Applic. Date: 1999-08-27; US1997-992073 Applic. Date: 1997-12-17; US1996-724613 Applic. Date: 1996-09-30; US1995-370576 Applic. Date: 1995-01-09

Inventor: STANIFORTH JOHN N [GB]; SHERWOOD BOB E [US]; HUNTER EDWARD A [US]

Title: Delivery system for omeprazole and its salts

Applicant/Assignee:

Application No.: 09/991059   Filing Date: 21/Nov/2001

Abstract:

The present invention provides a time-release dosage form for delivering an acid-labile pharmaceutical, such as omeprazole, into the upper portion of the gastrointestinal tract downstream of the stomach. The dosage form includes a drug-containing core surrounded by an inert time-release coating that delays release of the drug from the core until expiration of a certain time period after administration, generally 0.5-5.0 hours or 1-3 hours. When the gastrointestinal fluid contacts the core, the drug is released rapidly into the GI tract. The dosage form does not contain an enteric coating. The dosage form can also include one or more additional coatings exterior to the time-release coating to provide delivery of an immediately released loading dose of the acid-labile drug or another drug.

Priority: US20000253828P Applic. Date: 2000-11-29

Inventor: ROBINSON JOSEPH R [US]; MCGINITY JAMES W [US]

Title: Process for preparing non-hygroscopic sodium valproate composition

Applicant/Assignee: TARO PHARMACEUTICALS U.S.A., INC

Application No.: 10/057155   Filing Date: 24/Jan/2002

Abstract:

The invention is directed to non-hygroscopic oral pharmaceutical compositions of a salt of valproic acid, and processes for preparing the compositions. The non-hygroscopic pharmaceutical compositions are prepared by blending a hygroscopic salt of valproic acid, carbomer, and a non-hygroscopic additive.

Priority: US2001-767853 Applic. Date: 2001-01-24

Inventor: SAFADI MOHAMMED S [IL]; BARDER MAYA [IL]; GOLANDER YECHIEL [IL]; YACOBI AVRAHAM [US]; MOROS DANIEL A [US]; LEVITT BARRIE [US]; FRIEDMAN MICHAEL [IL]

Title: Soft tablet containing high molecular weight polyethylene oxide

Applicant/Assignee: MCNEIL-PPC, INC

Application No.: 10/097000   Filing Date: 13/Mar/2002

Abstract:

The invention relates to an immediate release tablet capable of being chewed or disintegrated in the oral cavity, which comprises a pharmaceutically active ingredient, and a matrix comprising polyethylene oxide having a weight average molecular weight of from about 500,000 to about 10,000,000. The tablet possesses exceptionally good mouthfeel and stability.

Priority:

Inventor: LUBER JOSEPH [US]; BUNICK FRANK J [US]

Title: Microparticle compositions and methods for the manufacture thereof

Applicant/Assignee: CHIRON CORPORATION

Application No.: 09/967462   Filing Date: 28/Sep/2001

Abstract:

Microparticles with adsorbed complexes of macromolecule and detergent, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(alpha-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. The surfaces of the microparticles have adsorbed thereon a complex of biologically active macromolecules, such as nucleic acids, polypeptides, antigens, and adjuvants, and a detergent. Preferred polymers are poly(D,L-lactide-co-glycolides), more preferably those having a lactide/glycolide molar ratio ranging from 40:60 to 60:40 and having a molecular weight ranging from 30,000 Daltons to 70,000 Daltons.

Preferred macromolecules are bacterial and viral antigens (such as HIV antigens, meningitis B antigens, streptococcus B antigens, and Influenza A hemagglutinin antigens) as well as polynucleotides that encode for such antigens.

Priority: US20000236077P Applic. Date: 2000-09-28

Inventor: FANG JIA-HWA [US]; SINGH MAMMOHAN [US]; O'HAGAN DEREK [US]; HORA MANINDER [US]

Title: TREATMENT OF PARKINSON'S DISEASE AND RELATED DISORDERS BY NOVEL FORMULATIONS OF THE COMBINATION CARBIDOPA-LEVODOPA

Applicant/Assignee:

Application No.: 08/835482   Filing Date: 08/Apr/1997

Abstract:

An oral antiparkinson drug delivery system consisting of carbidopa and levodopa in immediate and sustained release compartments provides a significant clinical advantage over currently available carbidopa-levodopa preparations.

Priority:

Inventor: RUBIN ALAN A [US]

Title: Amoxicillin and potassium clavulanate dosage form

Applicant/Assignee: BEECHAM PHARMACEUTICALS (PTE) LIMITED

Application No.: 10/462066   Filing Date: 13/Jun/2003

Abstract:

Bacterial infections may be treated using a high dosage regimen of amoxicillin and potassium clavulanate. Preferably, the dosage is provided by a bilayer tablet.

Priority: US2001-974572 Applic. Date: 2001-10-10; US20000239779P Applic. Date: 2000-10-12

Inventor: STORM KEVIN H [US]; CONLEY CREIGHTON P [US]; ROUSH JOHN A [US]

Title: Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents

Applicant/Assignee: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY

Application No.: 10/186070   Filing Date: 28/Jun/2002

Abstract:

The present invention provides a method for treating and preventing an epithelial cell-derived cancer in a subject in need thereof, comprising administering to the subject an amount of a 5-lipoxygenase inhibitor and PPAR ligand or derivatives thereof, effective to treat or prevent the epithelial cell-derived cancer. Also encompassed by the invention are inhibitors of enzymes that metabolize arachidonic acid.

Priority: US20010302155P Applic. Date: 2001-06-29

Inventor: MULSHINE JAMES L [US]; JETT MARTI [US]

Title: Drug delivery device

Applicant/Assignee: METRIS THERAPEUTICS LIMITED

Application No.: 09/840004   Filing Date: 20/Apr/2001

Abstract:

The invention relates to drug delivery devices for insertion into the vagina, rectum or nasal cavity comprising a body, a layer of fluid-impermeable material on at least part of said body and one or more pharmaceutical agents disposed on the surface of the material remote from said body, wherein said body comprises absorbent material. The devices exploit the highly vascularised nature of the vaginal, nasal and rectal mucosal tissue to deliver pharmaceutical agents to localised areas and/or into underlying tissues.

Priority: GB20000009914 Applic. Date: 2000-04-20

Inventor: KNOX PETER [GB]

Title: Process for the crystallization of xylitol

Applicant/Assignee: XYROFIN OY

Application No.: 09/674543   Filing Date: 27/Dec/2000

Abstract:

The invention relates to a novel process for the crystallization of xylitol by contacting a xylitol solution with particulate xylitol suspended in a gas, drying the material to produce a multitude of microrystals and conditioning the material into an agglomerated product. The invention also relates to a particulate crystalline xylitol product having novel properties, to the use thereof in confectionery, foodstuff pharmaceuticals and oral hygiene products, and to special products comprising the same.

Priority: FI19980001104 Applic. Date: 1998-05-18; WO1999FI00423 Applic. Date: 1999-05-17

Inventor: HEIKKILAE HEIKKI [FI]; NYGREN JOHANNA [FI]; SARKKI MARJA-LEENA [FI]; GROS HAAKAN [FI]; EROMA OLLI-PEKKA [FI]; PEARSON JULITA [GB]; PEPPER TAMMY [GB]

Title: High-content famciclovir tablets

Applicant/Assignee: NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD

Application No.: 09/101926   Filing Date: 24/Sep/1998

Abstract:

A pharmaceutical tablet wherein famciclovir is the active ingredient and wherein the percentage of famciclovir by weight in the tablet is 85% or greater.

Priority: WO1997EP00195 Applic. Date: 1997-01-13; GB19960000847 Applic. Date: 1996-01-16

Inventor: GREENWAY MICHAEL JOHN [GB]; SLATER JENNIFER MARY [GB]

Title: Taste masked pharmaceutical compositions

Applicant/Assignee: ORTHO-MCNEIL PHARMACEUTICAL, INC

Application No.: 10/083775   Filing Date: 26/Feb/2002

Abstract:

A taste masked pharmaceutical composition comprising a microcapsule, wherein the microcapsule comprises a pharmaceutically active agent core coated with a taste masking effective amount of a water-insoluble enteric coating, wherein the coating comprises a weakly acidic methacrylic acid-ethyl acrylate copolymer.

Priority: US20010273473P Applic. Date: 2001-03-05

Inventor: ULRICH STEPHEN A [US]; ZIMM KAREN R [US]

Title: Controlled release delivery system of solid dosage form

Applicant/Assignee: UNITECH PHARMACEUTICALS, INC

Application No.: 09/580232   Filing Date: 26/May/2000

Abstract:

This invention relates to a controlled release delivery system of solid dosage form with a plurality of controls on the release of the active ingredient or ingredients.

Priority:

Inventor: SHAW JIAJIU [US]

Title: Over-coated chewing gum formulations

Applicant/Assignee: WM. WRIGLEY JR. COMPANY

Application No.: 09/992122   Filing Date: 13/Nov/2001

Abstract:

Methods and products for delivering a medicament or agent to an individual are provided. The product includes a coating having a medicament or agent. The medicament or agent is present within the coating that surrounds a center comprising a gum base. By chewing the product, the medicament or agent is released from the product. Continuing to chew the product creates a pressure within the buccal cavity forcing the agent or medicament directly into the systemic system of the individual through the oral mucosa contained in the buccal cavity. This greatly enhances the absorption of the drug into the systemic system as well as the bioavailability of the drug within the system.

Priority: WO1999US29742 Applic. Date: 1999-12-14; US2000-510878 Applic. Date: 2000-02-23; US1999-286818 Applic. Date: 1999-04-06

Inventor: REAM RONALD L [US]; GREENBERG MICHAEL J [US]; WOKAS WILLIAM J [US]; CORRIVEAU CHRISTINE L [US]

Title: Mesalazine controlled release oral pharmaceutical compositions

Applicant/Assignee: COSMO S.P.A

Application No.: 10/009491   Filing Date: 13/Dec/2001

Abstract:

Controlled-release oral pharmaceutical compositions containing as active ingredient 5-amino-salicylic acid, comprising: a) an inner lipophilic matrix consisting of substances with a melting point below 90 DEG C. in which the active ingredient is at least partly inglobated

b) an outer hydrophilic matrix in which the lipophilic matrix is dispersed

c) optionally other excipients.

Priority: WO2000EP05321 Applic. Date: 2000-06-08; IT1999MI01316 Applic. Date: 1999-06-14

Inventor: VILLA ROBERTO [PA]; PEDRANI MASSIMO [PA]; AJANI MAURO [PA]; FOSSATI LORENZO [PA]

Title: Herbal composition of blend of active components prepared from murrya koenigii and piper betle useful for blocking of 5 lipoxygenase activity leading to the inhibition of leukotriene synthesis, suppression of interleukin-4 production, and enhancement of gamma interferon release

Applicant/Assignee: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH

Application No.: 09/985160   Filing Date: 01/Nov/2001

Abstract:

This invention relates to an herbal composition for the treatment and remedy of bronchial respiratory difficulties, more particularly this invention describes the process of separation, physicochemical characterization and biological response evaluation of active components obtained from extracts of any plant parts including leaves, barks, roots and seeds of plants M. koenigii and P. betle in order to establish their role on the treatment and remedy of bronchial respiratory troubles.

Priority: WO2000IN00127 Applic. Date: 2000-12-18; WO2000IN00102 Applic. Date: 2000-10-16; US2001-925415 Applic. Date: 2001-08-10

Inventor: BANDYOPADHYAY SANTU [IN]; ROY KESHAB CHANDRA [IN]; ROY MITALI [IN]; PAL BIKASH CHANDRA [IN]; BHADRA RANJAN [IN]; DAS KRISHNA [IN]; BHATTACHARYA SAMIR [IN]

Title: Compounds having lectinic properties and their biological applications

Applicant/Assignee: ASSOCIATION POUR LE DEVELOPPEMENT DE LA BIOTHERAPIE EXPERIMENTALE ET APPLIQUEE

Application No.: 09/077606   Filing Date: 30/Jul/1998

Abstract:

The invention relates to nucleotide sequences capable of coding for polypeptides having lectinic properties and to corresponding polypeptides of the sarcolectin type and their uses in therapeutics. In particular, the invention relates to the use of polypeptides of the sarcolection type to stimulate immunity, if necessary in combination with interferon or butyroids. The use of specific inhibitors or antagonist peptides allows opposition to the constituent production of SCL. The antibodies directed against said peptides can be used in diagnostics and therapeutics.

Priority: FR19950014336 Applic. Date: 1995-12-05; WO1996FR01937 Applic. Date: 1996-12-04

Inventor: JIANG PAN HONG [CN]; KABA ABOUBACAR [FR]; CHANY-FOURNIER FRANCOISE [FR]; CERUTTI ITALINA [FR]; CHANY CHARLES [FR]

Title: Substituted benzimidazole dosage forms and method of using same

Applicant/Assignee: THE CURATORS OF THE UNIVERSITY OF MISSOURI

Application No.: 10/260132   Filing Date: 30/Sep/2002

Abstract:

There is provided a solid pharmaceutical composition having active ingredients that include at least one non-enteric coated proton pump inhibitor and at least one buffering agent. The proton pump inhibitor, for example, omeprazole, lansoprazole, rabeprazole, esomeprazole, pantoprazole, pariprazole, and leminoprazole, or an enantiomer, isomer, derivative, free base, or salt thereof, is present in an amount of approximately 5 mg to approximately 300 mg

and the buffering agent is present in an amount of approximately 0.1 mEq to approximately 2.5 mEq per mg of proton pump inhibitor. The dosage form can be non-enteric coated and can be in the form of a suspension tablet, a chewable tablet, an effervescent powder, or an effervescent tablet.

Also provided is a method for treating an acid-related gastrointestinal disorder in a subject in need thereof by administering to the subject a solid pharmaceutical composition of the present invention.

Priority: US2000-481207 Applic. Date: 2000-01-11; US1998-183422 Applic. Date: 1998-10-30; US1996-680376 Applic. Date: 1996-07-15; US19960009608P Applic. Date: 1996-01-04

Inventor: PHILLIPS JEFFREY O [US]

Title: Composition comprising amoxicillin and potassium clavulanate

Applicant/Assignee: BEECHAM PHARMACEUTICALS (PTE) LIMITED

Application No.: 09/971560   Filing Date: 05/Oct/2001

Abstract:

Bacterial infections may be treated using a high dosage regimen of amoxicillin and potassium clavulanate. Preferably, the dosage is provided by a bilayer tablet.

Priority: US2000-689483 Applic. Date: 2000-10-12; US2000-544019 Applic. Date: 2000-04-06; US19990159813P Applic. Date: 1999-10-15; US19990150727P Applic. Date: 1999-08-25; US19990129074P Applic. Date: 1999-04-13

Inventor: STORM KEVIN H [US]; CONLEY CREIGHTON P [US]; ROUSH JOHN A [US]

Title: Topical application of opioid analgesic drugs such as morphine

Applicant/Assignee: EL KHOURY AND STEIN LTD

Application No.: 09/319735   Filing Date: 10/Jan/2000

Abstract:

The invention is directed to methods and pharmaceutical compositions for the topical administration of opioid analgesic drugs such as morphine. In particular, the invention relates to topical administration of an opioid analgesic agent, e.g., morphine sulfate, to produce a localized analgesic effect in inflamed skin or mucosal tissue, and without a transdermal or transmucosal migration of opioid agent, e.g., into the systemic circulation.

Priority: WO1996US19618 Applic. Date: 1996-12-12

Inventor: EL KHOURY GEORGE F [US]; STEIN CHRISTOPH [US]

Title: Anti-inflammatory pharmaceutical formulations

Applicant/Assignee: NORTON HEALTHCARE LTD

Application No.: 10/316236   Filing Date: 09/Dec/2002

Abstract:

An oral pharmaceutical dosage form including a mixture of a delay release formulation of a non-steroidal anti-inflammatory drug (NSAID) and a mixture containing a prostaqlandin and one or more excipients.

Priority: US2001-002411 Applic. Date: 2001-11-14; US2000-479430 Applic. Date: 2000-01-07; US1999-414673 Applic. Date: 1999-10-07; US1999-394179 Applic. Date: 1999-09-10; US19980099814P Applic. Date: 1998-09-10

Inventor: WOOLFE AUSTEN JOHN [GB]; GREENE SIOBHAN [IE]; MCINTYRE GORDON [GB]; SHETH NITIN VADILAL [US]

Title: Controlled release composition

Applicant/Assignee: BM RESEARCH A/S

Application No.: 08/693254   Filing Date: 19/Aug/1996

Abstract:

A composition for controlled delivery of at least one active substance into an aqueous medium by erosion at a preprogrammed rate of at least one surface of the composition, comprising the active substance, the matrix being erodible in the aqueous medium in which the composition is to be used, and a coating having at least one opening exposing at least one surface of said matrix, the coating comprising a first cellulose derivative which has thermoplastic properties and which is substantially insoluble in the aqueous medium in which the composition is to be used, and at least one of a second cellulose derivative which is soluble or dispersible in water, a plasticizer, and a filler. The coating is a coating which crumbles and/or erodes upon exposure to the aqueous medium such as a body fluid. The first cellulose derivative may be, e.g., ethycellulose, cellulose acetate, cellulose propionate or cellulose nitrate, and the second cellulose derivative may be, e.g., methylcellulose, carboxymethylcellulose or salts thereof, cellulose acetate phthalate, microcrystalline cellulose, ethylhydroxyethylcellulose, ethylmethylcellulose, hydroxyetylcellulose, hydroxyethylmethyl-cellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxymethylcellulose or hydroxymethylpropylcellulose.

Priority: DK19940000222 Applic. Date: 1994-02-23; WO1995DK00080 Applic. Date: 1995-02-23

Inventor: BAR-SHALOM DANIEL [DK]

Title: Pharmaceutical compositions using semi-solid delivery vehicle

Applicant/Assignee: AP PHARMA, INC AP PHARMA INC

Application No.: 10/409408   Filing Date: 07/Apr/2003

Abstract:

A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation

and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.

Priority: US2001-854180 Applic. Date: 2001-05-11; US20000325790P Applic. Date: 2000-05-11

Inventor: NG STEVEN Y [US]; SHEN HUI-RONG [US]; HELLER JORGE [US]

Title: Herbal pharmaceutical compositions for prophylaxis and/or treatment of cardiovascular diseases and the method of preparing the same

Applicant/Assignee: SUN TEN PHARMACEUTICAL CO., LTD

Application No.: 10/164568   Filing Date: 10/Jun/2002

Abstract:

The present invention provides an herbal pharmaceutical composition comprising the root of scutellaria, the rhizome of coptis, the root and rhizome of rhubarb, and the dry powders of the root of ginseng (or American ginseng) or the rhizome of ginger. The herbal pharmaceutical composition is effective in preventing patients from developing or treating patients with cardiovascular diseases, which include, but are not limited to, hypertension, coronary heart disease, cerebrovascular disease, peripheral vascular disease, heart failure, rheumatic heart disease, congenital heart disease, and cardiomyopathies. The present invention also provides methods for preparing and using the herbal pharmaceutical composition.

Priority: TW20010131897 Applic. Date: 2001-12-21

Inventor: SHEU SHUENN-JYI [TW]; SHEN CHUNG GUANG [US]

Title: Porous COX-2 inhibitor matrices and methods of manufacture thereof

Applicant/Assignee: ACUSPHERE, INC

Application No.: 10/441440   Filing Date: 19/May/2003

Abstract:

One or more COX-2 inhibitors are provided in a porous matrix form wherein the dissolution rate of the drug is enhanced when the matrix is contacted with an aqueous medium. The porous matrix yields upon contact with an aqueous medium nanoparticles and microparticles of COX-2 inhibitors having a mean diameter between about 0.01 and 5 mum and a total surface area greater than about 0.5 m<2>/mL. The dry porous matrix preferably is in a dry powder form having a TAP density less than or equal to 1.0 g/mL.

The porous COX-2 inhibitor matrices preferably are made using a process that includes (i) dissolving one or more COX-2 inhibitors in a volatile solvent to form a drug solution, (ii) combining at least one pore forming agent with the drug solution to form an emulsion, suspension, or second solution, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the dry porous matrix of COX-2 inhibitors. The resulting porous matrix has a faster rate of dissolution following administration to a patient, as compared to non-porous matrix forms of the drug.

Priority: US2001-881289 Applic. Date: 2001-06-14; US20000211723P Applic. Date: 2000-06-15

Inventor: ALTREUTER DAVID [US]; STRAUB JULIE [US]; BERNSTEIN HOWARD [US]; CHICKERING III DONALD E [US]; KOPESKY PAUL [US]; RANDALL GREG [US]

Title: Technical field

Applicant/Assignee: YAMANOUCHI PHARMACEUTICAL CO., LTD YAMANOUCHI PHARMA TECHNOLOGIES, INC

Application No.: 10/453422   Filing Date: 02/Jun/2003

Abstract:

The present invention relates to a quick disintegrating tablet in buccal cavity, comprising: a mixture, comprising a drug, a sugar (A), and an amorphous sugar (B), and after it is forming a tablet, it is humidified and dried. In particularly, the present invention relates to a quick disintegrating tablet in buccal cavity comprising: a mixture

comprising a drug, a sugar (A), and an amorphous sugar (B) which an amorphous-forming sugar in crystalline state is dissolved in a medicinally permitted solvent, the amorphous sugar is obtained from this solution by removing the solvent, and after it is forming a tablet, and it is humidified and dried.The tablet in the present invention is to provide stability against moisture at preserved, because the amorphous sugar changed to the crystalline state in a nonreversible reaction after it is humidified and dried in a manufacturing process.

The tablet in the present invention is to further provide a design for the pharmaceutical preparation with respect to the stability of a drug, because the tablet is manufactured by one kind of a sugar and an amorphous sugar. Furthermore, the tablet in the present invention is to provide a production process by utilizing a common granulating machine and by utilizing a common tablet machine.

Priority: US2000-646249 Applic. Date: 2000-09-14; US19980078761P Applic. Date: 1998-03-16

Inventor: MIZUMOTO TAKAO [JP]; MASUDA YOSHINORI [JP]; KAJIYAMA ATSUSHI [JP]; YANAGISAWA MASAHIRO [JP]; NYSHADHAM JANAKI RAM [US]

Title: Taste masked liquid pharmaceutical compositions

Applicant/Assignee: ORTHO -MCNEIL PHARMACEUTICAL, INC

Application No.: 10/083776   Filing Date: 26/Feb/2002

Abstract:

This invention is directed to a taste masked liquid pharmaceutical composition comprising a pharmaceutically active agent and a taste masking composition. In particular, the taste masking composition comprises a taste masking effective amount of an artificial sweetener.

Priority: US20010273472P Applic. Date: 2001-03-05

Inventor: ULRICH STEPHEN A [US]; ZIMM KAREN R [US]; FRANCOIS MARC KAREL JOZEF [BE]; DRIES WILLY MARIA ALBERT CARLO [BE]

Title: Pharmaceutical compositions and methods relating to fucans

Applicant/Assignee: UNIVERSITY OF BRITISH COLUMBIA

Application No.: 10/232850   Filing Date: 28/Aug/2002

Abstract:

Compositions, methods and the like comprising fucans such as fucoidan to treat surgical adhesions, arthritis, and psoriasis.

Priority: US20010315362P Applic. Date: 2001-08-29

Inventor: JACKSON JOHN K [CA]; BURT HELEN M [CA]

Title: Laboratory scale milling process

Applicant/Assignee: PHARMACIA & UPJOHN COMPANY

Application No.: 10/007515   Filing Date: 05/Dec/2001

Abstract:

There is provided a process for reducing particle size of a drug, the process comprising (a) a step of dispersing about 10 g or less of the drug in a suitable volume of a liquid dispersion medium to form a suspension

(b) a step of bringing together in a vessel grinding media, magnetically activatable means for stirring and the suspension

(c) a step of magnetically activating the means for stirring to effect milling of the suspension to a weight average particle size not greater than about 1 mum

and (d) a step of separating the resulting milled suspension from the grinding media and the magnetically activatable means for stirring.

Priority: US20000251750P Applic. Date: 2000-12-06

Inventor: HASKELL ROYAL J [US]

Title: Method for treating obesity and for inhibiting adipocyte activity

Applicant/Assignee: DAIICHI PHARMACEUTICAL CO., LTD

Application No.: 09/787397   Filing Date: 17/May/2001

Abstract:

A method for treating obesity includes administering to humans or animals a pharmaceutically effective amount of stanniocalcin in the form of a pharmaceutical composition. Stanniocalcin has an excellent activity of inhibiting the differentiation and maturation of adipocytes and therefore is useful as a drug for treating obesity.

Priority: JP19980263004 Applic. Date: 1998-09-17; WO1999JP05080 Applic. Date: 1999-09-17

Inventor: GOTO MASAAKI [JP]; TOMOYASU AKIHIRO [JP]; YAMAGUCHI KYOJI [JP]; KINOSAKI MASAHIKO [JP]; NAKAGAWA NOBUAKI [JP]

Title: Anti-RSV antibodies

Applicant/Assignee: MEDIMMUNE, INC

Application No.: 09/996288   Filing Date: 28/Nov/2001

Abstract:

The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.

The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a RSV antigen, and methods using said compositions for detection or diagnosis a RSV infection.

Priority: US2000-724531 Applic. Date: 2000-11-28

Inventor: YOUNG JAMES F [US]; KOENIG SCOTT [US]; JOHNSON LESLIE S [US]; HUSE WILLIAM [US]; WATKINS JEFFREY D [US]; WU HERREN [US]

Title: Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents

Applicant/Assignee: BAKER NORTON PHARMACEUTICALS, INC

Application No.: 10/242050   Filing Date: 12/Sep/2002

Abstract:

A method of increasing the bioavailability upon oral administration of a pharmacologically active target agent, particularly an antitumor or antineoplastic agent which exhibits poor or inconsistent oral bioavailability (e.g., paclitaxel, docetaxel or etoposide), comprises the oral co-administration to a mammalian patient of the target agent and an oral bioavailability-enhancing agent (e.g., cyclosporin A, cyclosporin D, cyclosporin F or ketoconazole). The enhancing agent may be administered orally from 0.5-24 hrs. prior to the oral administration of one or more doses of the target agent, substantially simultaneously with the target agent or both prior to and substantially simultaneously with the target agent.

A method of treating mammalian patients suffering from diseases responsive to target agents with poor oral bioavailability, as well as oral dosage forms containing such target agents, combination oral dosage forms containing bioavailability-enhancing agents and target agents and kits containing enhancing and target agent dosage forms and dosing information for the co-administration of the same are also disclosed.

Priority: US2001-829846 Applic. Date: 2001-04-10; US1996-733142 Applic. Date: 1996-10-16; US1996-608776 Applic. Date: 1996-02-29; US19950007071P Applic. Date: 1995-10-26

Inventor: BRODER SAMUEL [US]; DUCHIN KENNETH L [US]; SELIM SAMI [US]

Title: Biologically active materials

Applicant/Assignee: ML LABORATORIES PLC

Application No.: 10/018608   Filing Date: 30/Jul/2002

Abstract:

The present disclosure concerns biologically active materials, particularly materials that comprise a biodegradeable polymer linked to a biologically active agent. The disclosure further concerns materials known as polymer-drug conjugates that typically contain a therapeutic agent, for instance a bioactive cytotoxic drug linked to a polymer backbone. The linkage typically is a convalent linkage. However, in some embodiments the disclosure concerns other polymer conjugates including those where the biologically active agent is an imaging agent, such as a tyrosinamide, a diagnostic agent, or a targeting agent, such as biotin.

Priority: GB19990014187 Applic. Date: 1999-06-18; GB19990030252 Applic. Date: 1999-12-22; WO2000GB02216 Applic. Date: 2000-06-19

Inventor: DUNCAN RUTH [GB]; HRECZUK-HIRST DALE [GB]; GERMAN LISA [GB]

Title: Powdered/microfibrillated cellulose

Applicant/Assignee: IOWA RESEARCH FOUNDATION UNIVERSITY OF IOWA

Application No.: 09/946658   Filing Date: 05/Sep/2001

Abstract:

A new cellulose excipient suitable for use as a binder, filler, and/or disintegrant in the development of solid dosage forms and as a bodying agent or a drug carrier in the preparation of topical formulations is described. The cellulose excipient is formed by soaking a source of cellulose in an aqueous alkali metal hydroxide solution. The cellulose is then regenerated, washed, and optionally hydrolyzed with a dilute mineral acid. The cellulose excipient is also useful as an aqueous dispersion in topical formulations and in the manufacture of cellulose beads.

Priority: US20000232657P Applic. Date: 2000-09-14

Inventor: KUMAR VIJAY [US]

Title: Antibiotic-natural polysaccharide polymer adducts

Applicant/Assignee: ISTITUTO BIOCHIMICO PAVESE PHARMA S.P.A

Application No.: 09/979240   Filing Date: 19/Nov/2001

Abstract:

Antibiotic-natural polysaccharides polymer adducts based on non-covalent and non-ionic bonds, with an improved profile of activity compared with the corresponding antibiotic.

Priority: WO2000EP04374 Applic. Date: 2000-05-16; IT1999MI01085 Applic. Date: 1999-05-18

Inventor: ANZAGHI PIERGIORGIO [IT]; STEFLI ROSANNA [IT]

Title: Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants

Applicant/Assignee: CHIRON CORPORATION FIDIA ADVANCED BIOPOLYMERS SRL

Application No.: 09/724661   Filing Date: 28/Nov/2000

Abstract:

Compositions are provided which include hyaluronic acid derivatives in combination with vaccine antigens, and optionally adjuvants, for mucosal delivery. Also provided are methods of making the compositions, as well as methods of immunization using the same.

Priority: US19980087596P Applic. Date: 1998-06-01

Inventor: O'HAGAN DEREK [US]; PAVESIO ALESSANDRA [IT]

Title: Substantially pure cilostazol and processes for making same

Applicant/Assignee: TEVA PHARMACEUTICAL INDUSTRIES, LTD

Application No.: 10/336721   Filing Date: 06/Jan/2003

Abstract:

The present invention provides substantially pure cilostazol. The present invention also provides cilostazol particles that have reduced particle size.

Priority: US2001-929683 Applic. Date: 2001-08-14; US20000225362P Applic. Date: 2000-08-14

Inventor: MENDELOVICI MARIOARA [IL]; FINKELSTEIN NINA [IL]; PILARSKI GIDEON [IL]

Title: Film coating

Applicant/Assignee: ASTRAZENECA AB

Application No.: 10/450794   Filing Date: 16/Jun/2003

Abstract:

A film coating composition suitable for use in coating pharmaceutical formulations to provide modified release comprising a dispersion which includes: a) an acrylic polymer, b) a vinyl acetate polymer, and c) a water-containing liquid. The film coat is useful for the achievement of modified release from pharmaceutical formulations such as tablets, pellets, etc.

Priority: WO2002GB05739 Applic. Date: 2002-12-18; SE20010004327 Applic. Date: 2001-12-19; SE20010004328 Applic. Date: 2001-12-19

Inventor: LOEFROTH JAN-ERIK [SE]; SCHANTZ STAFFAN [SE]; WELIN ANDERS [SE]; HJARTSTAM LARS JOHAN PONTUS DE [SE]

Title: Fenofibrate-cyclodextrin inclusion complexes and their pharmaceutical composition

Applicant/Assignee: USV LIMITED

Application No.: 10/338562   Filing Date: 07/Jan/2003

Abstract:

The present invention relates to pharmaceutical compositions containing fenofibrate in the form of an inclusion complex with cyclodextrin, having high dissolution profile and in vivo enhanced bioavailability as compared with plain micronized fenofibrate compositions. An inclusion complex has a molar ratio of fenofibrate (preferably in micronized form) to cyclodextrin of from about 1:0.5 to about 1:4, preferably from about 1:1 to about 1:2. The immediate release fenofibrate composition is preferably in the form of a tablet or in the form of granules inside a capsule.

Priority: US20020382997P Applic. Date: 2002-05-23

Inventor: GIDWANI SURESH KUMAR [IN]; SINGNURKAR PURUSHOTTAM SHARSHI [IN]

Title: Reference standards for determining the purity or stability of amlodipine maleate and processes therefor

Applicant/Assignee: SYNTHON BV

Application No.: 09/938819   Filing Date: 27/Aug/2001

Abstract:

Amlodipine aspartate and amlodipine maleamide are used as reference standards or markers in determining the purity of amlodipine maleate substances and products.

Priority: BE20010000713 Applic. Date: 2001-11-05; US2001-809347 Applic. Date: 2001-03-16; US20000258601P Applic. Date: 2000-12-29

Inventor: LEMMENS JACOBUS M [NL]; PETERS THEODORUS H A [NL]; BAKKER PETER F A [NL]; PICHA FRANTISEK [CZ]

Title: Recombinant microorganisms expressing an oligosaccharide receptor mimic

Applicant/Assignee: WOMEN'S AND CHILDREN'S HOSPITAL ADELAIDE RESEARCH & INNOVATION PTY. LTD

Application No.: 09/658537   Filing Date: 09/Sep/2000

Abstract:

Chimeric carbohydrates produced by recombinant microorganism carrying exogenous glycosyltransferases act with or without exogenous enzymes required for synthesis or nucleotide synthesis precursors. These recombinant microorganism can be used for competitively inhibiting the binding of toxins or adhesins to receptors of mucosal surfaces, especially gastrointestinal surface. In particular chimeric sugar moieties have been made for lipopolysaccharides, in recombinant microorganism that present multiple copies of the oligosaccharides. The oligosaccharide moieties so presented act as receptor mimic for toxins and adhesins. A number have been synthesized and have been shown to confer protection against attack by pathogenic organisms or their products in vitro and in vivo.

Priority: AU1999PQ02757 Applic. Date: 1999-09-10

Inventor: PATON ADRIENNE W [AU]; MORONA RENATO [AU]; PATON JAMES C [AU]

Title: Pharmaceutical compositions and preparations for treatment of metabolic bone disease

Applicant/Assignee: YUYU INDUSTRIAL CO., LTD

Application No.: 10/111270   Filing Date: 19/Apr/2002

Abstract:

The present invention relates to a pharmaceutical composition for the treatment of metabolic bone disease and the method of preparation thereof, and more particularly, to an improved pharmaceutical composition for the therapeutic treatment of metabolic disease and the method of preparation thereof, wherein said composition is prepared as a composite pharmaceutical agent which comprises calcitriol

which reduces the rate of spine fractures and increases bone density

alendronate, a bone resorption inhibitor, as two main active ingredients in an optimal mixing ratio to exert the greatest synergistic therapeutic effect

and adequate amount of other additives such as a resorption fortifier of alendronate. Thereof, the pharmaceutical composition according to the present invention can inhibit hypercalcemia caused when administered by calcitriol alone, compensate the inhibitory activity of bone remodeling caused by alendronate due to the presence of calcitriol, and improve drug compliance associated with the usual difficulty in administration as well as a side effect in esophagus, thus effectively preventing the occurence of osteoporosis.

Priority: KR19990045623 Applic. Date: 1999-10-20; WO2000KR01188 Applic. Date: 2000-10-20

Inventor: KANG SUNG AN [KR]; LEE KYUNG HEE [KR]; KWAK CHUNG SHIL [KR]; KIM CHANG JONG [KR]; LEE YONG OH [KR]

Title: Treatment of abnormal increases in gastrointestinal motility with (R)-verapamil

Applicant/Assignee: AGI THERAPEUTICS, LTD

Application No.: 10/294692   Filing Date: 15/Nov/2002

Abstract:

The present invention is directed to methods of treating, preventing, and/or managing abnormal increases in gastrointestinal motility, and intestinal conditions that cause the same. Such conditions include, but are not limited to, irritable bowel syndrome (IBS), infectious diseases of the small and large intestines, and symptoms of any of the foregoing. In particular, the present invention discloses methods of using enriched (R)-verapamil, as well as compositions and formulations containing the same.

Priority: US2002-256261 Applic. Date: 2002-09-27

Inventor: KELLY JOHN [IE]; DEVANE JOHN [IE]; DINAN TED G [IE]; KEELING P W NAPOLEON [IE]

Title: Directly compressible high load acetaminophen formulations

Applicant/Assignee: J. RETTENMAIER & SOEHNE GMBH + CO. KG

Application No.: 10/113867   Filing Date: 01/Apr/2002

Abstract:

Direct compressed solid pharmaceutical dosage forms containing:a) from about 40 to about 95% by weight acetaminophen

b) from about 1 to about 60% by weight of a direct compression vehicle comprising microcrystalline cellulose

andc) from about 0.01 to about 4.0% by weight of a pharmaceutically-acceptable lubricant are disclosed. The acetaminophen and direct compression vehicle are combined under high shear conditions which are sufficient to transform acetaminophen and direct compression vehicle into a homogenous granulate without degradation. In preferred aspects of the invention, the lubricant is also combined with the acetaminophen and direct compression vehicle under high shear conditions. Methods of preparing the directly compressed solid pharmaceutical dosage forms and methods of treatment with the dosage forms are also disclosed.

The methods are particularly well suited for preparing directly compressed dosage forms containing high load (i.e., up to 80% or greater) amounts of acetaminophen based on the weight of the total tablet.

Priority: US2001-798755 Applic. Date: 2001-03-02; US1999-311210 Applic. Date: 1999-05-13; US1997-964917 Applic. Date: 1997-11-05; US1995-558335 Applic. Date: 1995-11-15

Inventor: HUNTER EDWARD A [US]; SHERWOOD BOB E [US]; ZELEZNIK JOSEPH A [US]

Title: Sustained release ranolazine formulations

Applicant/Assignee: CV THERAPEUTICS, INC

Application No.: 10/382266   Filing Date: 05/Mar/2003

Abstract:

A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 850 and 4000 ng base/mL.

Priority: US2002-254707 Applic. Date: 2002-09-25; US2000-520932 Applic. Date: 2000-03-08; US1999-321522 Applic. Date: 1999-05-27; US19980099804P Applic. Date: 1998-09-10

Inventor: WOLFF ANDREW A [US]

Title: Pharmaceutical excipient having improved compressibility

Applicant/Assignee: J. RETTENMAIER & SOEHNE GMBH + CO. KG

Application No.: 10/338361   Filing Date: 08/Jan/2003

Abstract:

A microcrystalline cellulose-based excipient having improved compressibility, whether utilized in direct compression, dry granulation or wet granulation formulations, is disclosed. The excipient is an agglomerate of microcrystalline cellulose particles and from about 0.1% to about 20% silicon dioxide particles, by weight of the microcrystalline cellulose, wherein the microcrystalline cellulose and silicon dioxide are in intimate association with each other. The silicon dioxide utilized in the novel excipient has a particle size from about 1 nanometer to about 100 microns. Most preferably, the silicon dioxide is a grade of colloidal silicon dioxide.

Priority: US2001-981319 Applic. Date: 2001-10-16; US2001-754760 Applic. Date: 2001-01-04; US1999-438646 Applic. Date: 1999-11-12; US1997-992073 Applic. Date: 1997-12-17; US1996-724613 Applic. Date: 1996-09-30; US1995-370576 Applic. Date: 1995-01-09

Inventor: SHERWOOD BOB E [US]; STANIFORTH JOHN H [GB]; HUNTER EDWARD A [US]

Title: Pharmaceutical compositions using semi-solid delivery vehicle

Applicant/Assignee: A.P. PHARMA, INC

Application No.: 10/765768   Filing Date: 26/Jan/2004

Abstract:

A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation

and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.

Priority: US2003-409408 Applic. Date: 2003-04-07; US2001-854180 Applic. Date: 2001-05-11; US20000325790P Applic. Date: 2000-05-11

Inventor: NG STEVEN Y [US]; SHEN HUI-RONG [US]; HELLER JORGE [US]

Title: Process for production of nanoparticles and microparticles by spray freezing into liquid

Applicant/Assignee: BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM

Application No.: 10/062648   Filing Date: 30/Jan/2002

Abstract:

The present invention provides a system and a method for the production of microparticles and nanoparticles of materials that can be dissolved. The system and method of the present invention provide quicker freezing times, which in turn produces a more uniform distribution of particle sizes, smaller particles, particles with increased porosity and a more intimate mixing of the particle components. The system and method of the present invention also produce particles with greater surface area than conventional methods. One form of the present invention provides a method for the preparation of particles. An effective ingredient is mixed with water, one or more solvents, or a combination thereof, and the resulting mixture is sprayed through an insulating nozzle located at or below the level of a cryogenic liquid. The spray generates frozen particles.

Priority: US20010264988P Applic. Date: 2001-01-30

Inventor: WILLIAMS III ROBERT O [US]; JOHNSTON KEITH P [US]; YOUNG TIMOTHY J [US]; ROGERS TRUE L [US]; BARRON MELISA K [US]; YU ZHONGSHUI [US]; HU JIAHUI [US]

Title: Anilide and cyclodextrin complexes, their preparation and their use as medicine in particular for treating dyslipidemiae

Applicant/Assignee: PIERRE FABRE MEDICAMENT

Application No.: 10/474781   Filing Date: 10/Oct/2003

Abstract:

The invention concerns more particularly dodecylthio-phenylacetanilide derivative complexes such as (S)-2',3',5'-trimethyl-4'-hydroxy-alpha-dodecylthio-phenylacetanilide or related derivatives thereof and cyclodextrins.

Priority: FR20010004855 Applic. Date: 2001-04-10; WO2002FR01224 Applic. Date: 2002-04-09

Inventor: BOUGARET JOEL [FR]; LEVERD ELIE [FR]; IBARRA MARIE-DOMINIQUE [FR]; GIL ALEXANDRE [FR]

Title: Stable amorphous celecoxib composite and process therefor

Applicant/Assignee: PHARMACIA CORPORATION

Application No.: 10/431853   Filing Date: 08/May/2003

Abstract:

A process is provided for preparing a celecoxib-crystallization inhibitor composite wherein at least a detectable amount of celecoxib is in amorphous form. Also provided are compositions prepared according to such a process. Also provided is a method of treating a medical condition or disorder in a subject where treatment with a cyclooxygenase-2 inhibitor is indicated, comprising administering, for example orally, a composition of the invention in a therapeutically effective amount.

Priority: US20020379968P Applic. Date: 2002-05-13

Inventor: ZHUANG HONG [US]; GAO PING [US]

Title: Process for preparing tannate liquid and semi-solid dosage forms

Applicant/Assignee: KIEL LABORATORIES, INC

Application No.: 10/119285   Filing Date: 09/Apr/2002

Abstract:

An active ingredient from the group of an antihistamine, a decongestant, an antitussive or anticholinergic is dissolved in a suitable solvent and added to a dispersion of tannic acid in water to form the tannate salt complex of the active ingredient. The active ingredient tannate salt complex without isolation or purification is then added to a liquid or semi-solid medium composed of thickening, suspending, coloring, sweetening and flavoring agents, with stirring. Thereafter, preservatives, pH-adjusting and anti-caking agents in a suitable solvent are mixed with the liquid or semi-solid medium to generate a therapeutic dosage form.

Priority: US20010282969P Applic. Date: 2001-04-10

Inventor: KIEL JEFFREY S [US]; THOMAS H GREG [US]; MANI NARASIMHAN [US]

Title: Combination of drospirenone and an estrogen sulphamate for HRT

Applicant/Assignee: SCHERING AG

Application No.: 10/194970   Filing Date: 15/Jul/2002

Abstract:

A pharmaceutical dosage unit comprising drospirenone and an estrogen sulphamate, such as an estradiol sulphamate or an estriol sulphamate for use in hormone replacement therapy is disclosed. This, combination therapy may comprise continuous or discontinuous administration of drospirenone and/or the estrogen sulphamate, such as weekly administration of both agents or weekly administration of the estrogen sulphamate and daily administration of the drospirenone.

Priority: DK20010001109 Applic. Date: 2001-07-13; US20010304760P Applic. Date: 2001-07-13

Inventor: SCHUERMANN ROLF [DE]; ELGER WALTER [DE]

Title: Meloxicam for oral administration

Applicant/Assignee: BOEHRINGER INGELHEIM PHARMA KG

Application No.: 09/277049   Filing Date: 26/Mar/1999

Abstract:

The invention relates in its first aspect to a rapidly decomposing tablet for pain therapy containing meloxicam [4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide] in the form of a salt with an inorganic or organic base providing rapid absorption of the active substance, the process of its preparation by direct tabletting, and furthermore relates in a second aspect to the crystalline meloxicam meglumin salt mono- and dihydrate and the preparation thereof.

Priority: EP19980105569 Applic. Date: 1998-03-27; US19980088850P Applic. Date: 1998-06-10

Inventor: BOCK THOMAS [DE]; SAEGMUELLER PAUL [DE]; SIEGER PETER [DE]; TUERCK DIETRICH [DE]

Title: STABLE PHARMACEUTICAL COMPOSITIONS CONTAINING AN ACE INHIBITOR

Applicant/Assignee: SANDOZ AG

Application No.: 10/618548   Filing Date: 11/Jul/2003

Abstract:

A stable pharmaceutical composition comprising about 1 wt. % to about 80 wt. % of an ACE inhibitor or a pharmaceutical acceptable salt thereof, about 1 wt. % to about 70 wt. % of an alkali or alkaline earth metal carbonate, and about 1 wt. % to about 80 wt. % of hydroxypropyl cellulose, wherein the ACE inhibitor is selected from the group consisting of quinapril, enalapril, spirapril, ramipril, perindopril, indolapril, lisinopril, alacepril, trandolapril, benazapril, libenzapril, delapril, cilazapril and combinations thereof

wherein the formation of an internal cyclization product, and/or ester hydrolysis product, and/or oxidation product, has been reduced or eliminated, and the weight percents are based on the total weight of the pharmaceutical composition. The stabilized pharmaceutical compositions of the invention exhibit a number of advantages as follows: (i) the ACE inhibitor or a pharmaceutical acceptable salt thereof present in the compositions is preserved from degradation

(ii) the compositions exhibit extended shelf-life under normal storage conditions

(iii) the effect of moisture on the compositions is minimized

(iv) the compositions exhibit minimal, if any, discoloration over a significant period of time

and (v) the compositions exhibit minimal, if any, instability when employed in the presence of colorants.

Priority:

Inventor: PATEL ASHISH ANILBHAI [US]; DAVILA PABLO [US]

Title: Monocyte-specific particulate delivery vehicle

Applicant/Assignee: GREENVILLE HOSPITAL SYSTEM

Application No.: 10/112036   Filing Date: 01/Apr/2002

Abstract:

The inventive vector specifically directs entry into a cell of monocytic origin. The vector is composed of a nucleic acid component, a lysosome evading component and a particle that can be phagocytized. The vector itself, or cells pretreated with the vector, are useful in all gene medicine applications. Because it is specific for monocytic cells, the inventive vector is particularly suited to vaccine applications. Due to the ability of monocytic cells to target tumors, the inventive vector also is suitable for use in anti-tumor applications, including conventional gene therapy.

Priority: US20010279769P Applic. Date: 2001-03-30

Inventor: WAGNER THOMAS E [US]; YU XIANZHONG [US]

Title: Echinacea angustifolia extracts

Applicant/Assignee: INDENA S.P.A

Application No.: 10/302842   Filing Date: 25/Nov/2002

Abstract:

An Echinacea angustifolia extract and a process for the preparation thereof are herein described. The extract is characterized by an alkylamides content lower than 0.1%, an echinacoside content ranging from 1 to 10% and containing from 1 to 15% of a polysaccharide characteristic of Echinacea angustifolia. The extract can be used for the treatment of pathological conditions in which it is desirable to strengthen the immune defenses.

Priority: IT2002MI01691 Applic. Date: 2002-07-30

Inventor: GIORI ANDREA [IT]; ANELLI ALESSANDRO [IT]; MORAZZONI PAOLO [IT]; DI PIERRO FRANCESCO [IT]

Title: Therapeutic compositions comprising excess enantiomer

Applicant/Assignee: PFIZER INC

Application No.: 09/930330   Filing Date: 15/Aug/2001

Abstract:

The present invention is concerned with pharmaceutical compositions comprising a mixture of amlodipine enantiomers, which compositions have both anti-hypertensive and additional cardiovascular properties derived respectively from their calcium channel-blocking activity and their ability to release vascular nitric oxide (NO).

Priority: GB20000020842 Applic. Date: 2000-08-23; US20000237168P Applic. Date: 2000-10-02

Inventor: CHAHWALA SURESH BABUBHAI [GB]; DODD MICHAEL GEORGE [GB]; HUMPHREY MICHAEL JOHN [GB]

Title: Liposome compositions of porphyrin photosensitizers

Applicant/Assignee: QLT, INC

Application No.: 09/589358   Filing Date: 08/Jun/2000

Abstract:

Liposomal pharmaceutical formulations incorporating porphyrin photosensitizers useful for photodynamic therapy or diagnosis of malignant cells. The liposomal formulations comprise a porphyrin photosensitizer, particularly the hydro-mono benzoporphyrine (BPD) having light absorption maxima in the range of 670-780 nanometers, a disaccharide or polysaccharide and one or more phospholipids.

Priority: US1995-489850 Applic. Date: 1995-06-13; US1992-832542 Applic. Date: 1992-02-05

Inventor: DESAI NARENDRA RAGHUNATHJI [US]; AGHA BUSHRA J [US]; KALE KALIDAS MADHAVRAO [US]; LAWTER JAMES R [US]

Title: Pharmaceutical composition for oral administration of a N-piperidino-3- pyrazolecarboxamide derivative, its salts and their solvates

Applicant/Assignee: SANOTI-SYNTHELABO

Application No.: 10/136148   Filing Date: 01/May/2002

Abstract:

The pharmaceutical compositions for oral administration according to the invention contain 0.5% to 20% of N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide in microcrystalline form, and pharmaceutical excipients

they are formulated by wet granulation.

Priority: FR19970003835 Applic. Date: 1997-03-28; US1999-381706 Applic. Date: 1999-09-22; WO1998FR00631 Applic. Date: 1998-03-27

Inventor: ABRAMOVICI BERNARD [FR]; CONDAMINE CHRISTIAN [FR]; GROMENIL JEAN-CLAUDE [FR]

Title: Stable pharmaceutical compositions without a stabilizer

Applicant/Assignee: ANDRX PHARMACEUTICALS, INC

Application No.: 10/301474   Filing Date: 21/Nov/2002

Abstract:

Stabilized controlled release pharmaceutical preparations are disclosed in which active ingredient degradation is prevented without the use of a stabilizer. The active ingredient is sealed away from excipients that can adversely affect stability by sealing the excipients rather than the active ingredient. The preparations are substantially unaffected by exposure to storage conditions of elevated temperature and/or elevated relative humidity.

Priority:

Inventor: LI BOYONG [US]; CHENG XIU XIU [US]

Title: Controlled release formulations using intelligent polymers

Applicant/Assignee: BIOVAIL CORPORATION

Application No.: 09/403437   Filing Date: 20/Dec/1999

Abstract:

An extended release dosage composition of pharmaceutically active substances that have a water contact angle (theta) such that cos theta is between +0.9848 and -0.9848 presented as a matrix tablet containing the said pharmaceutically active substances, with/without suitable pharmaceutical excipients in intimate mixture with two groups of intelligent polymers having opposing wettability characteristics, one demonstrating a stronger tendency towards hydrophobicity and the other a stronger tendency towards hydrophilicity, the polymer combination being between the ratios of 1:50 and 50:1 amounts effective to control the release of said pharmaceutically active substances in a mathematically predictable manner, wherein the polymer demonstrating a stronger tendency towards hydrophobicity is not less than 5% wt/wt and preferably between 5-70% wt/wt of the final formulation composition. The intelligent polymers being ethylcellulose (EC) as a more strongly hydrophobic and hydroxyethylcellulose (HEC) and/or hydroxypropyl methylcellulose (HPMC) as more strongly hydrophilic (the ratio of HEC to HPMC being between 1:100 and 100:1). The matrix tablet is optionally coated with an enteric coat, 0-5%-15% wt/wt to prevent the initial burst effect seen in such systems and to impart gastrointestinal tract (GIT) "stealth" characteristics especially in the presence of food.

Priority: WO1998CA00274 Applic. Date: 1998-04-03; US19970036551P Applic. Date: 1997-04-21

Inventor: ODIDI ISA [CA]; ODIDI AMINA [CA]

Title: Magnesium salt of S-omeprazole

Applicant/Assignee:

Application No.: 10/439233   Filing Date: 16/May/2003

Abstract:

A process of producing the magnesium salt of an enantiomer of omeprazole, said process comprising the steps of: i) reacting magnesium with a lower alcohol to produce magnesium alkoxide in solution in the lower alcohol as solvent, ii) adding the neutral form of the enantiomer of omeprazole to the solution, and iii) flash-evaporating the solvent.

Priority: CA20022386716 Applic. Date: 2002-05-17; US2002-129622 Applic. Date: 2002-05-09

Inventor: SHERMAN BERNARD CHARLES [CA]

Title: Multi-particulate form of medicament, comprising at least two differently coated forms of pellet

Applicant/Assignee: ROEHM GMBH & CO. KG

Application No.: 10/239209   Filing Date: 12/Feb/2003

Abstract:

The invention relates to a multiparticulate drug form suitable for uniform release of an active pharmaceutical ingredient in the small intestine and in the large intestine, comprising at least two forms of pellets A and B which comprise an active pharmaceutical ingredient in the core and have different polymer coatings which determine the release of the active ingredient at different pH values, characterized in that pellet form A is provided with an inner polymer coating which enables continuous release of active ingredient, and has an outer enteric coating which rapidly dissolves above about pH 5.5, and pellet form B is provided with a polymer coating which, in the USP release test, releases less than 20% of the active ingredient at pH 6.8 in 6 hours and releases more than 50% of the active ingredient at pH 7.2 in 6 hours.

The invention additionally relates to a process for producing the multiparticulate drug form and to the use of pellet forms A and B for producing the drug form.

Priority: DE20011004504 Applic. Date: 2001-01-31; DE20011004880 Applic. Date: 2001-02-01; WO2001EP02679 Applic. Date: 2001-03-09

Inventor: BECKERT THOMAS [DE]; PETEREIT HANS-ULRICH [DE]; DRESSMAN JENNIFER [DE]; RUDOLPH MARKUS [DE]

Title: Raised surface assay plate

Applicant/Assignee: TRANSFORM PHARMACEUTICALS, INC

Application No.: 10/439943   Filing Date: 16/May/2003

Abstract:

The assay plate includes a substrate having an substrate surface and at least one raised pad extending from the substrate surface. The raised pad includes a substantially planar sample receiving surface configured for holding a sample thereon for in-situ experimentation. The sample receiving surface preferably has at least one sharp edge at the junction between a sidewall coupling the sample receiving surface to the substrate surface. The sample receiving surface is preferably a circle, oval, square, rectangle, triangle, pentagon, hexagon, or octagon shape that is sized to hold a predetermined volume of the sample. A method of using the above described assay plate is also provided. Once a raised pad extending from a substrate is formed, a sample is deposited on the raised pad. Experiments are subsequently performed using the sample on the raised pad.

Priority: US20020428164P Applic. Date: 2002-11-21; US2002-282505 Applic. Date: 2002-10-28

Inventor: CIMA MICHAEL [US]; LEWIS WENDY PRYCE [US]; GONZALEZ-ZUGASTI JAVIER [US]; GYORY J RICHARD [US]; LEMMO ANTHONY V [US]; MONAGLE JULIE [US]

Title: COMPOSITIONS AND METHODS FOR TREATING ILEUS

Applicant/Assignee: VIPOGEN, L.L.C VIPOGEN, LLC

Application No.: 10/769803   Filing Date: 03/Feb/2004

Abstract:

The present invention is directed to compositions useful in treating or preventing ileus in a patient. The compositions of the invention include a pituitary adenylate cyclase activating peptide (PACAP) receptor antagonist and/or a vasoactive intestinal peptide (VIP) receptor antagonist in an amount sufficient to treat or prevent ileus in a patient. In one embodiment both a PACAP and VIP receptor antagonists are present, preferably in a combination that blocks vasoactive pituitary cyclase 1 (VPAC1), VPAC2 and pituitary adenylate cyclase 1 (PAC1) receptors. Methods of using such composition to treat or prevent ileus in a patient are also encompassed by the invention.

Priority: US20030507122P Applic. Date: 2003-10-01

Inventor: GANDHI SALIL ATUL [US]

Title: Methods for preparing pharmaceutical formulations

Applicant/Assignee: SMITHKLINE BEECHAM CORPORATION

Application No.: 10/149722   Filing Date: 13/Jun/2002

Abstract:

The invention relates to pharmaceutical formulations and methods for preparing pharmaceutical formulations of histamine releasers. The present invention provides methods for determining the concentration of physiologically acceptable excipients for use in the formulations of the invention. The present invention also provides methods for suppressing pharmaceutically-induced histamine release by administering to an animal, the formulations of the present invention. A kit useful for preparing pharmaceutical formulations of histamine releasers is also provided.

Priority: WO2000US33772 Applic. Date: 2000-12-13; US19990171696P Applic. Date: 1999-12-22

Inventor: FLOYD ALISON G [US]; HASHIM MIR A [US]; LIN PEIYUAN [US]; MOOK ROBERT A [US]; SEFLER ANDREA [US]; MESERVE KATHLEEN CORNELL [US]; RICCIARELLI PATRICIA NEAL [US]; SPITZER TIMOTHY DAVID [US]

Title: Pharmaceutical composition comprising a hmg-coa reductase inhibitor

Applicant/Assignee: SANDOZ AG

Application No.: 10/476816   Filing Date: 13/Apr/2004

Abstract:

A pharmaceutical composition comprising as an active ingredient an HMG-CoA reductase inhibitor and an aminosugar.

Priority: WO2002EP04891 Applic. Date: 2002-05-03; GB20010011077 Applic. Date: 2001-05-04

Inventor: HEGDE DEEPAK [IN]; KULKARNI SUSHRUT [IN]

Title: Pharmaceutical compositions comprising amlodipine maleate

Applicant/Assignee: SYNTHON BV

Application No.: 09/938816   Filing Date: 27/Aug/2001

Abstract:

An amlodipine maleate pharmaceutical composition is provided with good stability when formulated with a pH within the range of 5.5 to 7, when measured as a 20 wt % aqueous slurry. The stability can also be aided by making the pharmaceutical composition from amlodipine maleate particles having an average particle size of greater than 20 microns, preferably greater than 100 microns.

Priority: AT20010000634U Applic. Date: 2001-08-09; BE20010000706 Applic. Date: 2001-11-05; US2001-809346 Applic. Date: 2001-03-16; US20000258562P Applic. Date: 2000-12-29

Inventor: LEMMENS JACOBUS M [NL]; VAN DALEN FRANS [NL]; VANDERHEIJDEN ARLETTE [NL]

Title: Composition of medicine for treating headache disease and process of preparation and uses thereof

Applicant/Assignee: JIANGSU KANION PHARMACEUTICAL CO., LTD

Application No.: 10/380273   Filing Date: 23/Jul/2003

Abstract:

This invention relates to a medicine combination used to treat headache, which is made up of Chuanxiong and Tianma in a certain scientific weight proportion. The medicine combination can be made into any commonly used dosage form. The invention also provides other applications of this medicine combination in the production of an anti-oxidative drug, an antihypertensive drug, a platelet antiaggregation drug, an antithrombosis drug and an anticoagulant.

Priority: WO2000CN00272 Applic. Date: 2000-09-12

Inventor: XIAO WEI [CN]

Title: Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts

Applicant/Assignee: BOEHRINGER INGELHEIM PHARMA KG

Application No.: 10/235410   Filing Date: 05/Sep/2002

Abstract:

Pharmaceutical compositions and kits comprising: (a) a tiotropium salt

and (b) a salmeterol salt having a solubility in water of 0.1 mg/mL or less, processes for preparing them, and their use in the treatment of respiratory complaints, asthma, and chronic obstructive pulmonary disease (COPD).

Priority: DE20021009243 Applic. Date: 2002-03-04; DE20011045438 Applic. Date: 2001-09-14; US20020387060P Applic. Date: 2002-06-07

Inventor: LINZ GUENTER [DE]; SOYKA RAINER [DE]

Title: Cushioning wax beads for making solid shaped articles

Applicant/Assignee: UNIVERSITEIT GENT

Application No.: 09/831422   Filing Date: 24/Jul/2001

Abstract:

Biologically inactive cushioning beads comprise at least one compressible cushioning component consisting essentially of a microcrystalline hydrocarbon wax or a natural wax, the said wax being at least 30% by weight of the biologically inactive cushioning beads. Such beads are useful for making solid shaped articles containing biologically active ingredients by compression.

Priority: WO2000EP07175 Applic. Date: 2000-07-26; GB19990021933 Applic. Date: 1999-09-17

Inventor: REMON JEAN PAUL [BE]

Title: Compositions and methods for treatment of microbial infections

Applicant/Assignee: IMMUNOLOGY LABORATORIES, INC

Application No.: 10/367213   Filing Date: 13/Feb/2003

Abstract:

The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions.

Priority: US20020356483P Applic. Date: 2002-02-13

Inventor: PILLICH JIRI [CZ]; BALCAREK JOHN [US]

Title: Liquid pharmaceutical composition

Applicant/Assignee: RELIANT PHARMACEUTICALS, INC

Application No.: 10/198271   Filing Date: 17/Jul/2002

Abstract:

This invention relates to new pharmaceutical compositions and methods for their preparation, and in particular it relates to taste-masked liquid compositions comprising a solution of a histamine H2-antagonist complexed with an alginate and also containing a humectant. The solution is buffered to a pH of between about 6 to 7. The inventive solution may be flavored and sweetened and preserved.

Priority:

Inventor: BOBOTAS GEORGE [US]; FAWZY ABDEL A [US]

Title: Lyophilization method and apparatus for producing particles

Applicant/Assignee: FERRO CORPORATION

Application No.: 10/434435   Filing Date: 08/May/2003

Abstract:

A method and apparatus for producing particles, the apparatus includes a solution source that supplies a solution, and a fluid source that supplies a fluid. The solution includes a solvent and a solute. A mixer receives the solution and the fluid from the sources, and mixes the solution and the fluid together to form a mixture. The mixture is supplied from the mixer to an expansion assembly at first pressure. The expansion assembly sprays and expands the mixture substantially simultaneously to form frozen droplets, and preferably to form a low-density powder of frozen droplets. A freeze-dry apparatus sublimes the solvent from the particles. A high mass-transfer rate and a uniform open-structure of the powder bed enhances the freeze-drying process. Solid particles having a controlled size distribution are obtained.

The particles preferably have a hollow or porous morphology suitable for differing drug delivery applications to include aerosol formulations.

Priority: US20030445941P Applic. Date: 2003-02-07; US20030445942P Applic. Date: 2003-02-07

Inventor: SHEKUNOV BORIS Y [US]; CHATTOPADHYAY PRATIBHASH [US]; SEITZINGER JEFFREY S [US]

Title: Storage stable thyroxine active drug formulations and methods for their production

Applicant/Assignee: MYLAN PHARMACEUTICALS, INC

Application No.: 10/443135   Filing Date: 22/May/2003

Abstract:

This invention provides a storage-stable dosage form of a thyroxine active drug composition which exhibits an improved stability. The formulation contains a thyroxine active drug substance, an alditol, and a saccharide, and, optionally, additional pharmaceutically accepted excipients. Levothyroxine sodium is the preferred active drug substance, mannitol is the preferred alditol, and sucrose is the preferred saccharide. Additional preferred excipients include, for example, microcrystalline cellulose, crospovidone, magnesium stearate, colloidal silicon dioxide, and sodium lauryl sulfate.

Priority: US2001-987130 Applic. Date: 2001-11-13

Inventor: HANSHEW JR DWIGHT D [US]; WARGO DAVID JOHN [US]

Title: Treatment of inflammatory skin conditions

Applicant/Assignee: NUCRYST PHARMACEUTICALS CORP

Application No.: 10/131511   Filing Date: 23/Apr/2002

Abstract:

The invention relates to the use of one or more antimicrobial metals, most preferably silver, preferably formed with atomic disorder, and preferably in a nanocrystalline form, for the treatment of inflammatory skin conditions. The nanocrystalline antimicrobial metal of choice may be used in the form of a nanocrystalline coating of one or more antimicrobial metals, a nanocrystalline powder of one or more antimicrobial metals, or a solution containing dissolved species from a nanocrystalline powder or coating of one or more antimicrobial metals.

Priority: US2001-840637 Applic. Date: 2001-04-23; US20010285884P Applic. Date: 2001-04-23

Inventor: BURRELL ROBERT EDWARD [CA]; YIN HUA QING [CA]

Title: Composition and methods for treating Alzheimer's disease and other amyloidoses

Applicant/Assignee: UNIVERSITY OF WASHINGTON

Application No.: 09/079829   Filing Date: 15/May/1998

Abstract:

A pharmaceutical agent for treating an amyloid disease such as Alzheimer's Disease that includes a therapeutically effective amount of an extract obtained from the inner bark or root tissue of a plant of the genus Uncaria, species tomentosa, wherein the weight percentage of plant extract in the agent is in the range of from about 70% to about 95%.

Priority: US19970046602P Applic. Date: 1997-05-15

Inventor: CASTILLO GERARDO [US]; SNOW ALAN D [US]

Title: Process to concentrate insoluble proteins by vibrating membrane filtration

Applicant/Assignee: GLAXOSMITHKLINE BIOLOGICALS, S.A

Application No.: 10/250818   Filing Date: 09/Jul/2003

Abstract:

The present invention relates to a process for purifying proteins comprising applying protein extracts to a vibrating membrane fitter equipped with a hydrophilic membrane.

Priority: WO2002EP00063 Applic. Date: 2002-01-07; GB20010000513 Applic. Date: 2001-01-09

Inventor: CHAMPLUVIER BENOIT [BE]; PERMANNE PHILIPPE JEAN GERVAIS [BE]

Title: Cycloalkenone derivative

Applicant/Assignee: NIKKEN CHEMICALS CO., LTD

Application No.: 10/481060   Filing Date: 16/Dec/2003

Abstract:

(-)-3-[3-[(1R,2R,4S)-bicyclo[2.2.1]hept-2-yloxy]-4-methoxyanilino]-2-methyl-2-cyclopenten-1-one, or its hydrate or solvate, or a pharmaceutical composition containing the same.

Priority: JP20010199488 Applic. Date: 2001-06-29; WO2002JP06520 Applic. Date: 2002-06-27

Inventor: AKIYAMA TOSHIHIKO [JP]; INA SHINJI [JP]; TAKAHAMA AKANE [JP]

Title: Intravaginal drug delivery devices for the administration of an antimicrobial agent

Applicant/Assignee: GALEN (CHEMICALS) LIMITED

Application No.: 10/107997   Filing Date: 27/Mar/2002

Abstract:

An intravaginal antimicrobial drug delivery device is disclosed having an antimicrobial agent dispersed throughout a biocompatible elastomeric system. Also disclosed is a method of making the antimicrobial drug delivery device.

Priority: IE20010000307 Applic. Date: 2001-03-27

Inventor: MALCOLM KARL [GB]; WOOLFSON DAVID [GB]; ELLIOTT GRANT [GB]; SHEPHARD MARTIN [GB]

Title: Cyclodextrin-drospirenone inclusion complexes

Applicant/Assignee: SCHERING AKTIENGESELLSCHAFT SCHERING AG

Application No.: 10/022845   Filing Date: 20/Dec/2001

Abstract:

Pharmaceutical compositions comprising low doses of sensitive complexes between an estrogen and a cyclodextrin are provided with improved stability. In specific embodiments the composition comprises a complex between ethinyl estradiol and beta-cyclodextrin in a granulate preparation and in yet another embodiment the composition comprises a limited amount of polyvinylpyrrolidone since this excipient was found to degrade ethinyl estradiol. Furthermore, a method for improving the stability of an estrogen in a composition and for manufacturing such a stable composition is provided. Essentially, the granulate preparation are manufactured under careful control of the relative humidity.

Priority: EP20000610135 Applic. Date: 2000-12-20; US20000256484P Applic. Date: 2000-12-20

Inventor: BACKENSFELD THOMAS [DE]; HEIL WOLFGANG [DE]; LIPP RALPH [DE]

Title: Interferon gamma polypeptide variants

Applicant/Assignee: MAXYGEN HOLDINGS, LTD MAXYGEN, APS

Application No.: 10/195707   Filing Date: 15/Jul/2002

Abstract:

When interferon gamma (IFNG) is produced in mammalian cell lines a heterogenous population of IFNG polypeptides is obtained due to C-terminal processing of the IFNG polypeptide. Clearly, this constitutes a severe problem in that valuable polypeptide material is lost and, further, it is necessary to carry out time-consuming and cumbersome purification in order to obtain a homogenous population of active IFNG polypeptides having the desired length. It has now been found that an IFNG fragment containing 132 amino acid residues (truncated at the nucleotide level by introducing a stop-codon after the codon encoding amino acid residue no. 132) does not undergo C-terminal truncation or, at least, is not significantly C-terminally truncated.

Furthermore, as the IFNG fragment containing 132 amino acid residues is active, this opens up the possibility of producing a homogenous active IFNG polypeptide in eukaryotic host cells, such as CHO cells. More particularly, the present invention relates to an IFNG polypeptide variant exhibiting IFNG activity and having the amino acid sequence shown in SEQ ID NO:12. In a highly preferred embodiment of the invention, the variant comprises at least one further modification, such as 1-10 further modifications, relative to the amino acid sequence shown in SEQ ID NO:12. A particular preferred further modification is E38N+S40T.

Priority: US2002-116273 Applic. Date: 2002-04-04; US20020356321P Applic. Date: 2002-02-11; US20010289398P Applic. Date: 2001-05-07; US20010282254P Applic. Date: 2001-04-06

Inventor: VAN DEN HAZEL BART [DK]; JENSEN ANNE DAM [DK]; NYGAARD FRANK BECH [DK]; ANDERSEN KIM VILBOUR [DK]

Title: Orally administered drug delivery system providing temporal and spatial control

Applicant/Assignee: RANBAXY LABORATORIES LIMITED

Application No.: 09/347315   Filing Date: 02/Jul/1999

Abstract:

A pharmaceutical composition in the form of tablets or capsules provides a combination of temporal and spatial control of drug delivery to a patient for effective therapeutic results. The pharmaceutical composition comprises a drug, a gas generating component, a swelling agent, a viscolyzing agent, and optionally a gel forming polymer. The swelling agent belongs to a class of compounds known as superdisintegrants (e.g., cross-linked polyvinylpyrrolidone or sodium carboxymethylcellulose). The viscolyzing agent initially and the gel forming polymer thereafter form a hydrated gel matrix which entraps the gas, causing the tablet or capsule to be retained in the stomach or upper part of the small intestine (spatial control). At the same time, the hydrated gel matrix creates a tortuous diffusion path for the drug resulting in sustained release of the drug (temporal control). A preferred once daily ciprofloxacin formulation comprises 69.9% profloxacin base, 0.34% sodium alginate, 1.103% xanthan gum, 13.7% sodium bicarbonate, 12.1% cross-linked polyvinylpyrrolidone, and optionally other pharmaceutical xcipients, the formulation being in the form of a coated or uncoated tablet or capsule.

Priority: US1998-152932 Applic. Date: 1998-09-14; IN1997DE02660 Applic. Date: 1997-09-19

Inventor: TALWAR NARESH [IN]; SEN HIMADRI [IN]; STANIFORTH JOHN N [GB]

Title: Zinc-free and low-zinc insulin preparations having improved stability

Applicant/Assignee: AVENTIS PHARMA DEUTSCHLAND GMBH

Application No.: 10/102862   Filing Date: 22/Mar/2002

Abstract:

The invention relates to a formulation comprising a polypeptide selected from at least one of insulin, an insulin metabolite, an insulin analog, and an insulin derivative

at least one surfactant

optionally at least one preservative

and optionally at least one of an isotonicizing agent, a buffer or an excipient, wherein the formulation is free from or low in zinc. The invention also relates to the production of such insulin preparations and their use as pharmaceutical formulations.

Priority: DE20011014178 Applic. Date: 2001-03-23

Inventor: BODERKE PETER [DE]

Title: Methods and apparatus for making particles using spray dryer and in-line jet mill

Applicant/Assignee: ACUSPHERE, INC

Application No.: 10/324943   Filing Date: 19/Dec/2002

Abstract:

Methods and apparatus are provided for making particles comprising: (a) spraying an emulsion, solution, or suspension, which comprises a solvent and a bulk material (e.g., a pharmaceutical agent), through an atomizer and into a primary drying chamber, having a drying gas flowing therethrough, to form droplets comprising the solvent and bulk material dispersed in the drying gas

(b) evaporating, in the primary drying chamber, at least a portion of the solvent into the drying gas to solidify the droplets and form particles dispersed in drying gas

and (c) flowing the particles and at least a portion of the drying gas through a jet mill to deagglomerate or grind the particles. By coupling spray drying with "in-line" jet milling, a single step process is created from two separate unit operations, and an additional collection step is advantageously eliminated.

The one-step, in-line process has further advantages in time and cost of processing.

Priority:

Inventor: CHICKERING III DONALD E [US]; NARASIMHAN SRIDHAR [US]; ALTREUTER DAVID [US]; KOPESKY PAUL [US]; KEEGAN MARK [US]; STRAUB JULIE A [US]; BERNSTEIN HOWARD [US]

Title: Pharmaceutical compositions

Applicant/Assignee: DISPHAR INTERNATIONAL B.V

Application No.: 09/890104   Filing Date: 16/Oct/2001

Abstract:

A pharmaceutical composition for slow release of active ingredient in the gastrointestinal tract, comprising a plurality of active ingredient-containing particles coated with a material insoluble in gastric and intestinal juices, where the particles have as core a homogeneous mixture comprising an active pharmaceutical ingredient and a polymer insoluble in gastric and intestinal juices, with an average internal pore diameter not exceeding 35 mum, makes efficient and pH-independent delaying of release possible even with comparatively small amounts of polymer. It is additionally distinguished by a long shelf life and is particularly suitable also for nonspherical particles.

Priority: WO1999IB00180 Applic. Date: 1999-01-29

Inventor: HUBER GERALD [DE]; GRUBER PETER [DE]

Title: Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same

Applicant/Assignee: BAKER NORTON PHARMACEUTICALS, INC

Application No.: 09/055818   Filing Date: 06/Apr/1998

Abstract:

Pharmaceutical compositions for oral administration to mammalian subjects comprise a taxane or taxane derivative (e.g., paclitaxel or docetaxel) as active ingredient and a vehicle comprising at least 30% by weight of a carrier for the taxane, said carrier having an HLB value of at least about 10. The compositions may also comprise 0-70% of a viscosity-reducing co-solubilizer. The compositions may be incorporated into conventional oral pharmaceutical dosage forms, or can be in the form of a two-part medicament wherein the first part includes the taxane in a solubilizing vehicle and the second part comprises a carrier for the taxane to promote oral absorption. Methods of treatment of taxane-responsive disease conditions employing the novel compositions are also disclosed, whereby the compositions can be administered alone or in association with an oral bioavailability enhancing agent.

Priority: US1997-863513 Applic. Date: 1997-05-27; US1996-733142 Applic. Date: 1996-10-16; US1996-608776 Applic. Date: 1996-02-29; US19950007071P Applic. Date: 1995-10-26

Inventor: GUTIERREZ-ROCCA JOSE C [US]; CACACE JANICE L [US]; SELIM SAMI [US]; TESTMAN ROBERT [US]; RUTLEDGE J MICHAEL [US]

Title: Method of preparing biological materials and preparations produced using same

Applicant/Assignee: GAINFUL PLAN LIMITED

Application No.: 10/054914   Filing Date: 25/Jan/2002